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Summary 
Since its identification in neuroblastoma, increasing evidence points towards a central role for 
MYCN in the biology of neuroblastoma tumors. As a consequence, targeting MYCN and its 
downstream functions would be a promising strategy to treat neuroblastoma patients. However, 
the development of inhibitors targeting MYC proteins has been challenging, as MYC/MYCN 
proteins are composed of two extended alpha-helices with no obvious surfaces for small 
molecule binding. Therefore, a thorough understanding of MYCN's functions and the upstream 
mechanisms regulating its expression would contribute to the development of compounds 
specifically targeting the impact of MYCN in neuroblastoma cells. 
To address this issue, I initiated this thesis with the construction of an in vivo time-resolved 
miRNA and gene expression dataset of MYCN-driven neuroblastoma development, using the 
well-established TH-MYCN mouse model. After extensive validation of the dataset, I applied an 
exiting transcriptome-wide cross-species approach to search for transcriptional regulators that 
can be regarded as master regulators of neuroblastoma development. The corresponding 
miRNA expression dataset was exploited during the characterization of the complete MYCN-
miRNA interactome in neuroblastoma using the powerful combination of this dataset and an 
unbiased 3'UTR reporter screen. I next characterized how MYCN affects the expression of 
LIN28B, a highly conserved RNA-binding protein, which is shown to induce MYCN expression in 
neuroblastoma via the suppression of the MYCN-targeting let-7 family of miRNAs. 
Throughout this project, studying the genetic landscape of the well-established TH-MYCN 
mouse model has provided great insights in the perturbed miRNA-mRNA networks in 
neuroblastoma. Although representing an excellent and broadly used tool, this mouse model 
holds some limitations related to the transgene integration site, the anatomical location of the 
observed tumors, implementation of in vivo imaging and tumor incidence in different genetic 
backgrounds. I therefore present a novel mouse model with targeted Cre-conditional MYCN 
expression in the neural crest. Molecular characterization showed that the tumors arising in this 
model, strongly resemble the existing TH-MYCN mouse model and human neuroblastoma 
tumors. We expect that this new model, which addresses some of the major limitations of the 
TH-MYCN model, will play a major role in the investigation of neuroblastoma.  
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Samenvatting 
Sinds de identificatie van amplificatie van MYCN in neuroblastoom, duidt toenemend bewijs op 
een centrale rol voor MYCN in de biologie van neuroblastoom tumoren. Bijgevolg lijkt het 
veelbelovende strategie om therapieën te ontwikkelen die de activiteit en de functies van MYCN 
ondermijnen. Echter, de ontwikkeling van MYC inhibitoren is uitdagend, aangezien MYC/MYCN 
eiwitten bestaan uit twee lange alpha-helices zonder duidelijke oppervlakken waarop kleine 
moleculen zouden kunnen binden. Om deze beperking te kunnen omzeilen, zou een grondig 
begrip van de functies van MYCN en de stroomopwaartse mechanismen die MYCN reguleren, 
kunnen bijdragen tot de ontwikkeling van geneesmiddelen die specifiek gericht zijn om de 
activiteit van MYCN in neuroblastoom cellen uit te schakelen. 
Om dit probleem aan te pakken, heb ik dit proefschrift aangevat met de bouw van een 
dynamische miRNA en gen expressie dataset van MYCN-gedreven neuroblastoom 
ontwikkeling. Na uitgebreide validatie van de dataset, heb ik een veelbelovende data mining 
strategie toegepast om te zoeken naar belangrijke sleutel genen in de ontwikkelen van 
neuroblastoom tumoren. De bijbehorende miRNA expressie dataset werd benut tijdens de 
karakterisatie van het volledige MYCN-miRNA interactoom in neuroblastoom met behulp van de 
krachtige combinatie van deze dataset en een 3'UTR reporter screen. Daarnaast heb ik verder 
in kaart gebracht hoe MYCN een impact heeft op LIN28B, een recent geïdentificeerd oncogen 
in neuroblastoom tumoren.  
Doorheen dit project, heeft de studie van het genetische landschap van het gevestigde TH-
MYCN muismodel, nieuwe inzichten gebracht in de verstoorde miRNA-mRNA-netwerken in 
neuroblastoom. Het gebruikte TH-MYCN muismodel is een belangrijk model dat reeds vaak 
gebruikt werd voor dergelijke studies, maar dit model houdt enkele beperkingen in. Daarom heb 
ik, in samenwerking met het labo van prof Schulte (Essen, Duitsland), een nieuw muismodel 
ontwikkeld met een gerichte en conditionele over expressie van MYCN in de cellen van de 
neurale lijst. Moleculaire karaterisatie toont aan dat de tumoren die in dit model ontstaan, sterke 
gelijkenissen vertonen met het bestaande TH-MYCN muis model en humane neuroblastoom 
tumoren. We verwachten dat dit nieuwe model, die enkele belangrijke beperkingen van het TH-
MYCN model aanpakt, in de toekomst een belangrijke rol zal spelen in het onderzoek naar 
neuroblastoom. 
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An introduction to neuroblastoma biology 
I believe there is no need to demonstrate that cancer is a devastating disease; during our 
lifetime, each of us will be confronted with its consequences – either directly or through 
someone close by. Fortunately, as our understanding of normal and deregulated cellular 
biology increased, cancer research has resulted in means for curing cancer patients. In 
contrast to many other tumor entities, however, understanding the genetic basis of 
neuroblastoma has lagged behind, which is in part due to its infrequent appearance and the 
heterogenic nature of the disease. In the past decennium, the genetic landscape and the 
molecular implications have become increasingly clear, generating opportunities for the 
development of targeted therapies. 
The first part of this introduction is devoted to neuroblastoma biology, more specifically 
describing its cellular origin and its genetic landscape. The second part zooms in on the 
broad involvement of the oncogenic transcription factor MYCN in the biology of 
neuroblastoma tumors and highlights emerging therapeutic strategies that aim to tackle 
MYCN activity in a targeted fashion. Finally, this introduction also brings microRNAs 
(miRNAs) into the picture.  
Neuroblastoma 
Neuroblastoma is a rare childhood malignancy that originates from precursor cells of the 
sympatho-adrenal lineage of the peripheral nervous system. Neuroblastoma tumors arise at 
various sites of the developing sympathetic nervous system: at least half of the primary 
tumors are found in the adrenal gland while others originate in the paraspinal sympathetic 
ganglia or in pelvic ganglia (Figure 1.1). Neuroblastoma is the most common extra-cranial 
solid tumor in children and accounts for 8 to 10% of all childhood cancers. This disease is 
characterized by clinical and genetic heterogeneity: while young children (< 18 months) with 
favorable tumors have good survival chances due to spontaneous regression or 
differentiation of the tumor, older patients are often confronted with aggressive metastatic 
disease and rapid progression with fatal outcome, despite multimodal therapy.  
The following sections highlight the developmental origin of neuroblastoma tumors and the 
genetic defects that occur during neuroblastoma oncogenesis.  
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When development goes wrong 
Childhood malignancies are typically disorders of normal development. Embryonal 
development, beginning with a single population of stem cells and culminating in 
organogenesis, is marked by stages of proliferation and differentiation and is dependent 
upon communication between distinct populations of precursor cells. Strong mitogenic 
signals drive expansion and limit the ability of cells to terminally differentiate in G0-phase of 
the cell cycle. Changes in the concentrations of certain key regulators promote cell-cycle exit 
and the beginning of differentiation. The inability of progenitor cells to exit from a proliferative 
phase can potentially drive tumor formation. 1 
This paradigm of embryonal neoplasms contrasts that of adult cancers not only in 
dramatically shortened latency, but also in the cell populations from which tumors are 
currently thought to originate. Tumor formation in adults has been attributed classically to a 
reactivation of persistent cellular proliferation through genetic perturbations such as 
oncogenic activation and loss of apoptotic regulators. In contrast, childhood malignancies 
arise from progenitor cells which are already rapidly dividing as part of the normal 
developmental process. Embryonal tumors arise from embryonic or fetal tissues and 
develop through aberrations in normal developmental processes. 1 
 
Figure 1.1: Anatomical location of neuroblastoma tumors. 
Neuroblastoma may be found in the adrenal glands and paraspinal 
nerve tissue from the neck to the pelvis. Image from www.cancer.gov 
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From neuronal precursor to neuroblastoma tumor 
Neuroblastoma tumors develop from precursor cells of the sympatho-adrenal lineage that 
arise from the neural crest. The neural crest is a transient component of the ectoderm, and 
gives rise to diverse cell types, ranging from the peripheral nervous system to the 
craniofacial skeleton and pigment cells. Initially, at the end of the third and the beginning of 
the fourth week of embryonic development, the cells of the neural crest are located at the 
edge of the neural folds that arise during neurulation – the development of the neural tube 
from the neural plate. Shortly after neurulation, the neural crest cells migrate out of the 
neural tube to give rise to various structures, including the sympathetic nervous system that 
develops from the fate-restricted sympatho-adrenal progenitor cells, so-called neuroblasts, 
one of the major derivatives of the neural crest. Upon migration, these neuroblasts start 
expressing a series of factors that further allow their differentiation into either the ganglionic 
or the chromaffin lineage. Together, they form the differentiated cells that populate the 
sympathetic ganglia, paraspinal ganglia and the adrenal medulla. 2 
Studying the genetic differences between the neuroblasts and neuroblastoma tumors could 
provide insight in the aberrations that transform a sympatho-adrenal precursor into a 
malignant tumor. However, neuroblasts have long remained inaccessible for research, 
because they fully maturate or undergo apoptosis during development. In 2006, the 
pioneering isolation of neuroblasts from human fetal adrenal glands, performed by De Preter 
and colleagues 3, generated a benchmark dataset for the exploration of perturbed genetic 
networks in neuroblastoma development, and confirmed the hypothesis that neuroblasts are 
the progenitor cells of neuroblastoma tumors 3. Indeed, many genes involved in the 
development of the sympathetic nervous system have now been implicated in 
neuroblastoma development, further corroborating the link between neuroblastoma and its 
cell-of-origin. 
Oncogenic neuroblastoma driver genes and genetically engineered animal models 
Genetically, the majority of neuroblastoma tumors is characterized by loss and/or gain of 
genomic regions: numerical whole-chromosomal gains are typically found in low-risk tumors, 
whereas segmental chromosomal gains or losses are associated with high-risk disease. 
Recurrent structural chromosomal alterations commonly associated with advanced stage of 
disease and poor outcome in neuroblastoma include amplification of the oncogene MYCN, 
deletion of chromosome arms 1p, 3p, 4p and 11q, and gain of chromosome arm 17q. 
Recently, whole genome and exome next generation sequencing studies 4%6 have revealed 
that, besides these genomic regions, few single genes are recurrently affected in 
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neuroblastoma patients. This is in line with the general observation that pediatric tumors 
acquire far less genetic alterations compared to adult cancers. Three genes have been 
convincingly shown to act as oncogenic drivers: MYCN, ALK and LIN28B, all of which are 
involved in early sympathetic nervous system development.  
MYCN – v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog 
Amplification of MYCN, an oncogenic transcription factor on 2p24, was the first genetic 
aberration established in neuroblastoma 7,8. High-level amplification of MYCN defines 
approximately 20% of all neuroblastoma tumors and 45% of high-risk cases 9, and is 
frequently associated with loss of 1p and gain of 17q, together delineating a subgroup of 
patients with unfavorable prognosis 10. Oncogenes of the MYC family – to which MYCN 
belongs – are important in normal development; perturbed expression may give rise to 
deregulated growth and proliferation of cells, ultimately leading to cancer development (see 
below). Interestingly, high-risk neuroblastoma tumors without MYCN amplification often 
express elevated levels of MYC 11, which similarly results in activation of MYCN/MYC 
signaling pathways inferring a poor outcome similar as in MYCN amplified cases 11,12. This 
highlights the importance of both MYC and MYCN signaling in neuroblastoma.  
To proof a causal relationship between MYCN amplification or overexpression and high-risk 
neuroblastoma, a first neuroblastoma mouse model was developed by targeting MYCN 
overexpression to the cells of the developing sympathetic nervous system 13. These 
transgenic TH-MYCN mice develop tumors that faithfully recapitulate biological and genetic 
features of human high-risk neuroblastoma, thus serving as a useful pre-clinical model 13,14. 
However, being a transcription factor, MYCN has proven difficult to target therapeutically, 
warranting the search for new, drugable neuroblastoma oncogenes. 
ALK – anaplastic lymphoma kinase 
The genetic study of familial neuroblastoma tumors, comprising <2% of all neuroblastoma 
cases 15, led to the identification of mutations in the ALK gene in the majority of familial 
cases 16%19. Subsequent analysis of sporadic tumors showed that ALK is an important 
neuroblastoma predisposition gene, with activating mutations occurring in about 8% of 
sporadic cases 17. ALK is tyrosine kinase receptor which is preferentially expressed in the 
developing peripheral and central nervous systems 20, and mutations result in constitutive 
receptor activation and subsequent signaling to pro-survival pathways 16,18,19. More recently, 
chromosome 2 copy gain, including the ALK locus, was shown to be associated with an 
increased ALK expression and a significantly worse out-come in the global population 21,22. 
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Interestingly, ALK appears to be functionally connected to MYCN: initially, the ALKF1174L 
mutant, which shows increased transforming capacity as compared to the ALKR1275Q mutant 
19, was observed more often in tumors with MYCN amplification, suggesting a cooperative 
effect between both aberrations in neuroblastoma tumors 21. Shortly after these 
observations, mutant ALK was found to accelerate neuroblastoma tumorigenesis in MYCN-
driven tumors in mice 23%25 and zebrafish 26 by stabilizing MYCN protein. ALK activates the 
PI3K/AKT/mTOR pathway resulting in inactivation of GSK3ß and PP2A, two proteins 
involved in MYCN degradation 27 (see below). This direct effect on MYCN stabilization was 
shown to be complemented by an anti-apoptotic effect of ALKF1174L that allows transformed 
cells to evade MYCN-induced apoptosis 23,26 (see below). Indeed, early in the 
embryogenesis of MYCN transgenic zebrafish, MYCN overexpression results in a profound 
loss of neural crest-derived cells within the sympatho-adrenal cell lineage. Nevertheless, 
these animals can develop neuroblastoma, and both the onset and penetrance of the 
disease are markedly enhanced by constitutively expressed ALKF1174L (ref. 26). Furthermore, 
ALK was recently found to be a MYCN target gene 28, and ALK can, in its turn, stimulate 
initiation of MYCN transcription in neuroblastoma 29, thus creating a strong feed-forward loop 
in which MYCN and ALK enhance each others expression and activity. 
In the abovementioned animal models, constitutively activated ALK is not able to generate 
neuroblastoma tumors in absence of prior driving events. This observation is contradicted by 
the findings of Heukamp and colleagues 24 who showed that targeted expression of ALK can 
induce neuroblastoma tumors, albeit with low penetrance. However, as the mutant ALK 
construct in this model is integrated in the mouse genome by random insertion, and as this 
insertion location is not known, it cannot be excluded that the disruption of a potential 
neuroblastoma tumor suppressor co-operates with ALK in these mice to cause 
neuroblastoma. 
LIN28B – lin-28 homolog B (C. elegans) 
More recently, LIN28B was identified as a bona fide neuroblastoma oncogene 30, although it 
had been associated to neuroblastoma susceptibility through genome-wide association 
studies 31. LIN28B and its paralog LIN28A are highly conserved RNA-binding proteins that 
play important roles in development and stem cell reprogramming by regulating the self-
renewal of stem cells 32, and in glucose metabolism 33. They mediate these pleiotropic 
functions by enhancing the translation of target mRNAs and by inhibiting let-7 miRNA 
biogenesis, both in a sequence-specific manner (reviewed in ref. 34). The let-7 family of 
miRNAs comprises a group of 9 sequence-related miRNAs, processed from 12 transcripts 
encoded in 8 genomic loci. In a myriad of tumor entities, decreased let-7 expression levels – 
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through LIN28 overexpression or other mechanisms – cause the activation of multiple bona 
fide oncogenes, including RAS and MYC (reviewed in ref. 35). 
Initially, over-expression of LIN28B was found to be associated with the presence of an 
intronic SNP in neuroblastoma. 31 Recently, elevated LIN28B expression was found to 
contribute to neuroblastoma tumorigenesis via let-7 dependent de-repression of MYCN 30, 
connecting yet another neuroblastoma oncogene to MYCN. Indeed, murine and human 
tumors overexpressing LIN28B show a drastic reduction in expression levels of the let-7 
family of miRNAs and subsequent loss of MYCN repression. 30 Of note, MYCN itself has 
been suggested to induce LIN28B transcription, which would create another feed-forward 
mechanism. 36,37 However, as MYCN-mediated regulation of LIN28B in various 
neuroblastoma cell line models and TH-MYCN tumors could not be confirmed 30, this 
remained an unresolved interaction. In Chapter 5, we present evidence that MYCN does 
regulate LIN28B expression in neuroblastoma tumors, via both direct and indirect 
mechanisms. 
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MYCN as central nexus of neuroblastoma biology 
Since its first discovery of amplification in high-risk neuroblastoma tumors (in 1983), MYCN 
has been a central theme in neuroblastoma research. The transcriptional activities of MYCN 
have far-reaching consequences for neuroblastoma tumorigenesis, and as such, the 
promise of finding a targeted therapy against MYCN fueled relentless efforts to gain a 
deeper understanding of MYCN function and regulation. The recent lessons from 
neuroblastoma animal models have only strengthened the central position of MYCN in 
neuroblastoma tumor biology: all roads appear to lead to MYCN. This chapter zooms in on 
MYCN, its transcriptional activities and impact on neuroblastoma biology, and illustrates the 
promising progression of MYCN-targeting therapies towards the clinic.  
MYCN is a MYC family member 
MYCN is a member of the MYC-family of proto-oncogenic transcription factors that 
comprises three members: MYC, MYCN and MYCL. The MYC proteins are one of the most 
widely studied proto-oncogenes, and are part of the larger MYC/MAX/MAD network that 
comprises a group of transcription factors whose distinct interactions result in transcriptional 
activation or repression 38. Initially isolated from chicken tumor DNA as the human 
homologue of a retroviral oncogene (v-myc), MYC is now documented to be involved 
broadly in many cancers, in which its expression is estimated to be elevated or deregulated 
in up to 70% of human cancers. Early in vitro studies of MYC revealed its potential to 
transform normal embryonic fibroblasts in cooperation with other oncogenes. 39 Nowadays, it 
is clear that the proto-oncogene MYC lies at the crossroads of many growth-promoting 
signal transduction pathways and is an early response gene immediately downstream of 
many ligand-membrane receptor complexes. 40 
MYCN was identified as an amplified gene homologous to v-myc but distinct from MYC, in 
human neuroblastoma. 7,41 Structurally, the coding regions of both MYC and MYCN are 
highly homologous, particularly around the functional domains of the resulting proteins. 
Because of the structural and sequence homology between the MYC-family genes, the 
function and biochemical properties of MYC proteins are closely related. 42 Biologically, 
MYCN, like MYC, was found to promote transformation in rat embryo fibroblasts, and to 
induce proliferation and cell cycle progression in quiescent fibroblasts. 43,44 Furthermore, 
cloning of MYCN into the MYC locus in MYC knockout mice could rescue embryonic lethality 
and restore immune functions. Of note, MYCN knock-in animals were smaller, developed 
dystrophy of skeletal muscles, and showed differences in growth responses in some cell 
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types. These findings suggest that MYC and MYCN show prominent, albeit incomplete, 
redundancy. 45 
The inability of endogenous MYCN and MYC to fully compensate for the abovementioned 
knockout phenotypes may be due to the distinct spatiotemporal expression patterns 
displayed by MYC family proteins. MYC is ubiquitous and highly expressed in most rapidly 
proliferating cells during development and continues to be expressed in dividing cells of 
adult tissues. 40 MYCN, on the other hand, has a more restricted expression pattern: it is 
expressed during embryogenesis in pre-B cells, kidney, forebrain, hindbrain, and intestine, 
with highest expression in the developing brain. After embryonic development, MYCN is 
downregulated and it is not significantly expressed in adult tissues. In accordance, MYCN 
amplification or overexpression is often restricted to tumors of embryonic or neuro-
ectodermal origin such as neuroblastoma, retinoblastoma 46, Wilm’s tumor 47, glioblastoma 48 
and medulloblastoma 49, while MYC is activated in a broad range of tumors. Further 
supporting functional differences between both family members, is their differential 
preference for binding to similar, yet distinct, DNA sequences in the promoters of target 
genes. 50 As a consequence, despite that MYC genes may share many related targets, at 
the same time they retain other, unique ones, suggesting that they may have independent 
and tissue-specific functions. 42 
Transcriptional regulation by MYC proteins  
MYC family members are transcription factors that bind to DNA at conserved elements 
within the promoters of an extensive network of genes, either directly inducing gene 
transcription or silencing of expressed genes. 40 
MYC proteins as transcriptional activators 
Transcriptional activation of MYC target genes occurs via sequence-specific (E-box = 
CANNTG) DNA binding upon MYC-MAX dimerization. 40,51 In line with the diverging 
functional implications of MYC and MYCN, MYCN preferentially binds the E-box CATGTG 
as well as the canonical CACGTG. Under MYCN–amplified conditions, however, MYCN 
becomes less specific and can bind additional non-canonical E-box motifs. 50 The binding of 
MYC-MAX heterodimers to DNA initiates the organized recruitment of many associated 
factors into a large, chromatin-associated complex whose precise constituents may be 
determined by a variety of both cell- and growth-specific conditions. 52 A crucial role in the 
recruitment and assembly of these complexes seems to be assigned to the bromodomain 
and extraterminal (BET) family of adaptor proteins, which comprises BDR2, BRD3, BRD4, 
and BRDT and performs diverse roles in regulating transcription by RNA polymerase II. 
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Common to all four BET proteins are two conserved N-terminal bromodomains – BD1 and 
BD2, which are chromatin interaction modules that recognize acetylated lysine residues on 
histone tails and other nuclear proteins 53, and an extraterminal domain, which has been 
linked to transcriptional regulation by interacting with several histone modifiers. Recruitment 
of the MYC-MAX heterodimer and its associated proteins to the DNA seems to be 
associated with enhanced histone acetylation, an event which appears crucial for the binding 
of BET proteins through their bromodomains 54,55. 
 
 
Figure 1.2: Transcriptional regulation by MYC proteins. (A) Transcriptional activation of 
target genes occurs via binding of the MYC-MAX heterodimer to an E-box sequence in the 
target promoter region, and subsequent recruitment of many associated factors into a large, 
chromatin-associated complex. (B) E-box dependent transcriptional repression occurs via 
displacement of the MYC-MAX heterodimer by a repressive MAX-MAD heterodimer. (C) E-box 
independent transcriptional silencing occurs via interaction of the MYC-MAX heterodimer with 
basal transcription factors, upon which silencing chromatin modifiers are recruited. 
MYC proteins as transcriptional repressors 
As described above, the role of MYC as a positive regulator of gene expression is well-
established, mechanistically diverse and important for transformation. 40 However, genome-
wide analyses demonstrate that MYC represses at least as many targets as it activates. 56 
One of the first indicators that MYC might also function as a transcriptional repressor came 
from studies published in the 1980s that suggested that MYC participates in a negative 
feedback loop. 40 The present mechanistic model includes E-box dependent and E-box 
independent mode of actions that can co-exist (Figure 1.2). In E-box dependent gene 
silencing, MYC-MAX complexes are displaced by MAX-MAD complexes that recruit the 
mSin3 repressor complex, which will lead to histone deacetylation and increased chromatin 
compaction. 38 In E-box independent gene silencing, MYC-MAX complexes interact with 
18 Chapter 1 
 
basal transcription factors such as SP1 and MIZ1. 57 Occurrence of this E-box independent 
process is supported by the observation that more than 40% of MYC binding sites lack 
recognizable E-box sequences. 58 More recently, Valentijn and colleagues 59 showed that 
genes downregulated by MYCN are not enriched for MYCN binding, supporting a 
mechanism in which MYC proteins indirectly associated with repressed genes via 
intermediate factors such as SP1 and MIZ1. 59 There is evidence that E-box independent 
MYC-mediated transcriptional repression involves DNA-methylation and silencing chromatin 
modifications: MYC can recruit the DNA methyltransferase DNMT3A to the promoter region 
of genes to induce gene silencing. 60 The proposed model involves MYC binding to the 
cofactor MIZ1 to form a ternary complex with DNMT3A, inducing methylation. Although 
structural differences exist between MYC and MYCN within the N-terminal domain, both 
proteins contain the functional domains which are required to associate with DNMT3A 60, 
indicating that MYCN could interact in a similar manner. In addition, MYCN directly interacts 
with the histon methyltransferase EZH2 61, implicated in the trimethylation of histone H3 on 
lysine 27, a transcriptional silencing mark. Finally, MYCN can indirectly mediate the 
repression of multiple genes simultaneously via activation of noncoding RNAs, such as 
miRNAs and long noncoding RNAs (see below). 
Identification of MYC target genes 
Knowledge of MYCN target genes provides insight in the molecular mechanisms that 
contribute to the transforming effect of MYCN. Analysis of gene expression in 
neuroblastoma cell lines where MYCN levels can be experimentally manipulated have 
identified many genes and miRNAs whose expression is altered in response to changes in 
MYCN levels. 62-64 Distinguishing direct versus indirect effects based on expression profiling, 
however, is difficult since MYCN regulates other transcription factors as well as regulatory 
RNAs. In recent years, the chromatin immunoprecipitation assay (ChIP) has allowed 
researchers to better identify true direct targets of MYCN. 11,50,59,65,66 
Transcriptional regulation of non-coding RNAs, including miRNAs, contributes to the overall 
effect of MYCN on the cellular transcriptome (see below). The identification of miRNAs as 
transcriptional targets of MYCN, however, has been complicated by the difficulty of 
predicting promoters from short conserved sequence features. 67,68 miRNAs, whether they 
are located in intergenic regions or embedded within introns of protein-coding genes, are – 
in most cases – generated from long primary transcripts. The rapid processing of these 
transcripts, which can be up to several kb long, by DROSHA presents a technical barrier for 
large-scale identification of miRNA transcription start sites, as they can be located very far 
away from the mature miRNA and therefore cannot be easily inferred from the genomic 
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location of the mature miRNA. The difficulty of experimentally detecting and consequently 
annotating miRNA promoters has limited our ability to identify the regulatory circuits that 
control miRNA expression. 69 
The heterogeneous nature of MYCN and its impact on neuroblastoma biology 
Via activation or repression of its target genes, MYCN leaves a profound footprint on 
neuroblastoma biology, affecting all hallmarks of cancer (Figure 1.3). The observed 
oncogenic effects in neuroblastoma are the net result of all affected pathways. 
One of the key biological functions of MYC proteins contributing to cell proliferation, is their 
ability to promote cell-cycle progression. 40,70 Specifically, MYCN amplified neuroblastoma 
tumors show an inability to arrest in G1-phase in response to irradiation and DNA damage, 
possibly via up-regulation of both CDK4 71 and SKP2 72, allowing CDK2 to escape p21 
inhibition. This results in hyperphosphorylation of RB1 and subsequent release of E2F 
transcription factors that activate genes encoding many of the proteins involved in G1 
progression and DNA and RNA synthesis. 70 Furthermore, MYCN-mediated upregulation of 
CHK1, an important regulator of S-phase and G2/M checkpoints, has been suggested as a 
mechanism through which MYCN amplified neuroblastoma becomes refractory to standard 
chemotherapy. 73 In parallel, MYCN also exerts important influences on the cell cycle by 
repressing genes: the CDK inhibitors INK4B[p15] and WAF1[p21] — which are involved in 
cell-cycle arrest — are inactivated because the MYC–MAX heterodimer interferes with 
positively acting transcription factors such as MIZ1 74 and/or SP1. 
Intriguingly, MYCN – like MYC – not only activates proliferation, it also sensitize cells to 
apoptosis. 40,70 Ectopic MYCN expression increases apoptosis in response to DNA damage 
in MYCN non-amplified cell lines 75 and MYCN amplified neuroblastoma cell lines were found 
to undergo significantly higher levels of apoptosis after DNA damage than MYCN non-
amplified neuroblastoma cell lines 76. Whether MYCN promotes a net proliferative response 
is dependent on the status of cooperating factors, such as the anti-apoptotic protein BCL2 77 
or p53 78. Interestingly, TP53 mutations are rare in neuroblastoma at diagnosis 79, suggesting 
that MYCN likely cooperates with suppressors of p53 signaling. A number of these p53 
signaling suppressors are directly regulated by MYCN, supporting its dual role in cellular 
hemostasis: miRNA-380-5p 80, CUL7 81, BMI1 82, TWIST1 83, and the primary p53 antagonist 
MDM2 65 are MYCN target genes. In contrast, mutations in TP53 and p53 pathway members 
occur in neuroblastoma at relapse, consistent with the idea that such mutations, which drive 
therapy-resistant disease, may arise in response to cytotoxic chemotherapy79. 
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Figure 1.3: The impact of MYCN on neuroblastoma biology. MYCN plays multiple roles in 
malignancy and maintenance of stem-like state. MYCN can activate transcription of genes 
involved in metastasis, survival, proliferation, pluripotency, self-renewal, and angiogenesis. 
Additionally, MYCN can suppress expression of genes that promote differentiation, cell cycle 
arrest, immune surveillance, and genes that antagonize metastasis and angiogenesis. [Adapted 
from Huang, M. and Weiss W. A. Cold Spring Harb Perspect Med (2013), Figure 2 84] 
Besides its seemingly contradictory involvement in both cell proliferation and apoptosis, 
MYCN also exerts opposing roles in the differentiation process. Downregulation of MYCN is 
necessary to induce retinoic acid mediated differentiation in neuroblastoma cells. 85 The 
regulation of the MYCN/MAD/MAX network is important in this process: during differentiation 
the turnover of MYCN and the expression of MAD are increased, resulting in a shift from 
MYCN-MAX promoter occupancy to MAD-MAX at MYCN target genes involved in cell cycle 
progression. 86 In contrast, Guglielmi and colleagues 87 recently showed that MYCN protein 
expression is required to activate the differentiation processes in neuroblastoma cells. The 
authors hypothesize that MYCN is necessary during the activation of neuroblastoma 
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differentiation to induce apoptosis in cells that are not committed to differentiation but are still 
proliferating. 87 
These opposing roles of MYCN in differentiation are illustrated by the relative high frequency 
of spontaneous tumor regression in disseminated neuroblastoma tumors – termed stage 4S 
tumors. 88 These tumors display higher MYCN mRNA and protein levels than low-risk 
localized MYCN non-amplified tumors, despite their lack of MYCN amplification. It has been 
suggested that moderate MYCN function gain in this subtype is still compatible with, or might 
even favor, spontaneous regression 11 that resembles the concurrence of massive apoptosis 
and differentiation of a few neurons along the sympatho-adrenal cell lineage in the normal 
development of the sympathetic nervous system. 
Despite the apparently incompatible functions of MYCN, its amplification or overexpression 
ultimately leads to tumor formation in sympathetic precursor cells. In this process, the 
balance of MYCN activity is shifted towards an oncogenic nature (summarized in Figure 
1.3); in parallel, the pro-apoptotic functions of MYCN are repressed via the acquisition of 
additional aberrations – be there chromosomal imbalances, point mutations, epigenetic 
alterations – as illustrated by the cooperative effects of ALK activation in mouse en zebrafish 
models of MYCN-driven neuroblastoma. 23 
Therapeutic targeting of MYCN in neuroblastoma 
Giving the enormous impact of MYCN on neuroblastoma biology and that several 
observations point towards a central role for MYCN, therapeutic targeting of MYCN seems a 
very promising option in neuroblastoma. There is indeed a need for novel therapies in 
neuroblastoma: 50% of neuroblastoma patients are classified as high-risk, and outcome 
remains poor in this patient cohort despite intensified multimodal treatment. 89 A 
considerable proportion of patients experience disease relapse and are refractory to 
conventional treatment approaches. 89 The impact of inhibiting MYCN on neuroblastoma 
tumor progression is evident from RNAi-mediated knockdown of MYCN expression in MYCN 
amplified neuroblastoma, where it results in increase in apoptosis and differentiation, and 
suppression of cell growth. 90,91 However, direct inhibition of MYCN in vivo is cumbersome, 
as MYC proteins are composed of two extended alpha-helices with no obvious surfaces for 
small molecule binding. Therefore the regulatory mechanisms governing MYCN 
transcription, translation and function are currently being explored as therapeutic targets. 
Strategies to circumvent blocking MYCN directly include: (1) targeting transcription of 
MYCN, (2) targeting regulators of MYCN mRNA and protein stability, and (3) triggering 
differentiation (Figure 1.4). 
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Targeting transcription of MYCN 
Recently, interest in the MYC-targeting field increased following the recognition that BET 
family adaptor proteins (see above) localize to MYC promoters: the development of BET 
inhibitors appeared to be a promising therapeutic strategy for targeting MYC in different 
tumor entities. Unfortunately, BET inhibition does not inhibit MYC expression to a similar 
extent in all tumor cells, likely due to different unique regulatory mechanisms regulating MYC 
expression in different entities. For instance, in multiple myeloma and acute myeloid 
leukemia, the expression of MYC is enhanced from unique distant BRD4-occupied 
enhancers, making these specific cases highly sensitive to BET inhibition. 92 In 
neuroblastoma cell lines, responses to BET inhibition varied from highly sensitive to 
resistant 93, suggesting that the transcriptional control of MYCN occurs via different 
mechanisms, either BET-dependent or -independent. Given that BET proteins might 
enhance MYCN expression from distant enhancer sites, resistance to BET inhibition in 
MYCN amplified cells could be explained by a disconnection from MYCN and its enhancing 
elements, uncoupling MYCN from BET-mediated control. Currently, a number of BET 
inhibitors are undergoing early-phase clinical testing, for different tumor entities. † 
Targeting regulators of MYCN mRNA and protein stability 
The occurrence of high nuclear MYCN protein levels, even in cases in which MYCN is not 
amplified or overexpressed at the mRNA level 59, supports MYCN protein stability as another 
relevant mechanism for MYCN regulation. MYCN protein turnover is cell-cycle dependent 
with MYCN degradation occurring during mitosis. 42 MYC and MYCN proteins are 
proteolyzed through a stepwise set of phosphorylation events. Initially, MYC and MYCN are 
phosphorylated at serine 62 (S62) via kinases in the RAS signaling pathway, such as 
MAPK 94 – which lies downstream of ALK – and CDK1 95. This post-translational modification 
stabilizes MYCN and primes it for subsequent phosphorylation at threonine 58 (T58) via 
GSK-3ß 96, a direct target of the PI3K/AKT/mTOR pathway. Dephosphorylation of S62 via 
PP2A next sensitizes MYCN phosphorylated at T58 to bind a proteasomal degradation 
complex that includes AURKA, E3 ubiquitin ligases (FBXW7 and HUWE1) and undefined 
additional proteins, leading to the ubiquitination and degradation in the proteasome 97-99 
(Figure 1.4). Consequently, inhibition of PI3K or mTOR and subsequent GSK-3ß activation 
can decrease MYCN protein levels by promoting T58 phosphorylation. A number of 
compounds active against either PI3K or mTOR are currently in clinical development. 100 
 
                                                
† https://clinicaltrials.gov 
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Figure 1.4: Therapeutic targeting of MYCN in neuroblastoma. Possible strategies to treat MYCN- amplified 
neuroblastoma patients include (a) blocking MYCN-dependent transcription with BET-bromodomain inhibitors, 
(b) antagonizing proteins involved in stabilizing MYCN protein and (c) suppressing MDM2 that stabilizes MYCN 
mRNA and disrupts p53-mediated apoptosis. [Adapted from Huang, M. and Weiss, W. A. Cold Spring Harb 
Perspect Med (2013), Figure 4. Ref. 84] 
Proteins that prevent dephosphorylation at T58 stabilize MYCN, which may be the case with 
AURKA in neuroblastoma. 101 Interestingly, increased expression of AURKA is found in 
MYCN amplified neuroblastoma, mediated potentially by MYCN itself. 102 Therefore, 
promoting dissociation of the AURKA-MYCN complex, which results in rapid proteasomal 
degradation of MYCN, represent another strategy to target oncogenic stabilization of MYCN. 
Certain AURKA inhibitors, such as MLN8237, induce a particular conformational change in 
the kinase that actively reinitiates MYCN degradation through this mechanism, independent 
of any requirement for enzymatic inhibition of the kinase itself. 103 MLN8237 was identified as 
a promising agent for neuroblastoma 104 but has not displayed robust antitumor activity in 
early-phase pediatric studies 105, warranting the development of improved inhibitors. 
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The majority of drugs described here are in early-phase clinical testing in adult and pediatric 
settings 100, making targeted therapeutics a reality for neuroblastoma cure. It is anticipated, 
however, that a number of drugs might induce secondary mutations rendering a tumor 
insensitive to a promising targeted therapy. Therefore, further scrutinizing MYCN functions 
and interactors remains of interest to the field. In this respect, the implementation of non-
coding RNAs – playing key roles in normal development and oncogenesis – in the MYCN 
network holds great promise. 
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The role of microRNAs in cancer 
The discovery that non-coding RNAs (ncRNAs) – once believed to be genomic trash – 
interfere with the expression of coding genes implicated in virtually all biological processes, 
has revolutionized the field of molecular biology in the last decades. miRNAs, a specific 
class of small ncRNAs, have drawn particular attention. miRNAs are very short non-coding 
transcripts that act by regulating protein expression during cellular processes such as 
growth, development, and differentiation at the transcriptional, posttranscriptional, and/or 
translational level. The exact role of an individual miRNA strictly depends on its 
spatiotemporal expression pattern and that of its target genes. Given the involvement of 
miRNAs in a myriad of biological processes, researchers investigated consequences of 
deregulated miRNA expression and found implication in multiple diseases such as 
inflammatory 106 and cardiovascular disease 107 and cancer 108. 
miRNA biogenesis and function 
Most miRNAs are transcribed by RNA polymerase II from intergenic, intronic or polycistronic 
loci to long primary transcripts (pri-miRNAs). Pri-miRNAs are processed sequentially first in 
the nucleus by the Drosha–DGCR8 complex to approximately 70 nt pre-miRNA hairpin 
structures and then in the cytoplasm by the Dicer–TRBP complex to approximately 22 nt 
miRNA duplexes. In addition to the canonical miRNA biogenesis pathway, many Drosha-
DGCR8-independent pathways can produce pre-miRNAs. The most common alternative 
pathway involves short intronic hairpins that are spliced and debranched to form pre-miRNA 
hairpins. In the cytoplasm, miRNA duplexes are incorporated into an Argonaute protein-
containing miRNA-induced silencing complex (miRISC), followed by unwinding of the duplex 
and retention of the mature miRNA strand in miRISC, while the complementary strand is 
released and degraded. Recent work has identified a battery of proteins that regulate 
processing – positively or negatively – either by interacting with Drosha or Dicer or by 
binding to miRNA precursors. Although the activity of some of the regulators is restricted to 
specific miRNA families, most affect the processing of a broader range of miRNA 
precursors, suggesting that their activity can affect the expression of entire gene networks. 
One such miRNA-specific regulator is LIN28A and its paralog LIN28B that affect pri- and 
pre-let-7 levels by sequence-specific interaction and subsequent blocking of processing or 
pre-miRNA degradation (see above). 109 
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Figure 1.4: Canonical and non-canonical miRNA biogenesis pathways. In the canonical pathway, 
microRNAs (miRNAs) are typically transcribed by RNA polymerase II to produce primary miRNA (pri-miRNA) 
hairpins, which are then processed by the Drosha–DGCR8 (DiGeorge syndrome critical region 8) complex to 
generate precursor miRNAs (pre-miRNAs). These molecules are transported by exportin 5 into the cytoplasm, 
where they are further processed by Dicer–TRBP (TAR RNA-binding protein 2) and loaded into Argonaute 2 
(AGO2)-containing RNA-induced silencing complexes (RISCs) to suppress downstream target gene expression. 
miRNAs are also produced though non-canonical pathways, such as spliceosome-dependent mechanisms, as 
shown here. The miRNA biogenesis pathway is a tightly regulated process. For example, Drosha is dependent 
on phosphorylation by glycogen synthase kinase 3β (GSK3β) for proper nuclear localization168; Drosha 
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regulates DGCR8 expression by suppressing DGCR8 mRNA20; DGCR8 stabilizes Drosha protein20; AGO2 is 
hydroxylated by C-P4H169 and phosphorylated by MAPK-activated protein kinase 2 (MAPKAPK2)170, which 
stabilizes the protein and regulates its localization to processing bodies (P-bodies); and TRBP is stabilized by 
extracellular signal-regulated kinase 1 (ERK1) or ERK2 phosphorylation25. miRNAs themselves are regulated by 
a number of modifications, including uridylation (Ud)171. [From Li, Z. and Rana, T. M. Nat Rev Drug Discov 
(2014), Figure 1 109] 
Upon processing, the miRNA incorporated in the miRISC acts as a guide and leads the 
miRISC to mRNA transcripts with complementary sequences in their 3' untranslated region 
(3'UTR). The miRISC may affect its target genes in two non-mutually exclusive ways: 
repression of translation and degradation of the mRNA. 110 Experimental bioinformatics 
approaches have shown that the major determinant of target recognition by a miRNA is the 
perfect or nearly perfect complementarity between the proximal 5' region of the miRNA, the 
so-called seed, and the mRNA. 111 The region in the 3'UTR of the target gene that is 
complementary to the miRNA seed, comprising nucleotides 2 to 7 of the miRNA, is called 
the miRNA recognition element and may exhibit different degrees of complementarity with 
the miRNA seed. 112 Bioinformatics algorithms designed to detect potential mRNA targets of 
miRNAs suggest that a single miRNA can regulate up to 200 coding genes. 113 In total, more 
than 60% of the protein coding fraction of the genome is under the influence of one or more 
miRNAs. 114 Of these, only a minor portion of target genes is so far confirmed by 
experimental research. The verified target genes are often involved in signal transduction 
pathways that are essential for the proper homeostasis of all cell types. As such, they are 
amongst others involved in regulation of differentiation, control of cell proliferation and 
apoptosis, which are important processes in cancer. 
Deregulated miRNA expression in cancer 
In 2004, Calin and colleagues found that more than half of miRNA genes, known at that 
time, are located at cancer-associated genomic regions or in fragile sites. 115 It can be 
assumed that genes – or ncRNAs – located in cancer-associated genomic regions 
contribute to the development of cancer. For instance, 13q14 deletions are observed in 50% 
of patients with chronic lymphocytic leukemia (CLL), suggesting that one or more genes in 
this locus play a key role in the pathogenesis of CLL. 116 However, for long, a causal gene 
contributing to CLL could not be identified. The breakthrough came with the discovery that 
two miRNAs, miR-15 and miR-16, reside in this genomic locus and that both miRNAs are 
downregulated in the majority of CLL cases. 116 Several research groups confirmed these 
results and pointed to the involvement of these and other miRNAs in various tumor 
entities. 117-119 Besides the location at cancer-associated genomic regions, aberrant miRNA 
expression in tumors can arise from additional mechanisms, including perturbed 
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transcriptional regulation, defects in miRNA-processing machinery and mutations in miRNA 
genes and miRNA binding sites within target genes. 120 As transcription of miRNA genes 
occurs in a similar fashion as regular gene transcription, the mechanisms leading to 
perturbed expression of coding genes also apply to miRNAs: a deregulated balance of 
activating and repressing transcription factors, such as p53 or MYC(N) (see below) and 
altered epigenetic regulation, such as DNA and histone modifications (reviewed in 121) can 
lead to aberrant miRNA expression. Downstream of miRNA transcription, defects in miRNA 
processing machinery can further contribute to perturbed miRNA profile. Somatic and germ-
line mutations in DICER1, TARBP2 – part of the Dicer-containing complex – or EXPO5 – 
which mediates the nuclear export of pre-miRNAs – result in impaired miRNA maturation in 
different tumor entities. 122%124 Finally, genetic variations within miRNA binding sites can 
modulate gene expression and protein output levels and affect phenotypes or cause 
disease. 125,126 
The importance of miRNA function and dysfunction in various cancer entities suggest that 
modulation of miRNA expression may serve as a novel therapeutic modality for these 
malignancies. 109 
miRNAs in cancer therapy 
The research community has turned towards the implementation of miRNAs in cancer 
therapy for several reasons. Conventional chemotherapy is known to induce severe 
cytotoxicity in normal dividing cells. The targeted therapies that were developed in an 
attempt to circumvent this general cytotoxicity, can display off-target effects (small molecule 
inhibitors), might be difficult to deliver to tumor cells (monoclonal antibodies) and are 
confronted with secondary mutations rendering a tumor insensitive to the administered 
drug. 127 In this respect, there are two major advantages in using miRNAs in cancer therapy: 
first, miRNAs occur as “natural” molecules produced in human cells, showing reduced 
immune response and low toxicity when compared to protein-based drug molecules 127, and 
second, they can target multiple genes from the same pathway and therefore they can act at 
multiple levels in the same pathway, significantly reducing the development of resistance 
because multiple mutations in multiple genes would be needed. 128 
In using miRNAs as cancer therapeutics, there are two main strategies that can be followed: 
restoring the miRNAs that are downregulated – with miRNA mimics or miRNAs encoded in 
expression vectors – and silencing the miRNAs that are upregulated – via miRNA sponges, 
small molecule inhibitors and antisense oligonucleotides. 109,128 In 2013, MRX34, a miRNA 
therapeutic, has entered clinical trials for cancer therapy. MRX34 is a liposome-formulated 
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mimic of the tumor suppressor miR-34, and has been developed in a clinical phase 1 trial for 
patients with advanced or metastatic liver cancer. 129 
Several problems encountered in clinical development of miRNA delivery, however, limit the 
further application of miRNAs as a therapeutic option to treat cancer 127: the penetration of 
miRNAs into tumor tissues is modest due to mechanical and biological barriers, miRNAs still 
have some potential to induce immunotoxicity, and unmodified miRNA antagonists and 
miRNA mimics are quickly degraded and cleared in the blood circulation, and are associated 
with off-target effects of miRNAs. Therefore, several chemical modifications that can 
enhance the stability of miRNA modulators and improve the target specificity and systemic 
delivery efficacy, are currently under development. 109,127 
miRNAs in neuroblastoma 
A number of expression profiling studies have demonstrated dysregulation of miRNAs in 
neuroblastoma. During the last decade, distinct miRNAs were shown to be differentially 
expressed in favorable versus unfavorable tumor subtypes 130, in MYCN amplified 
neuroblastoma versus non-amplified cases 131,132 and low-risk versus high-risk tumors 133%135. 
Interestingly, a significant number of dysregulated miRNAs in neuroblastoma now appear to 
be transcriptional targets of MYCN 133,136, suggesting that regulation of these miRNAs could 
serve as an additional mechanism for MYCN-induced transcriptional changes. A more global 
study of miRNAs in neuroblastoma observed that MYCN/MYC signaling, rather than MYCN 
amplification alone, underlies the differential expression of miRNAs in neuroblastoma. 
Furthermore, MYCN/MYC activated miRNAs contribute to widespread transcriptional 
repression, in contrast to MYCN/MYC downregulated miRNAs that were not associated with 
transcriptional activation. 133 However, also global miRNA downregulation by MYC activation 
was previously reported to significantly contribute to tumorigenesis. 137 
In follow-up of some of the abovementioned profiling studies, interesting candidates were 
further studied for their involvement in neuroblastoma biology. The two most commonly 
reported miRNAs are miR-34a-5p and the miR-17-92 cluster. The miR-17-92 cluster was 
among the first miRNAs to be validated as showing oncogenic potential. The precursor 
transcript derived from the mir-17-92 gene contains six tandem stem-loop hairpin structures 
that ultimately yield 12 mature miRNAs: miR-17-5p, -17-3p, -18a-5p, -18a-3p, -19a-3p, -19a-
5p, -20a-5p, -20a-3p, -19b-3p, -19b-1-5p, -92a-3p, and -92a-1-5p. Amplification or 
overexpression of this locus was observed in different cancer entities 138%140 and its role in 
oncogenesis was further substantiated when MYC proteins were shown to directly activate 
the cluster, inducing high miR-17-92 expression in MYC(N) activated tumors and cell lines, 
30 Chapter 1 
 
including neuroblastoma. 64,133,141,142 Being a MYCN target gene, the miR-17-92 cluster was 
found to be overexpressed in unfavorable 131 and MYCN amplified 143,144 neuroblastoma 
tumors. Overexpressing the miR-17-92 cluster in a MYCN non-amplified neuroblastoma cell 
line led to increased tumorigenicity in vitro and in vivo. 143 Furthermore, in vitro or in vivo 
inhibition of miR-17-5p abolishes the growth of MYCN amplified and therapy-resistant 
neuroblastoma through de-repression of CDKN1A and BCL2L11, leading to cell cycling 
blockade and activation of apoptosis, respectively. In line with this observation, the majority 
of primary neuroblastoma tumors show a rise of miR-17-5p level leading to CDKN1A 
repression, which is particularly severe in patients with MYCN amplification and poor 
prognosis. 144 Interestingly, Kumps and colleagues 145 found a focal 5 kb genomic gain 
encompassing the miR-17-92 cluster as sole affected gene, in a neuroblastoma cell line. 
Furthermore, they demonstrated that focal genomic losses in MYCN amplified tumors harbor 
miR-17-92 target genes. These observations suggest that focal genomic aberrations in 
MYCN amplified neuroblastoma tumors reinforce MYCN oncogene addiction by altering the 
expression of direct and indirect MYCN target genes. 145 
miR-34a-5p, another extensively studied miRNA in neuroblastoma, is located on 1p36, a 
region often deleted in high-risk neuroblastoma tumors. Consequently, miR-34a-5p is 
expressed at lower levels in primary tumors with a hemizygous deletion of the mir-34a locus 
compared with those without a 1p36 deletion. 146 miR-34a-5p is a direct transcriptional target 
of p53 147 and contributes to p53-mediated apoptosis via repression of BCL2, SYT1, STX1A, 
E2F3 and MYCN 148. In line with the great potential of miRNAs as cancer therapeutics, 
Tivnan and colleagues 149 demonstrated that in vivo delivery of nanoparticles encapsulating 
miR-34a results in significantly decreased tumor growth, increased apoptosis and a 
reduction in vascularization. These nanoparticles were conjugated to an antibody directed 
against GD2, a glycolipid highly expressed on the cell surface of neuroblastoma and several 
other cancers 150; this facilitated tumor-specific delivery following systemic administration into 
tumor bearing mice. The authors further establish a novel, multi-step molecular mechanism 
by which miR-34a-5p leads to increased levels of TIMP2, an inhibitor of matrix 
metalloproteinases, accounting for the highly reduced vascularization noted in miR-34a-5p-
treated tumors. 149 
Additional miRNAs downregulated in neuroblastoma tumors include miR-27b-3p 151, 
miR-29a-3p, miR-29b-3p, and miR-29c-3p 152, miR-128-3p 153, miR-137 154, miR-145-5p 155, 
miR-149-3p 156, miR-200b-3p 157, miR-204-5p 158 and miR-542-3p 159. 
Introduction 31 
 
Further understanding the mechanisms by which MYCN alters the expression of miRNAs, 
and through which targets and pathways deregulated miRNAs may subsequently contribute 
to oncogenic transformation in aggressive neuroblastoma, will possibly explain missing 
molecular links in the pathogenesis of this disease, and further elucidate how oncogenic 
MYCN signaling is executed.  
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Since its identification in neuroblastoma, increasing evidence points towards a central role 
for MYCN in the biology of neuroblastoma tumors. As a consequence, targeting MYCN and 
its downstream functions would be a promising strategy to treat neuroblastoma patients. 
However, the development of inhibitors targeting MYC proteins has been challenging, as 
MYC/MYCN proteins are composed of two extended alpha-helices with no obvious surfaces 
for small molecule binding. Therefore, a thorough understanding of MYCN's functions and 
the upstream mechanisms regulating its expression would contribute to the development of 
compounds specifically targeting the impact of MYCN in neuroblastoma cells. 
To address this issue, I initiated this thesis with the construction of an in vivo time-resolved 
miRNA and gene expression dataset of MYCN-driven neuroblastoma development, using 
the well-established TH-MYCN mouse model. After extensive validation of the dataset, I 
applied an exiting transcriptome-wide cross-species approach to search for transcriptional 
regulators that can be regarded as master regulators of neuroblastoma development 
(chapter 3, paper 1). The corresponding miRNA expression dataset was exploited during 
the characterization of the complete MYCN-miRNA interactome in neuroblastoma using the 
powerful combination of this dataset and an unbiased 3'UTR reporter screen (chapter 4, 
paper 2). In chapter 5 (i.e. paper 3), I next characterized how MYCN affects the expression 
of LIN28B, a highly conserved RNA-binding protein, which is shown to induce MYCN 
expression in neuroblastoma via the suppression of the MYCN-targeting let-7 family of 
miRNAs. 
Throughout this project, studying the genetic landscape of the well-established TH-MYCN 
mouse model has provided great insights in the perturbed miRNA-mRNA networks in 
neuroblastoma. Although representing an excellent and broadly used tool, this mouse model 
holds some limitations related to the transgene integration site, the anatomical location of 
the observed tumors, implementation of in vivo imaging and tumor incidence in different 
genetic backgrounds. In chapter 6 (i.e. paper 4), we therefore present a novel mouse model 
with targeted Cre-conditional MYCN expression in the neural crest.  
Comparing the implications of perturbed MYCN activity in this new mouse model with similar 
insights obtained from ALK- or LIN28B-driven mouse tumors or the insights obtained from 
chapter 3, could contribute to a more thorough understanding of both common and different 
effects of these important neuroblastoma oncogenes in the biology of this embryonic tumor.  
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Abstract 
Neuroblastoma is a childhood malignancy with high clinical and genetic heterogeneity. At 
least half of aggressive neuroblastoma tumors are characterized by MYCN amplification. 
MYCN is a MYC family member and has also been reported to be amplified or 
overexpressed in other embryonal tumor such as medulloblastoma as well as adult cancers 
including lung cancer (ref). Until recently, targeted drugging of MYC(N) driven tumor entities 
was beyond reach but novel insights into gene regulation and MYC(N) mode of action are 
now opening the way for precision medicine. Discovering additional key interactors and 
vulnerable nodes in the MYCN network will further contribute to our understanding of 
neuroblastoma etiology and hence the development of efficient targeted therapy for patients 
facing aggressive neuroblastoma. To this end, we explored the dynamic transcriptional 
changes in MYCN-driven tumor development using an established MYCN neuroblastoma 
mouse model. Integrative cross-species data-analysis of the developmental gene signatures 
revealed a total of 22 master regulators and 16 synergistic master regulator pairs involved in 
MYCN-driven neuroblastoma development. Further characterization of these master 
regulators and their regulated neuroblastoma signatures, highlighted MYB, E2F2, MXD3, 
EZH2 and PLAGL2 as key master regulators of both MYCN-driven and MYCN-independent 
neuroblastoma development. Finally, we showed that synergistic master regulator pairs are 
associated with patient survival and constitute promising targets for combination therapy. 
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Introduction 
Neuroblastoma is a deadly childhood cancer arising from sympatho-adrenergic nervous 
progenitor cells 1. The neuroblastoma genomic landscape is dominated by DNA copy 
number alterations while mutational burden is very low, as observed in other embryonal 
tumors. In addition to highly recurrent whole chromosome and segmental chromosomal 
imbalances, MYCN amplification is observed in a substantial proportion of cases and marks 
poor prognosis. Rare amplifications allowed to uncover two further bona fide oncogenes 
implicated in this disease, namely ALK 2-5 and LIN28B 6. Both genes are part of 
developmental regulatory pathways and were shown to activate MYC(N) activity through 
distinct mechanisms 6,7. For each of these driver genes, transgenic mouse models have 
reinforced the causal relationship between aberrant overexpression or somatic mutation and 
neuroblastoma tumor development. In addition, the established mouse models have been – 
and continue to be – of great value to the study of neuroblastoma tumor biology and the 
development of new therapeutic strategies.  
The identification of neuroblastoma driver genes and their study in preclinical models has 
lead to the execution of phase 1 clinical trials testing the safety and clinical activity of 
compounds targeting ALK 8,9 or MYCN 10. Regardless of these encouraging findings, intrinsic 
and acquired resistance almost inevitably occurs when using single compound treatment, 
warranting the exploration of opportunities for rationally designed combinatorial treatment 
approaches. While second generation ALK inhibitors are now emerging and insights into 
down stream signaling is growing 11, allowing further design of optimized drugging, interest 
for uncovering further venues to drug MYCN or MYCN governed regulatory pathways is a 
strongly emerging focus of research.  
While MYCN clearly plays a central role in neuroblastoma initiation and progression, both its 
exact mode of action and the critically involved regulatory partners are still under intensive 
investigation 12. Recently, the Califano team developed an algorithm coined the MAster 
Regulator INference algorithm (MARINa) 13,14, in order to identify so-called master 
regulators. While this is an ill defined term 15, the concept used here is that master regulators 
act as transcriptional regulators controlling the regulation of multiple genes in a given gene 
signature of biological or clinical significance. These master regulators are positioned at the 
top of the regulatory network in the given gene signature and, as such, could constitute 
vulnerable drugable targets. In this study, we assembled gene signatures reflecting MYCN-
driven neuroblastoma development using dynamic gene expression data from murine 
MYCN-driven neuroblastoma tumorigenesis, and screened for cooperating master 
regulators in neuroblastoma development using MARINa. Using this approach, we identified 
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five core master regulators, MYB, E2F2, MXD3, EZH2 and PLAGL2. Our approach thus 
unraveled for the first time a unique network of master regulators offering the basis for 
further research to explore novel approaches to drug the MYCN governed oncogenic 
regulatory network in neuroblastoma. 
Results 
Composing the hyperplasia dataset reflecting gene expression alterations 
during neuroblastoma development 
To gain insight in neuroblastoma development, we performed gene expression profiling of 
different stages of tumor development in the TH-MYCN mouse model, a MYCN-driven 
neuroblastoma model 16. In brief, we sacrificed TH-MYCN+/+ mice at one (n = 4) and two 
weeks (n = 4) after birth to harvest superior cervical and celiac ganglia containing foci of 
neuroblast hyperplasia, and 6-week old (n = 4) TH-MYCN+/+ mice to dissect advanced 
neuroblastoma tumors, arisen from the neuroblast hyperplasia 17. Additionally, we dissected 
the superior cervical and celiac ganglia from TH-MYCN-/- mice at one (n = 4), two (n = 4) 
and six weeks (n = 4) after birth to control for gene expression changes during normal 
postnatal development of the sympathetic ganglia. We assayed each individual harvested 
sample with a murine-specific gene expression microarray. 
To obtain a global view of the gene expression patterns in these samples, principal 
component analysis was performed and the first and second principal component were 
plotted (Figure 3.1a). The first principal component showed a strong genotype effect and 
accounted for 43.2% of data variability, while the second principal component showed a 
strong time effect and accounted for an additional 18.7% of data variability. This 
representation thus shows the main variability of mRNA expression levels of all samples. 
The first time point (1 week after birth) from both genotypes (TH-MYCN+/+ and TH-MYCN -/-
) map together implying that the overall changes of the transcriptome in this set of samples 
were comparable with the average variability between biological replicates. At later time 
points (2 and 6 weeks after birth), the overall changes of the transcriptome increase relative 
to the average variability between replicates and both genotypes cluster further apart, 
suggesting strong transcriptional differences between neuroblastoma tumors and normal 
ganglionic tissue. Indeed, as time progresses and as can be expected, an increasing 
number of genes are significantly differentially expressed between TH-MYCN+/+ and TH-
MYCN-/- samples (Supplemental Figure 3.1a). 
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Figure 3.1. Characterization of the hyperplasia dataset. (a) Principal component analysis visualizes the 
variation in the hyperplasia dataset. The vertical axis corresponds to the first principal component of the mRNA 
data, mainly discriminating genotypes, and the horizontal axis shows the second principal component, primarily 
discriminating age of mice. (b) The expression of candidate neuroblastoma oncogenes (!) and tumorsuppressor 
genes (") in the hyperplasia dataset. Each instance in the heatmap represents mean expression of 4 samples. 
(c) Signature score analysis of MYCN activity in the hyperplasia dataset. Data represent mean signature score ± 
standard deviation of 4 samples. Y-axis represents arbitrary units. Black: TH-MYCN+/+ samples; gray: TH-
MYCN-/- samples. P-value corresponds to the interaction term of a two-way ANOVA analysis. (d) Signature 
score analysis of late neuronal sympathetic differentiation (19) in the hyperplasia dataset. Data represent mean 
signature score ± standard deviation of 4 samples. Y-axis represents arbitrary units. Black: TH-MYCN+/+ 
samples; gray: TH-MYCN-/- samples. P-value corresponds to the interaction term of a two-way ANOVA analysis. 
To validate the biological relevance of the hyperplasia dataset for the study of 
neuroblastoma tumor biology, we first evaluated the expression of known neuroblastoma 
oncogenes and tumor suppressor genes in the hyperplasia dataset. The expression of 
known oncogenes increased, whereas the expression of known tumor suppressor genes 
decreased over time in the TH-MYCN+/+ samples compared to TH-MYCN-/- samples 
(Figure 3.1b). Subsequently, we assessed the expression of known MYC(N) transcriptional 
target genes 18 in the hyperplasia dataset, summarized in a MYCN activity score.  
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Figure 3.2. Strategy for genome-wide cross-species analysis of neuroblastoma development. Schematic 
representation of the overall strategy. (a) Step I: delineation of murine neuroblastoma signatures via clustering of 
gene expression data from the hyperplasia dataset with Self Organizing Maps. (b) Step II: construction of a 
human neuroblastoma-specific interactome. (c) Step III: identification of master regulators of neuroblastoma 
development using the murine neuroblastoma development signatures and a human neuroblastoma-specific 
interactome. Step I and III were iterated 100 times to ensure robust master regulator analysis. 
The MYCN activity score increased significantly over time in the TH-MYCN+/+ samples 
compared to TH-MYCN-/- samples (Figure 3.1c). This observation is in keeping with the 
hypothesis that sustained MYCN activity in the sympathetic ganglia of TH-MYCN+/+ mice 
gives rise to the appearance of neuroblastoma tumors in these anatomic locations 17. 
Furthermore, genes involved in late neuronal sympathetic differentiation 19, summarized in a 
late neuronal sympathetic differentiation activity score, decreased significantly over time in 
the TH-MYCN+/+ samples compared to TH-MYCN-/- samples (Figure 3.1d), implying that 
late neuronal sympathetic differentiation markers are suppressed during neuroblastoma 
development. Together these observations indicate that we have generated a highly 
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valuable transcriptome dataset reflecting gene expression alterations during MYCN-driven 
neuroblastoma development. 
Inferring master regulators of MYCN-driven neuroblastoma development 
Having established a highly valuable transcriptome dataset reflecting gene expression 
alterations during MYCN-driven neuroblastoma development, we next set out to identify 
master regulators of MYCN-driven neuroblastoma development. To this end, we first 
constructed neuroblastoma development signatures through clustering of genes in the 
hyperplasia dataset in 12 distinct gene signatures according to similar gene expression 
patterns using Self-Organizing Maps (SOM) (Figure 3.2a and Supplementary Figure 3.2). 
To identify master regulators of these neuroblastoma development signatures, we used the 
MARINa algorithm, which identifies candidate master regulators based on the concerted 
differential expression of their targets genes 13,14. To allow for this analysis, we constructed a 
human neuroblastoma-specific interactome using ARACNe (Figure 3.2b). ARACNe is an 
unbiased algorithm that infers direct transcriptional interactions based on the mutual 
information between transcriptional regulators and their potential targets, based on gene 
expression profiles. To assemble a human neuroblastoma-specific interactome, we analyzed 
the gene expression in a large heterogeneous cohort of primary neuroblastoma tumors (n = 
200), enabling optimal ARACNe analysis. This resulted in a regulatory network representing 
371,783 interactions between 601 transcriptional regulators and their inferred target genes 
(Figure 3.2b). Thus having established the murine neuroblastoma development signatures 
and the human neuroblastoma-specific interactome, we screened the 601 transcriptional 
regulators for their putative role as master regulator of neuroblastoma development, with the 
MARINa algorithm (Figure 3.2c). To ensure robust identification of master regulators of 
neuroblastoma development, we iterated the process of signature generation (Figure 3.2a) 
and master regulator inference (Figure 3.2c) 100 times (see Materials and Methods). 
Finally, we retained all master regulators that were inferred for neuroblastoma development 
signatures with a significant increasing or decreasing activity during murine neuroblastoma 
development, as measured with two-way ANOVA with interaction of the activity score in the 
hyperplasia dataset (see Materials and Methods). 
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Figure 3.3. Master regulator analysis of neuroblastoma development. (a) Percentage of gene signatures 
with increasing or decreasing pattern in neuroblastoma development, for which master regulators were inferred. 
Fisher's Exact test, p < 2.2 x 10-16. (b) Results of 100 iterations of gene expression clustering with self-organizing 
maps and subsequent master regulator analysis (including shadow and synergism analysis; see Materials and 
methods). In total, 22 master regulators were identified in at least 1 SOM analysis (left). Black circles indicated 
master regulators that are not associated with patient survival (see panel d). The majority of master regulators 
were found to regulate 1/12 gene signatures per SOM analysis (right). (c) Kaplan-Meier survival analysis based 
on gene expression levels of MYB, E2F2, MXD3, EZH2 or PLAGL2 in a large cohort of primary neuroblastoma 
patients with respect to time to cancer-specific death (two-sided log rank test). (d) Number of master regulators 
or non-master regulator transcriptional regulators tested in the master regulator analysis (non-master regulator), 
that are associated with patient survival. FDR value corresponds to a log-rank test with Benjamini-Hochberg 
multiple testing correction. Fisher's Exact test, p = 6.6 x 10-8.  
The constructed neuroblastoma development signatures were highly similar across the 100 
iterations (Supplementary Figure 3.3). In each of the 100 iterations, on average 11/12 gene 
signatures (range: 9 - 12) showed significant differential activity between TH-MYCN+/+ and 
TH-MYCN-/- mice: on average 4.4 signatures (range: 4 - 5) showed increasing and 6.6 
signatures (range: 5 - 8) decreasing activity. In each of the 100 iterations, on average 3.2 
increasing gene signatures (range: 2 - 4) and 0.8 decreasing gene signatures (range: 0 - 2) 
were found to be significantly regulated by master regulators (Figure 3.3a). Thus, master 
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regulators were more likely to be inferred from gene signatures with increasing gene 
signature scores during murine neuroblastoma development. 
In total, 22 distinct master regulators could be inferred for at least one neuroblastoma 
development signature in at least one iteration (Figure 3.3b and Supplementary Table 
3.1). These master regulators were either activated (n = 15) or repressed (n = 7): activated 
master regulators have induced and repressed target genes significantly enriched among 
up- and downregulated genes in the neuroblastoma development signatures, respectively, 
while repressed master regulators show the opposite pattern. We focused our subsequent 
analysis on the master regulators that were inferred as regulators of neuroblastoma 
development in at least half of the 100 iterations, each of which is an activated master 
regulator: MYB, E2F2, MXD3, EZH2 and PLAGL2. We next asked whether expression of 
these master regulators is associated with neuroblastoma progression and/or outcome by 
analysis of gene expression in our neuroblastoma patient cohort. Of the five retained master 
regulators, high expression of four master regulators was significantly associated with 
adverse outcome of neuroblastoma patients (Figure 3.3c). Notably, the five master 
regulators were more likely to be associated with disease outcome, as assessed by a log-
rank test, than transcriptional regulators not inferred as master regulators (Figure 3.3d). 
Thus, genome-wide cross-species integrative transcriptome analysis identified master 
regulators of MYCN-driven neuroblastoma development of potential clinical relevance.  
MYB, E2F2 and EZH2 are MYCN-regulated master regulators 
Given that the five master regulators were inferred as regulators of MYCN-driven 
neuroblastoma development signatures, we set out to investigate the relation between the 
expression levels of MYCN and each of the master regulators. To this end, we evaluated the 
gene expression of the master regulators as well as their ARACNe-inferred transcriptional 
activity in different neuroblastoma models. In the TH-MYCN mouse model, the mRNA 
expression and inferred activity of each of the five master regulators increased significantly 
during MYCN-driven tumor development (Figure 3.4a-b). These observations were 
confirmed in a second, independent, murine MYCN-driven neuroblastoma model, the LSL-
MYCN;Dbh-iCre model 20 as four out of five master regulators were found to be higher 
expressed and all five master regulators had higher inferred transcriptional activity in tumors 
as compared to normal adrenal tissue (Supplementary Figure 3.4). 
To verify that the increased expression of MYB, E2F2, MXD3, EZH2 and PLAGL2 in these in 
vivo models is a direct consequence of increased MYCN activity, we evaluated their 
expression in public data of an in vitro model of MYCN activity in neuroblastoma 21. 
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Figure 3.4. Characterization of identified master regulators. (a) Expression of MYB, E2F2, MXD3, EZH2 or 
PLAGL2 in the hyperplasia dataset. Data represent mean gene expression ± standard deviation of 4 samples. 
Black: TH-MYCN+/+ samples; gray: TH-MYCN-/- samples. P-value corresponds to the interaction term of a two-
way ANOVA analysis. (b) Signature score analysis of inferred master regulator activity in the hyperplasia dataset. 
Data represent mean signature score ± standard deviation of 4 samples. Y-axis represents arbitrary units. Black: 
TH-MYCN+/+ samples; gray: TH-MYCN-/- samples. P-value corresponds to the interaction term of a two-way 
ANOVA analysis. (c) Expression of MYB, E2F2, MXD3, EZH2 or PLAGL2 upon MYCN silencing in SHEP-
Tet21N cells. Asterisk indicates significant differential expression before and after MYCN silencing (paired T-test; 
P < 0.05). 
The SHEP-Tet21N system is a conditional tetracycline-regulated MYCN expression system 
established in the MYCN non-amplified SHEP neuroblastoma cell line 22. Expression of 
MYCN is switched off by the addition of tetracycline to the growth medium. Levels of MYCN 
protein and RNA in the absence of tetracycline are comparable with those present in MYCN 
amplified cell lines 23. We observed a significant decrease in the expression of MYB, E2F2 
and EZH2 upon silencing of MYCN, while the expression of MXD3 and PLAGL2 did not 
change significantly (Figure 3.4c). Together these in vivo and in vitro data demonstrate that 
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MYCN could induce the expression of MYB, E2F2 and EZH2 in neuroblastoma cells. These 
data further show that MXD3 and PLAGL2 are up-regulated during murine MYCN-driven 
neuroblastoma development; however, these data do not provide evidence that this is a 
direct consequence of MYCN activity. 
Having studied the relationship between MYCN and the five master regulators, we also 
assessed whether the master regulators were of clinical relevance for all neuroblastoma 
patients irrespective of MYCN amplification status. To this end, we evaluated the mRNA 
expression levels of the master regulators as well as their ARACNe-inferred transcriptional 
activity in our neuroblastoma patient cohort. For 3 master regulators (E2F2, EZH2 and 
PLAGL2), the observed clinical impact was independent of MYCN amplification status since 
high expression of these master regulators was associated with worse outcome in a 
subgroup of patients without MYCN amplification (Supplementary Table 3.2). Moreover, for 
all five master regulators high ARACNe-inferred transcriptional activity was associated with 
worse outcome in a subgroup of patients without MYCN amplification (Supplementary 
Table 3.2). Thus, cross-species master regulator analysis revealed master regulators 
regulating both MYCN-driven and MYCN-independent neuroblastoma development 
MYB, E2F2, MXD3, EZH2 and PLAGL2 regulate cancer-related biological 
processes 
To gain insight into the inferred master regulators and their regulated neuroblastoma 
development signatures, we subsequently focused on one representative iteration, i.e. 
iteration 31 (Supplementary Figure 3.3). Here, MYB, E2F2, MXD3, EZH2 and PLAGL2 
were inferred for three gene signatures with increasing activity during neuroblastoma 
development (Supplementary Table 3.1); no master regulators for gene signatures with 
decreasing activity were found. To attain deeper knowledge of the biological processes that 
are regulated by the inferred master regulators, we performed Gene Ontology (GO) 
enrichment analysis of the neuroblastoma development signatures constructed in iteration 
31. GO enrichment analysis of gene signatures with increasing activity during 
neuroblastoma development revealed an overrepresentation of genes involved in DNA 
metabolism (DNA replication and repair), RNA metabolism (transcription, RNA processing 
and splicing) and cell cycle regulation, while genes involved in immune response and 
translation were overrepresented in gene signatures with decreasing activity 
(Supplementary Figure 3.5). In line with these observations, the ARACNe-inferred target 
genes of the five master regulators were enriched for genes involved in biological processes 
similar to those enriched in their regulated gene signatures (Figure 3.5): the targets of  
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Figure 3.5. Results from Gene Ontology enrichment analysis of the three neuroblastoma development gene 
signatures in iteration 31 and of the ARACNe-inferred master regulator regulons. Black boxes represent 
significant enrichment of the GO term (right), in the respective gene signature or regulon (top). 
MXD3, master regulator of neuroblastoma development signature 3, were enriched for 
genes involved in DNA metabolism; while the targets of MYB, E2F2, EZH2 and PLAGL2, 
master regulators of signature 10, were enriched for genes involved in RNA metabolism.  
Synergistic master regulator pairs are associated with patient survival 
We further prioritized the five master regulators by computationally evaluating their potential 
synergistic interactions. In particular, any pair of master regulators was considered 
‘‘synergistic’’ if their co-regulated MARINa-inferred targets were more significantly enriched 
in the co-regulated neuroblastoma development signature than their individual targets 14. 
Among all possible pairs of inferred master regulators, two pairs were statistically significant: 
MYB-PLAGL2 and E2F2-PLAGL2 (Figure 3.6a and Supplementary Table 3.3). 
To more thoroughly investigate the role of these synergistic master regulators pairs in 
neuroblastoma development, we performed patient survival analysis to assess the potential 
impact of co-alterations in gene pairs. In this analysis, each gene has one of two states: 
"high" if the gene in the sample is expressed at a high level relative to the average level of 
the gene across all samples; and "low" if the gene is expressed at a low level. For each 
synergistic master regulator pair, we examined each of four scenarios, namely, "high-high", 
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"high-low", "low-high" and "low-low". By comparing the survival time of patients with high 
expression of both genes to survival time of patients with high expression of only one gene, 
we found that for both synergistic master regulator pairs, combined high expression of both  
master regulators was associated with worse outcome of neuroblastoma patients (Figure 
3.6b). This property is independent of the MYCN amplification status since the association 
was also discovered in MYCN non-amplified patients. Notably, the observed association 
between patient outcome and co-alterations in synergistic master regulator pairs is 
significant compared to the association between patient outcome and the co-alteration of 
random selected pairs of transcriptional regulators not inferred as  master regulators of 
neuroblastoma tumor development (data not shown). These data indicate that information 
on synergistic master regulator pairs can be useful for risk assessment and outcome 
prediction of neuroblastoma patients. 
Discussion 
We have identified MYB, E2F2, MXD3, EZH2 and PLAGL2 as master regulators of MYCN-
driven neuroblastoma development through genome-wide cross-species integrative 
transcriptome analysis. The MARINa algorithm 13,14 used for these analyses infers master 
regulators as genes that most significantly regulate the transcriptional program associated 
with a particular phenotype – in this case, neuroblastoma development.  
Using GO enrichment analysis of master regulator-regulated genes, we showed that the 
inferred master regulators control cancer-related biological processes. The targets of MXD3 
were enriched for genes involved in DNA metabolism (i.e. DNA replication and repair); while 
the targets of MYB, E2F2, EZH2 and PLAGL2 were enriched for genes involved in RNA 
metabolism (i.e. transcription, (m)RNA processing and RNA splicing), chromosome 
organization and mitotic cell cycle. These processes closely relate to the biological 
processes overrepresented in genes that are required for MYCN-driven neuroblastoma cell 
proliferation: transcription, cell cycle, and apoptosis 24. This concordance supports the 
hypothesis that the inferred Master regulators strongly contribute to, and could be necessary 
for, MYCN-driven neuroblastoma development. 
Interestingly, the MARINa algorithm also provides an effective computational tool for the 
identification of synergistic interactions among master regulators. Indeed, our unbiased 
interrogation of 602 transcriptional regulators represented in the human neuroblastoma-
specific interactome, led to identification of two synergistic master regulator pairs.  
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Figure 3.6. Synergistic master regulator pairs are associated with patient survival. (a) Computational 
synergy analysis depicting PLAGL2 and MYB regulons (left) and PLAGL2 and EF2E regulons (right) showing 
shared and nonshared targets. Red corresponds to overexpressed targets and blue to underexpressed targets in 
the hyperplasia dataset; NES = normalized enrichment score; FDR = false discovery rate. (b) Kaplan-Meier 
survival analysis based on combined gene expression levels of PLAGL2 and MYB (left) and PLAGL2 and E2F2 
(right) in a large cohort of primary neuroblastoma patients with respect to time to cancer-specific death (two-sided 
log rank test). (c) Kaplan-Meier survival analysis based on combined gene activity of PLAGL2 and MYB (left) and 
PLAGL2 and E2F2 (right) in a large cohort of primary neuroblastoma patients with respect to time to cancer-
specific death (two-sided log rank test). 
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Both identified synergistic master regulator pairs involved PLAGL2, a ubiquitously expressed 
C2H2 zinc finger transcription factor that is involved in cellular transformation and apoptosis, 
and has been reported to have both oncogenic and tumor suppressor functions. PLAGL2 
was shown to increase proliferation in acute myeloid leukemia in cooperation with the CBFB-
MYH11 fusion gene 25. Further, in glioblastoma, PLAGL2 expression suppressed cellular 
differentiation and promoted cellular capacity for self-renewal by activating the Wnt/β-catenin 
pathway 26. In contrast, under hypoxic conditions or in response to or iron deficiency, 
PLAGL2 may have an apoptotic role via induction of the pro-apoptotic factor BNIP3 by 
promoter activation 27. The data presented here suggest an oncogenic function for PLAGL2 
in neuroblastoma development. Moreover, we hypothesize that PLAGL2 and its the 
synergistic partners, E2F2 and MYB, may act together to execute (some of) their functions in 
neuroblastoma development. While these master regulators have been implicated in various 
cancers, their synergistic actions have been identified here for the first time. The underlying 
biological mechanism resulting in these in silico observed cooperation events can not be 
deduced from our data, warranting further experiments to elucidate the biological 
cooperation of these synergistic master regulator pairs. Putative mechanistic models include 
co-localization at promoters of target genes and / or functional cooperativity as co-repressor 
or -activator. In analogy with similar studies in other tumor entities 14,28, we anticipate that the 
combined therapeutic targeting of synergistic master regulators may help to overcome the 
complex feedback mechanisms that hinder therapeutic targeting of signaling pathways. 
Both MYB and E2F2 have previously been associated to neuroblastoma tumor biology, 
validating the findings of our strategy. MYB is a transcription factor with a well-established 
role in hematopoiesis, and its oncogenic activation is associated with leukaemogenesis in 
several species including humans. A key function of MYB in these processes is to maintain 
the proliferative progenitor-cell phenotype, whereas its downregulation is necessary for 
differentiation 29. Similar functions for MYB were reported in neuroblastoma cells, where the 
expression of MYB declined during retinoic-acid induced maturation 30. Moreover, it was 
recently shown that MYCN overexpressing neuroblastoma cells are strongly dependent on 
high MYB levels to sustain their proliferative state. Upon MYB knock down, MYCN 
overexpressing cells displayed massive apoptosis, while non-MYCN overexpressing cells 
were unaffected 24. Previously, MYBL2 (alias B-MYB), a MYB family member, was shown to 
be necessary for proliferation of neuroblastoma cells with MYCN amplification 31. In addition, 
the same study showed that MYBL2 and MYCN act in a reciprocal regulatory loop, 
enhancing each others expression levels and maintaining the proliferative state of 
aggressive neuroblastoma cells. Here, we showed that MYCN induces the expression of 
MYB in the SHEP-Tet21N model system, which explains increasing MYB expression levels 
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during neuroblastoma development in the TH-MYCN mouse model. Both the addiction of 
MYCN overexpressing cells to MYB, and the involvement of MYB in the maintenance of 
proliferative state of neuroblastoma cells, are in keeping with our identification of MYB as an 
master regulator of MYCN-driven neuroblastoma development, and support the validity of 
our approach. 
E2F2 belongs to a family of cell-cycle regulated transcription factors that stimulate 
proliferation. The activating members of the E2F family – E2F-1, E2F-2, and E2F-3 – 
regulate MYCN transcription and are required for full activity of the MYCN promoter in 
neuroblastoma cells 32. In addition, E2F2 and its family member E2F3 are required for MYC 
to induce S phase in quiescent fibroblasts 33. Finally, MYC in turn was shown to induce 
transcription of the activating members of the E2F family, E2F-1, E2F-2, and E2F-3 33, 
forming yet another positive feedback loop between MYCN and an inferred master regulator 
of MYCN-driven neuroblastoma development. 
Finally, also for the two remaining inferred master regulators, MXD3 and EZH2, evidence 
exists for a contributing role to neuroblastoma development. EZH2, a histone–lysine 
methyltransferase, is the enzymatically active component of the Polycomb Repressor 
Complex 2 (PRC2) that catalyzes the addition of methyl groups to histone 3 at lysine 27 
(H3K27me2/me3), a well-known histone mark associated with gene silencing. In line with 
our identification of EZH2 as master regulator of neuroblastoma development, high EZH2 
expression levels have been associated with poor outcome of neuroblastoma patients 34. 
Moreover, silencing of EZH2 inhibited neuroblastoma cell growth and induced neuronal 
differentiation in KCNR cells 34. In the same study, EZH2 was found to silence a number of 
tumor suppressors which control differentiation in neuroblastoma, such as CLU, RUNX3, 
and NGFR 34. Notably, in our study, we identified EZH2 as an master regulator of genes 
activated – rather than repressed – during neuroblastoma development. Indeed, apart from 
the canonical role of EZH2 as a transcriptional repressor, recent literature reports highlight 
its less-known function as a transcriptional activator (reviewed in 35). In castration resistant 
prostate cancer cells, AKT1 mediated phosphorylation of EZH2 allows EZH2 to methylate 
the transcriptional activator AR (androgen receptor) and interact with it to induce gene 
expression 36. In breast cancer cells, EZH2 has been reported to induce gene transcription in 
two different ways depending on the ESR1 (estrogen receptor) status. In ESR1-positive 
breast cancer cells, EZH2 acts as a bridge to physically link ESR1 and Wnt signaling 
components CTNNB1 (β-catenin) and LEF1, on the CCNB1 (cyclin B1) and MYC 
promoters 37. EZH2 further also interacts with Mediator complex and induces transcription by 
its interaction with RNA polymerase II. In ESR1-negative breast cancer cells, EZH2 forms a 
ternary complex with NF-κB components RELA and RELB and activates transcription of NF-
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κB target genes such as TNF and IL6 38. Although EZH2 has been reported to silence the 
expression of a number of genes in neuroblastoma cells, it is not unlikely that in addition to 
is repressor activity, EZH2 can also act as a transcriptional activator in neuroblastoma. In 
order to gain insight in the mode of action of EZH2 in neuroblastoma cells, additional 
experiments are required, at least including whole-transcriptome gene expression profiling 
upon EZH2 perturbation. 
MXD3 is a member of the MYC/MAX/MAD superfamily of basic helix-loop-helix leucine 
zipper transcriptional regulators to which MYCN also belongs. Both MYC (MYC, MYCN, 
MYCL) and MAD (MXD1, MXI1, MXD3, MXD4) proteins form heterodimers with the cofactor 
MAX thereby permitting binding to specific DNA sequences known as E-boxes in target 
gene promoters 39. These MYC/MAX or MAD/MAX DNA-bound heterodimers respectively 
recruit coactivator or corepressor complexes that generate alterations in chromatin structure 
and transcriptional activity 39. Members of the MAD family have been shown to induce cell 
cycle arrest, inhibit proliferation and promote differentiation in cell lines and in transgenic 
mice 40. Together, these and other studies have led to the “switch” model in which 
MAD/MAX complexes antagonize MYC/MAX complexes to regulate the transition between 
proliferation and differentiation 41,42. Several reports, however, suggest that MXD3 is an 
atypical member of the MAD family. Mice with a targeted deletion of Mxd3 showed a mild 
phenotype consisting of increased sensitivity to apoptosis in response to DNA damage 43. In 
the developing mouse embryo, Mxd3 is only expressed during the S-phase of the cell cycle 
while the remaining Mad genes are expressed in postmitotic cells 44. Moreover, MXD3 
appears to be an important regulator of Shh-dependent GNP proliferation and MYCN 
expression, an unexpected role for a MAD family member 45. Finally, MXD3 is expressed in 
medulloblastoma cells, where, intriguingly, sustained high levels of the protein negatively 
influence proliferation by the induction of programmed cell death 46. These observations are 
in line with our identification of MXD3 as a master regulator of neuroblastoma development 
and warrant the further exploration of MXD3 in the context of neuroblastoma. 
Notably, MYCN itself was not inferred as an master regulator of the defined neuroblastoma 
development signatures, although these signatures have been established through analysis 
of a MYCN-driven neuroblastoma mouse model. We believe it is not unlikely that the large 
group of MYCN target genes, involved in the execution of MYCN's pleiotropic functions, is 
distributed across different neuroblastoma development signatures, each of which 
encompassing a subgroup of MYCN target genes involved in distinct MYCN functions. This 
would indeed result in a lack of overrepresentation of MYCN target genes in one particular 
neuroblastoma development signature, as observed in our study. 
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Thus, our approach unraveled for the first time a unique network of master regulators 
offering the basis for further research to explore novel approaches to drug the MYCN 
governed oncogenic regulatory network in neuroblastoma. Cumulatively, our findings 
suggest that co-expression of PLAGL2 and MYB or E2F2 in neuroblastoma leads to co-
regulation of transcriptional programs, which ultimately contributes to neuroblastoma 
development. Although our findings need wet-lab confirmation, we speculate that therapeutic 
targeting of these synergistic master regulator pairs will contribute to the regression of 
MYCN-driven neuroblastoma tumors. However, because transcription factors mediate their 
action largely through protein-protein and protein-DNA interactions rather than enzymatic 
activities, they have been traditionally been regarded as undruggable targets. Another 
challenge of inhibiting transcription factors is their predominant nuclear localization, which 
makes them less accessible to therapeutic agents. Despite these obstacles, there have 
been numerous advances in the development of both pharmacologic agents and delivery 
strategies to specifically target cancer cells 47. Potential strategies include inhibition of 
expression via RNA interference or perturbation of regulator microRNAs, targeting protein 
maturation and stability, interference of protein-protein or protein-DNA interactions by 
oligonucleotide decoys, and altering the chromatin accessibility via, for example, 
bromodomain inhibitors 47. 
Materials and methods 
TH-MYCN neuroblastoma progression model 
TH-MYCN+/+ mice 16 were sacrificed at day seven (n = 4) and day fourteen (n = 4) of life to 
harvest sympathetic ganglia containing foci of neuroblast hyperplasia, and at week 6 of life 
to harvest advanced neuroblastoma tumors (n = 4). Additionally, we have dissected the 
same sympathetic ganglia from TH-MYCN-/- mice at day seven (n = 4), day fourteen (n = 4) 
and week 6 (n = 4) of life to control for miRNA expression changes during normal 
development. Murine total RNA was isolated using the miRNeasy Mini Kit (Qiagen, 217004) 
according to the manufacturer’s instructions. The samples were profiled on Agilent SurePrint 
G3 Gene Expression Microarrays according to the manufacturer’s protocol. Data were 
summarized and normalized with the vsn method 48, in the R statistical programming 
language using the limma package. Probes with a log2 expression of less than 4 in more 
than 20/24 samples were considered not expressed and filtered out. Additionally, for each 
unique gene symbol, only the probe with the most significant differential expression between 
TH-MYCN+/+ and TH-MYCN-/- samples (two-way ANOVA, p-value of interaction term) was 
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retained for further analysis. Microarray profiling results for all samples are available in the 
ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-
3247. Furthermore, the processed data can be visualized via the R2 microarray analysis and 
visualization platform (http://r2.amc.nl) under experiment "Exp Nb Hyperplasia TH-MYCN - 
Ghent - 28 - custom - agmge8x60".  
Delineation of murine neuroblastoma development signatures 
Murine gene expression profiles were clustered using SOM. To this end, per gene, the 
average group expression was calculated for each of the six sample groups: WT.1week, 
WT.2weeks, WT.6weeks, TG.1week, TG.2weeks and TG.6weeks (WT = TH-MYCN-/-; TG = 
TH-MYCN+/+). With the resulting dataset containing average gene expression of 17185 
genes in 6 groups, SOM analysis was performed with a 3x4 rectangular grid. Subsequently, 
a value representing the differential gene expression in TH-MYCN+/+ and TH-MYCN-/- 
samples over time, was assigned to each gene in each cluster. To this end, for each gene, a 
two-way ANOVA assessing the interaction between the genotype and the age of the mice, 
was performed. Subsequently, the resulting p-value and estimate of the interaction term 
were combined into one π-value per gene as follows: π = - log10(P) x estimate. While 
performing 100 iterations of the described SOM analysis, a new random seed was set prior 
to each analysis to ensure random iterations. Randomness was verified by visual inspection 
of the profiles of the 100 x 12 SOM clusters. Gene signatures with a significant differential 
gene signature score during murine neuroblastoma development were retained for further 
analysis. gene signature scores were calculated as described elsewhere 19 and two-way 
ANOVA was applied to assess the interaction between the genotype and the age.  
Human neuroblastoma expression dataset  
In total, 200 primary tumor samples of neuroblastoma patients were collected prior to 
therapy at the Ghent University Hospital (Ghent, Belgium), the University Children’s Hospital 
Essen (Essen, Germany), the Hospital Clínico Universitario (Valencia, Spain), the Academic 
Medical Center (University of Amsterdam, Netherlands) and the National Children's 
Research Centre (Dublin, Ireland). Informed consent was obtained from the patients’ 
relatives. Total RNA was isolated using the miRNeasy Mini Kit (Qiagen, 217004) according 
to the manufacturer’s instructions. The samples were profiled on Affymetrix Human Exon 1.0 
ST Microarrays according to the manufacturer’s protocol. Exon level expression was 
recovered using Affymetrix power tools 1.10.0. Expression data from 113 samples is 
available at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo; Accession 
Numbers GSE32664 & GSE21713).  
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Assembly of a human neuroblastoma-specific interactome 
The human neuroblastoma-specific interactome was assembled by analyzing the 
aforementioned human neuroblastoma expression dataset with the ARACNe algorithm 49, 
which is available in geWorkbench v2.5.1. A custom list of HUB markers was provided to the 
algorithm. To this end, a total of 718 well-characterized sequence-specific TFs were 
retrieved from Vaquerizas et al. 50, of which 601 were expressed in the aforementioned 
human neuroblastoma expression dataset. In addition, the following parameters were used: 
Mode = "Complete", Algorithm = "Adaptive Partitioning", Threshold Type = "P-Value 0.01, 
Corrected by # of Markers", DPI Tolerance = "Do Not Apply", Bootstrap Number = 1.  
Master Regulator Analysis  
Master regulator analysis was performed using the MARINa algorithm 13,14 available as an R 
script from bioconductor in the VIPER package 51. The default parameters were applied. 
Upon master regulator analysis, shadow analysis was performed on significantly enriched 
master regulators to correct for regulon overlap, a frequent event in mammalian networks 
13,52 leading to false-positive master regulator inference. Indeed, if the regulons of an master 
regulator and of a non-master regulator gene overlapped significantly, then the latter would 
also be enriched in the tested gene signature, yielding a false positive master regulator. 
These regulators – shadow regulators – can be identified and removed by determining 
whether their enrichment is significantly reduced when shared targets are disregarded. 
Finally, synergism analysis was performed on true master regulators (further referred to as 
master regulator), not being a shadow of any other master regulator. Shadow and synergism 
analysis are described in detail elsewhere 14 and are available as an R script in the VIPER 
package 51. 
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Supplementary Figure 3.2. Representative example of clustering of genes in the hyperplasia dataset in 12 
distinct gene signatures according to similar gene expression patterns using Self-Organizing Maps (SOM). Green 
and red lines represent gene expression in TH-MYCN-/- and TH-MYCN +/+ mice samples respectively., in 
function of age. 
 
2 
1 2 3 4
5 6 7 8
9 10 11 12
0
5
10
15
0
5
10
15
0
5
10
15
2 4 6 2 4 6 2 4 6 2 4 6
age (weeks)
ex
pr
es
sio
n (
log
2)
genotype
TH−MYCN
wild−type
Supplementary Figure 2 
Supplementary Figure 2. Representative example of clustering of genes in the 
hyperplasia dataset in 12 distinct gene signatures according to similar gene 
expression patterns using Self-Organizing Maps (SOM). Green and red lines represent 
gene expression in TH-MYCN-/- and TH-MYCN +/+ mice samples respectively., in function of 
age. 
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Supplementary Figure 3.3. Comparison of 100 SOM analyses clustering the hyperplasia gene expression data 
set. The heatmap represent the average Jacquard score (between 0 and 1) for each pairwise comparison of the 
12 clusters in the 100 iterations. Iteration 31, which considered to be a representative iteration, is highlighted with 
a black arrow. 
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Supplementary Figure 3 
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Supplementary Figure 3. Comparison of 100 SOM analyses clustering the hyperplasia 
gene expression data set. The heatmap represent the average Jacquard score (between 0 
and 1) for each pairwise comparison of the 12 clusters in the 100 iterations. Iteration 31, 
which considered to be a representative iteration, is highlighted with a black arrow. 
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Supplementary Figure 3.4. MR mRNA expression (a) and ARACNe-inferred transcriptional MR activity (b) in 
the LSL-MYCN;Dbh-iCre mouse model.  
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transcriptional MR activity (b) in the LSL-MYCN;Dbh-iCre mouse model.  
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Supplementary Figure 3.5. Overview of enriched biological processes in the 12 distinct neuroblastoma 
development gene signatures from iteration 31. Blue and black squares represent significant enrichment of the 
GO term (right), in the respective gene signature (top). For three genes signature (blue) independent MRs could 
be inferred. 
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Supplementary Figure 5. Overview of enriched biological processes in the 12 distinct 
neuroblastoma development gene signatures from iteration 31. Blue and black squares 
represent significant enrichment of the GO term (right), in the respective gene signature (top). 
For three genes signature (blue) independent MRs could be inferred. 
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Supplementary Figure 3.6. Co-alterations of synergistic MR pairs are significantly associated with clinical 
outcome in neuroblastoma patients. (a) Kaplan–Meier curves of overall survival in patients with high E2F2 
expression, high PLAGL2 expression or both (two-sided log rank test). (b) Kaplan–Meier curves of overall 
survival in patients with high MYB expression, high PLAGL2 expression or both (two-sided log rank test). (c) 
Kaplan–Meier curves of overall survival in patients without MYCN amplification (MNSC), with high E2F2 
expression, high PLAGL2 expression or both (two-sided log rank test). (d) Kaplan–Meier curves of overall 
survival in patients without MYCN amplification (MNSC), with high MYB expression, high PLAGL2 expression or 
both (two-sided log rank test). (e) Kaplan–Meier curves of overall survival in patients with high or low E2F2 - 
PLAGL2 activity as measured by a signature score of the genes co-regulated by E2F2 and PLAGL2 (two-sided 
log rank test). (f) Kaplan–Meier curves of overall survival in patients with high or low MYB - PLAGL2 activity as 
measured by a signature score of the genes co-regulated by MYB and PLAGL2 (two-sided log rank test).  
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Supplementary Figure 5. Co-alterations of synergistic MR pairs are significantly 
ass ciated with clinical outcome in neuroblast ma patients. (a) Kaplan–Meier curves of 
overall survival in patients with high E2F2 expression, high PLAGL2 expres ion or both (two-
sided log rank test). (b) Kaplan–Meier curves of overall survival in patients with high MYB 
expression, high PLAGL2 expression or both (two-sided log rank test). (c) Kaplan–Meier 
curves of overall survival in patients without MYCN amplification (MNSC), with high E2F2 
expression, high PLAGL2 expression or both (two-sided log rank test). (d) Kaplan–Meier 
curves of overall survival in patients without MYCN amplification (MNSC), with high MYB 
expression, high PLAGL2 expres ion or both (two-side log rank test). (e) Kaplan–Meier 
curves of overall survival in patients with high or low E2F2 - PLAGL2 activity as measured by 
a signature score of the genes co-regulated by E2F2 and PLAGL2 (two-sided log rank test). 
(f) Kaplan–Meier curves of overall survival in patients with high or low MYB - PLAGL2 activity 
as measured by a signature score of the genes co-regulated by MYB and PLAGL2 (two-
sided log rank test).  
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Abstract 
MYCN is a transcription factor that plays key roles in both normal development and cancer. 
In neuroblastoma, MYCN acts as a major oncogenic driver through pleiotropic effects 
controlled by multiple protein encoding genes as well as microRNAs (miRNAs). MYCN 
activity is tightly controlled at the level of transcription and protein stability through various 
mechanisms. Like most genes, MYCN is further controlled by miRNAs, but the full 
complement of all miRNAs implicated in this process has not been determined through an 
unbiased approach. To elucidate the role of miRNAs in regulation of MYCN, we thus 
explored the MYCN-miRNA interactome to establish miRNAs controlling MYCN expression 
levels. We combined results from an unbiased and genome-wide high-throughput miRNA 
target reporter screen with miRNA and mRNA expression data from patients and a murine 
neuroblastoma progression model. We identified 29 miRNAs targeting MYCN, of which 12 
miRNAs are inversely correlated with MYCN expression or activity in neuroblastoma tumor 
tissue. The majority of MYCN-targeting miRNAs in neuroblastoma showed a decrease in 
expression during murine MYCN-driven neuroblastoma tumor development. Therefore, we 
provide evidence that MYCN-targeting miRNAs are preferentially downregulated in MYCN-
driven neuroblastoma, suggesting that MYCN negatively controls the expression of these 
miRNAs, to safeguard its expression. 
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Introduction 
MYCN acts as a major driver oncogene in neuroblastoma, a pediatric tumor of the 
sympathetic nervous system. Genomic amplification of this gene occurs in about half of all 
high-stage neuroblastoma tumors and has been associated with poor survival. As such, 
MYCN amplification has been used as one of the first biomarkers for therapeutic decision-
making.  
MYC proto-oncogenes (MYC, MYCN, MYCL) are transcription factors that play key roles in 
both normal development and cancer. The MYC proteins act as direct amplifiers of 
transcriptionally active genes through sequence-specific binding to consensus E-box DNA 
binding sites 1-3. In addition, MYC proteins can also silence genes, by a mechanism that is 
uncoupled from E-box binding and dependent upon initiator elements in the basal promoter 
region 1,4. Apart from the broad impact on transcriptional regulation of protein coding genes, 
MYCN has also been shown to tightly control the expression of many microRNAs (miRNAs) 
1,5. 
Numerous signal transduction pathways and regulatory mechanisms keep the expression of 
MYC family members under tight control. This regulation occurs at multiple levels, including 
gene transcription, messenger RNA (mRNA) turnover, and protein activity and stability 1-3. 
miRNAs have also been shown to contribute to the regulation of MYC expression 2,3. 
miRNAs are involved in the regulation of virtually all signaling circuits within a cell, and their 
dysregulation has been shown to play an essential role in the development and progression 
of cancer 6,7. This class of small non-coding RNA molecules typically inhibits the translation 
and stability of mRNA molecules and thus eventually controls protein levels. 
In previous studies, individual miRNAs targeting MYCN have been identified, using miRNA 
target reporter assays to confirm predicted miRNA target sites in the 3' untranslated region 
(3'UTR) of MYCN 3,8. Eleven MYCN-targeting miRNAs have thus been identified, of which 
miR-34a, miR-101, let-7e and miR-202 were shown to affect neuroblastoma proliferation in 
vitro 3,8. Although the applied approach is valuable, it is biased towards canonical miRNA-
mRNA interactions, identified by available prediction algorithms.  
Here, we performed a comprehensive, genome-wide exploration of the miRNA-MYCN 
interactome in neuroblastoma. We combined results from an unbiased and genome-wide 
high-throughput miRNA target reporter screen with miRNA and mRNA expression data from 
patients and identified 12 MYCN-targeting miRNAs in neuroblastoma tumor tissue. 
Subsequently, the dynamic regulation of MYCN-targeting miRNAs during neuroblastoma 
development was evaluated in a murine neuroblastoma progression model. We provide 
evidence that MYCN targeting miRNAs are preferentially downregulated in MYCN-driven 
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neuroblastoma tumors, suggesting that MYCN negatively controls the expression of these 
miRNAs, and as such safeguards its own expression. Hence, our findings further clarify the 
role of miRNAs in the regulation of MYCN in neuroblastoma and describe a negative 
feedback loop from MYCN to its targeting miRNAs. 
Results 
An unbiased MYCN 3’UTR-miRNA library screen identifies 29 miRNAs 
targeting MYCN.  
Potential interactions of 470 miRNAs with the 3'UTR of MYCN were assayed in a high-
throughput luciferase reporter screen. In brief, human embryonic kidney cells (HEK293T) 
were co-transfected with a reporter construct, containing the MYCN 3’UTR downstream of a 
luciferase reporter gene, and each of the individual miRNA mimics from a 470 miRNA mimic 
library. Based on the relative luciferase activities in two independent screens 
(Supplementary Figure 4.1), an interaction score was calculated for each miRNA-MYCN 
combination (see Material and Methods). This effort was part of a large-scale 3'UTR 
screening in which the interactions of 470 miRNAs with 17 selected cancer- and disease-
associated genes were probed (Van Peer et al., submitted). 
Applying this strategy, we identified 29 miRNAs with a high probability of targeting MYCN 
(interaction score < -1.94; see Material and Methods; Figure 4.1a, Figure 4.2a and 
Supplementary Table 4.6). All 11 previously established miRNA-MYCN interactions 3,8 
were validated in our screen (Figure 4.1a). In the same studies, 9 miRNAs predicted to 
target MYCN could not be validated; this is now confirmed by our data. Additionally, 18 new 
MYCN targeting miRNAs were identified, of which only 2 are predicted to target MYCN by 
MirTarget2, underscoring the value of this screening method to detect novel, predicted as 
well as non-predicted, miRNA-target gene interactions. The top 5 miRNAs (miR-449b-5p, 
miR-767-5p, miR-98-5p, let-7b-5p and let-7f-5p) not reported in literature were validated by 
demonstrating rescue of reporter gene downregulation upon mutation of potential binding 
sites (Van Peer et al., submitted). Among the strongest hits in the screen, a significant 
enrichment was observed for both miRNAs with seed-matched sites present in the MYCN 
3‘UTR (Figure 4.1b) and MirTarget2 (Supplementary Figure 4.2) predicted miRNAs, thus 
further underscoring the sensitivity and robustness of the screen.  
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Figure 4.1: An unbiased MYCN 3’UTR-miRNA library screen identifies 29 miRNAs potentially targeting 
MYCN. (a) Average interaction scores are plotted (Y-axis) for 470 tested miRNAs (X-axis). The 29 miRNAs with 
an interactions core of < -1.94 are listed in Figure 4.2A. The 11 interactions that have been reported in literature, 
are indicated in black. (b) Cumulative distributions (Y-axis) of the interaction scores (X-axis) of miRNAs that 
respectively have 6-, 7- or 8-mer seed-matches in the MYCN 3'UTR.  
Integration of 3'UTR-miRNA library screen and patient expression data 
identifies 12 MYCN-targeting miRNAs in neuroblastoma. 
miRNAs are known to regulate their target genes in a highly tissue- and cell type specific 
manner 9. As the MYCN 3'UTR-miRNA library screen was performed in HEK293T cells, we 
next aimed to specifically select miRNAs targeting MYCN in neuroblastoma cells by 
integrating the obtained screen results with miRNA expression data from primary 
neuroblastoma tumors. We reasoned that the expression of a targeting miRNA is inversely 
correlated to MYCN mRNA expression levels or MYCN activity in primary tumor samples. 
Assuming that miRNAs would have more impact on MYCN expression levels and activities 
in MYCN non-amplified cells, we chose to assess miRNA correlations with MYCN mRNA 
levels and activity only in this tumor subset to infer a potential regulatory relationship.  
Correlation to MYCN mRNA expression 
Overall, MYCN targeting miRNAs showed stronger inverse correlation to MYCN mRNA 
levels compared to non-targeting miRNAs (Figure 4.2b), as indicated by a shift of the 
cumulative distribution of -values (-log10 p-value x Pearson correlation coefficient) to more 
negative values. Of the 25 MYCN-targeting miRNAs that were included on the human 
miRNA expression platform, 8 miRNAs showed statistically significant inverse correlation to 
MYCN mRNA expression, suggesting that they can indeed downregulate MYCN expression 
in primary MYCN non-amplified tumors. 
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Figure 4.2: Integration of 3'UTR-miRNA library screen and patient expression data identifies 12 MYCN-
targeting miRNAs in neuroblastoma. (A) MYCN targeting miRNAs are filtered for their relevance in 
neuroblastoma according to two criteria: significant negative correlation to MYCN expression in a MYCN non-
amplified neuroblastoma patient cohort and negative enrichment for MYC(N) gene sets, using Gene Set 
Enrichment Analysis. 12/29 miRNAs match with at least one of these criteria and are considered to be relevant 
for neuroblastoma. n.s.: not significant (Spearman correlation, Benjamini & Hochberg multiple testing corrected 
p-value > 0.05); n.d.: no data available. (B) The cumulative distribution (Y-axis) of the π-value for the correlation 
between miRNA and MYCN expression (X-axis) of miRNAs that were identified as either MYCN-targeting (black) 
or not MYCN-targeting (gray). Kolmogorov-Smirnov test, p-value = 1.4 x 10-3. (C) 2x2 contingency table for 
negative enrichment of MYC(N) gene sets of MYCN-targeting and other miRNAs. Chi-Square test. 
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Three miRNAs were positively correlated to MYCN expression. Two of these miRNAs, 
miR-19a-3p and miR-19b-3p, are part of the oncogenic miR-17-92 cluster and were already 
known to be directly induced by MYCN in neuroblastoma cells 10. 
Correlation to MYCN activity 
miRNAs are known to regulate their targets by inducing mRNA destabilization and 
translational inhibition. Assessing the correlation between miRNA and MYCN mRNA levels, 
however, will not identify potential regulatory effects at protein level. Therefore, we 
additionally evaluated which miRNAs are inversely correlated to MYCN activity as a 
surrogate for MYCN protein levels. MYCN activity is reflected in the expression of MYCN 
regulated genes and can be assessed using Gene Set Enrichment Analysis (GSEA) 11. In 
brief, for each miRNA, mRNAs were ranked according to decreasing expression correlation 
in MYCN non-amplified neuroblastoma tumors. Subsequently, GSEA was performed using 
six selected gene sets of MYC(N) upregulated genes 12-17 (see Materials and Methods). A 
miRNA negatively correlated to MYCN protein levels – and thus activity – is expected to be 
negatively correlated to genes that are positively regulated by MYCN. In this case an 
enrichment of MYCN upregulated genes can be expected among the most negatively 
correlated genes at the bottom of the ranked list. Here, a miRNA was considered to be 
negatively correlated to MYCN activity in case such negative enrichment could be observed 
for at least one MYC(N) gene set (normalized enrichment score < -2 and false discovery 
rate < 0.25). As expected, the MYCN-targeting miRNAs identified in the 3'UTR-miRNA 
library screen were significantly enriched for miRNAs that showed negative enrichment for at 
least one MYC(N) gene set and thus for miRNAs that are negatively correlated to MYCN 
activity (Figure 4.2c). Of the 25 MYCN-targeting miRNAs that were included on the human 
miRNA expression platform, 11 miRNAs showed this inverse relation to MYCN activity, 
whereas 6 miRNAs showed a positive relation to MYCN activity (Figure 4.2a, 
Supplementary Table 4.7). 
In summary, 12 of 29 MYCN-targeting miRNAs were inversely correlated to either MYCN 
expression or MYCN activity in MYCN non-amplified tumor samples, and therefore likely 
regulate MYCN in neuroblastoma (Figure 4.2a, Table 4.1).  
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Figure 4.3: Overview of results from different analyses. Numbers listed represent the number of miRNAs. 
(A) Of 470 screened miRNAs, 29 miRNAs interact with the 3’UTR of MYCN. (B) Of these 29 miRNAs, 25 
miRNAs could subsequently be analyzed in primary neuroblastoma tumors: 12 miRNAs are inversely correlated 
to MYCN expression or activity, whereas 5 miRNAs are positively correlated to MYCN expression or activity. (C) 
Of the 12 miRNAs inversely correlated to MYCN expression or activity, 10 miRNAs are downregulated during 
MYCN-driven tumor development in the TH-MYCN mouse model, 9 miRNAs are lower expressed in LSL- 
MYCN;Dbh-iCre tumors compared to wild-type adrenals, and 2 miRNAs are repressed upon induction of MYCN 
in the SHEP-MYCN-ER model system. On the other hand, of the 5 miRNA correlated to MYCN expression or 
activity, 3 miRNAs are upregulated during MYCN- driven tumor development in the TH-MYCN mouse model, 
these miRNAs are also higher expressed in LSL-MYCN;Dbh-iCre tumors compared to wild-type adrenals, and 3 
miRNAs are induced upon induction of MYCN in the SHEP-MYCN-ER model system.  
Interestingly, 5 MYCN-targeting miRNAs were positively correlated to MYCN expression or 
activity (Figure 4.2a), suggesting that MYCN induces their expression in neuroblastoma. 
One miRNA, miR-34b-5p, shows both negative correlation to MYCN mRNA levels and 
positive correlation to MYCN activity (Figure 4.2a) and is therefore excluded from further 
analyses. 
miRNAs that regulate MYCN are downregulated during murine MYCN-driven 
neuroblastoma tumor formation. 
In a next step, we explored how expression levels of miRNAs that target MYCN are 
dynamically regulated during MYCN-driven tumor formation. To this end, we performed 
miRNA expression profiling of the TH-MYCN mouse model, a murine MYCN-driven 
neuroblastoma progression model 18. In brief, we sacrificed TH-MYCN+/+ mice one and two 
weeks after birth to harvest superior cervical and celiac ganglia containing foci of neuroblast 
hyperplasia, and 6-week old TH-MYCN+/+ mice to dissect advanced neuroblastoma tumors, 
arising from the neuroblast hyperplasia 19.  
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Figure 4.4: miRNAs that regulate MYCN are downregulated during murine MYCN-driven neuroblastoma 
tumor formation. (a) The MYCN miRNA signature score, representing expression of known MYC(N)-regulated 
miRNAs, increases during neuroblastoma progression in ganglia from TH-MYCN mice (TG, black) compared to 
ganglia from wild-type mice (WT, gray dashed). Data are presented as mean ± standard deviation of four 
samples. (b) Heatmap of average miRNA expression levels during murine MYCN-driven neuroblastoma 
development. Data are presented as row normalized. TG: transgenic; WT: wild-type; ∆ slope: the difference in 
regression slope between TG and WT samples; n.s.: non-significant difference (Benjamini & Hochberg multiple 
testing corrected p-value > 0.05). (c) The 12 MYCN-targeting miRNAs in neuroblastoma show significantly more 
downregulation during MYCN-driven tumor development, compared to non-targeting miRNAs. Kolmogorov-
Smirnov test, p-value = 9.2 x 10-3. (d) Heatmap of miRNA expression levels in 11 LSL-MYCN;Dbh-iCre tumors 
and 5 normal adrenals. For miR-29c-3p and -34a-5p, no expression data was available; miR-98-5p was not 
expressed in LSL-MYCN;Dbh-iCre tumors. Data are presented as row normalized. gray: no data available. FC: 
log2 fold change; n.d.: no data available; n.s.: non-significant fold change (Student T-test, Benjamini & Hochberg 
multiple testing corrected p-value > 0.05). 
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Additionally, we dissected the superior cervical and celiac ganglia from TH-MYCN-/- mice 
one, two and six weeks after birth to control for miRNA expression changes during normal 
postnatal development of the sympathetic ganglia. In the following analyses we only 
considered those murine miRNA assays that target sequences similar to the sequences of 
the human miRNAs included in our 3’UTR-miRNA library screen (n = 187, Supplementary 
Table 4.6). To validate this MYCN-driven neuroblastoma progression model, we evaluated 
the expression of 50 known MYC(N)-regulated miRNAs 5, summarized in a MYCN signature 
score. This MYCN signature score increases significantly throughout tumor progression from 
tumor-prone ganglia to tumors in transgenic mice, compared to wild-type ganglia (Figure 
4.3a and Supplementary Figure 4.3). This observation is in keeping with the hypothesis 
that sustained MYCN activity in the sympathetic ganglia of homozygous transgenic mice 
gives rise to the appearance of neuroblastoma tumors in these anatomic locations 19. 
The majority of the MYCN-targeting miRNAs in neuroblastoma (10 out of 12) showed a 
significantly decreased expression during tumor development in TH-MYCN+/+ mice 
compared to normal development, while 2 of them showed no significantly different 
expression pattern (Figure 4.3b, Table 4.1). Interestingly, of the 5 MYCN-targeting miRNAs 
with positive correlation to MYCN expression or activity, 3 miRNAs, miR-19a-3p, miR-19b-3p 
and miR-494-3p, showed significantly increased expression during tumor development 
(Figure 4.3b), further supporting the hypothesis that MYCN induces the expression of these 
miRNAs. The 2 remaining positively correlated miRNAs, miR-34c-5p and miR-449a, are, 
respectively, significantly downregulated and not regulated during tumor development 
(Figure 4.3b). Overall, the 12 MYCN-targeting miRNAs in neuroblastoma, show significantly 
more downregulation during MYCN-driven tumor development, compared to non-targeting 
miRNAs, as indicated by a shift of the cumulative distribution of the -values (-log10 p-
value x ∆ slope) to more negative values (Figure 4.3c). 
The above findings could be confirmed in an additional, recently developed, MYCN-driven 
neuroblastoma mouse model, the LSL-MYCN;Dbh-iCre mouse model 20. All 9 MYCN-
targeting miRNAs that could be evaluated are significantly lower expressed in 
LSL-MYCN;Dbh-iCre tumors compared to wild-type adrenals (Figure 4.3d, Table 4.1). 
Considering the 5 MYCN-induced miRNAs, the data in the LSL-MYCN;Dbh-iCre tumors 
again fully recapitulated the findings from the TH-MYCN progression model: miR-19a-3p, 
miR-19b-3p and miR-494-3p showed increased expression in tumors compared to wild-type 
control 
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Figure 4.5: Induction of MYCN activity is associated with altered expression levels of particular miRNAs 
that target its 3'UTR. Summary of significantly differentially expressed miRNAs upon MYCN induction relative to 
control treatment (Student t-test, Benjamini & Hochberg multiple testing corrected p-value < 0.05). Data are 
represented in a horizontal bar graph as log 2 fold changes ± standard error of the mean (5 biological replicates). 
tissue (Figure 4.3d), whereas miR-34c-5p and miR-449a are respectively significantly 
downregulated and not regulated in LSL-MYCN;Dbh-iCre tumors. 
MYCN can directly modulate the expression levels of particular miRNAs that 
target its 3'UTR. 
In a final step, we explored to what extent MYCN directly controls, as transcriptional 
activator and repressor, the expression levels of the 12 selected MYCN-targeting miRNAs. 
To this end we measured miRNA expression levels in a MYCN-inducible model system. Two 
out of 12 MYCN-targeting miRNAs in neuroblastoma (Figure 4.2a), miR-29a-3p and miR-
29b-3p, showed significant reduction in expression 48h after MYCN activation (Figure 4.4, 
Table 4.1).  
Of the five MYCN-targeting miRNAs with positive correlation to MYCN expression or activity 
(Figure 4.2a), three miRNAs, miR-19b-3p, miR-19a-3p and miR-34c-5p, showed induction 
of expression (Figure 4.4), supporting the assumption that MYCN induces the expression of 
these miRNAs. 
Discussion 
Previous studies have highlighted the importance of miRNAs in the regulation of MYCN, a 
major driver oncogene in neuroblastoma. Nonetheless, a comprehensive, genome-wide 
exploration of the miRNA-MYCN interactome has not yet been performed. Thus far, studies 
have only focused on individual miRNAs or a small subset of miRNAs predicted to target 
MYCN by algorithms that are biased towards the limited knowledge of miRNA binding site 
architecture. Here, we report on the first  unbiased and genome-wide high-throughput 
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miRNA target reporter screen to identify miRNAs targeting MYCN. From the total of 29 
MYCN-targeting miRNAs identified in this study, 18 interactions were novel whereas all 11 
previously established MYCN-targeting miRNAs 3,8 were confirmed, thus underscoring the 
validity of our genome-wide high-throughput screen. 
Previously identified MYCN-targeting miRNAs have not been confirmed to regulate MYCN in 
primary neuroblastoma tumor cells. To address this shortcoming, we integrated our screen 
results with matching miRNA and mRNA expression profiles from primary neuroblastoma 
tumors. For 12 MYCN-targeting miRNAs we observed significant inverse correlation to 
MYCN expression or activity and thus provide evidence that they regulate MYCN in a 
neuroblastoma tissue context: eight let-7 family miRNAs (let-7a-5p, let-7b-5p, let-7c-5p, let-
7d-5p, let-7f-5p, let-7g-5p, let-7i-5p and miR-98), three miR-29 family miRNAs (miR-29a-3p, 
miR-29b-3p, miR-29c-3p) and miR-34a-5p. 
In a next step, we investigated the dynamic regulation of these miRNAs during the process 
of MYCN-driven tumor formation, using the extensively validated TH-MYCN mouse model. 
Notably, we observe that MYCN-targeting miRNAs are preferentially downregulated during 
MYCN-driven tumor development, suggesting that MYCN negatively regulates the miRNAs 
by which it is targeted, to safeguard its own expression. Growing evidence suggests that 
MYCN predominantly acts repressively on the overall miRNA composition 5,21-24 and we 
indeed observed widespread downregulation of miRNA expression during murine MYCN-
driven neuroblastoma development (Figure 4.3c, gray line). Nonetheless, the fraction of 
MYCN-targeting miRNAs that is downregulated is larger than expected by chance (Figure 
4.3c, black line). The mechanisms by which MYCN directly represses transcription are not 
fully understood. Several lines of evidence suggest that it acts in a protein complex including 
SP1 and/or MIZ-1 25-29 to recruit histone writers 25,27-30 and/or DNA-methyltransferases 26,30 to 
the promoter regions of its repressed target genes. Whether binding of MYCN to the 
canonical E-box sequence is required for this process is still unclear 26,31. Notably, only two 
MYCN-targeting miRNAs in neuroblastoma (miR-29a-3p and miR-29c-3p) are directly 
downregulated upon induction of MYCN in a neuroblastoma cell line model, suggesting that 
downregulation of MYCN-targeting miRNAs during tumor formation is likely to result from 
secondary (epi)genetic events downstream of increased MYCN activity.  
The integration of the screen results with miRNA expression data from MYCN non-amplified 
primary neuroblastoma tumors further identified 5 MYCN-targeting miRNAs with positive 
correlation to MYCN expression or activity. Subsequent analysis of these miRNAs in in vivo 
MYCN model systems showed that activation of MYCN is associated to increased 
expression of miR-19a-3p, miR-19b-3p and miR-494-3p. Indeed, miR-19a-3p and miR-19b-
3p, members of the oncogenic miR-17-92 cluster, have been shown to be direct 
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transcriptional targets of MYCN in neuroblastoma cells 5,24, and the region upstream to miR-
494-3p contains E-box sequences (data not shown), suggesting that MYCN can induce its 
expression. It is conceivable that these miRNAs act both in a MYCN negative regulatory 
feed-back loop as well as via repression of important neuroblastoma tumor suppressor 
genes: indeed, miR-19a-3p targets ESR1 32, a ligand-inducible transcription factor implicated 
in neuronal differentiation, whereas miR-19b-3p represses DKK3 expression 33, a marker of 
tumor differentiation with elevated expression levels in favorable tumors. The MYCN model 
systems, however, cannot confirm the positive correlation between miR-34c-5p and miR-
449a and MYCN expression or activity observed in primary neuroblastoma tumors: miR-34c-
5p is consistently downregulated in the murine models, whereas the expression of miR-449a 
is not altered. Furthermore, there is no evidence that MYCN could induce the expression of 
these miRNAs directly. Although the expression of miR-34c-5p increases upon MYCN 
activation in the in vitro SHEP-MYCN-ER model system, the upstream region of miR-34c-5p 
does not contain E-box sequences (data not shown), and miR-449a, residing in the second 
intron of CDC20B, was not identified by Shohet and colleagues 24 in their screen for intronic 
miRNAs regulated by MYCN. Nevertheless, the different relation between MYCN and 
miR-34c-5p expression in MYCN non-amplified versus amplified environment should not be 
surprising: activation of miR-34c-5p, either direct or indirect, could be one of the 
mechanisms through which normal physiological levels of MYCN affect apoptosis. In cases 
where MYCN exceeds its physiological levels and oncogene-induced apoptosis is triggered, 
a transforming cell will need to circumvent MYCN-mediated apoptosis, for instance via 
downregulation of miR-34c-5p, which seems to occur in TH-MYCN and LSL-MYCN;Dbh-
iCre tumors. 
Of further notice, 17 out of 29 identified MYCN-targeting miRNAs were considered not to be 
relevant for MYCN regulation in the context of neuroblastoma, due to lack of inverse 
correlation to MYCN expression and/or activity, or due to unavailable expression data. Given 
the tissue specific nature of miRNA function, it is not excluded that these miRNAs regulate 
MYCN in an other cellular context, such as that of normal brain development 34 and a 
number of childhood malignancies with demonstrated involvement of MYCN: 
medulloblastoma 31,35, retinoblastoma 35,36, Wilms' tumor 36,37, rhabdomyoscaroma 37,38 and 
T-cell acute lymphoblastic leukemia 38. Notably, three of these excluded miRNAs, let-7e-5p, 
miR-101-3p and miR-202-3p, have been reported to target MYCN in a MYCN amplified 
neuroblastoma cell line 3. This discrepancy between literature and our data could be 
explained by the fact that our integrative approach identifies MYCN-targeting miRNAs in 
neuroblastoma using gene expression data from MYCN non-amplified primary tumors. 
Buechner and colleagues 3 showed that let-7e-5p, miR-101-3p and miR-202-3p are able to 
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affect MYCN expression in a MYCN amplified neuroblastoma cell line, whereas we found no 
evidence that they are regulating MYCN in MYCN non-amplified primary neuroblastoma 
tumors. 
In conclusion, we identify 12 MYCN-targeting miRNAs in with regulatory effects on MYCN 
expression levels or activity in MYCN non-amplified neuroblastoma (Figure 4.2A). 
Furthermore, we provide evidence that these miRNAs are preferentially downregulated 
during MYCN-driven neuroblastoma tumor formation, suggesting that MYCN negatively 
controls the expression of these miRNAs, and as such safeguards its own expression. 
Understanding this regulatory miRNAome upstream of MYCN in neuroblastoma can open 
new perspectives for targeting the MYCN pathway in neuroblastoma tumors, a strategy that 
holds great promise 39. Moreover, the identification of additional target genes of the miRNAs 
in the described MYCN-miRNA interactome might prove useful in the search for novel 
therapeutic targets. 
Methods 
MYCN 3’UTR-miRNA library screen 
HEK293T cells were seeded at a density of 10 000 cells/well in 96-well plates. Twenty-four 
hours after seeding, cells were co-transfected with 100 ng of a reporter vector with the wild-
type MYCN 3’UTR (ENST00000281043, Ensembl release 75) cloned downstream of the 
Firefly luciferase gene (SwitchGear Genomics, S207230) and 20 ng of pRL-TK control 
vector containing the Renilla luciferase gene (Promega) together with a library of 470 miRNA 
mimics (2.5 pmol) (Ambion's Pre-miR miRNA Precursor Library - Human V3, design based 
on miRBase v9.2 with exclusion of hsa-miR-122a). Lipid based transfections were 
performed using 0.4 µl Dharmafect Duo reagent (Dharmacon). Forty-eight hours post-
transfection, luciferase reporter gene activities were assayed using the Dual-Luciferase 
Reporter assay system (Promega) according to the manufacturer’s protocol with minor 
changes (LARII and Stop & Glo buffer volumes were reduced to 50 µl). Firefly reporter gene 
activities were normalized to Renilla values and then log-transformed. Subsequently, robust 
z-scores were calculated and median centered to the distribution of robust z-scores from 36 
analogous screens (of 17 selected cancer and disease associated genes) on a per miRNA 
basis in order to remove potential systematic bias. The resulting interaction scores are thus 
more negative for miRNAs that interact with the 3'UTR. In order to determine the interaction 
score cutoff that separates interactions from non-interactions, the scores for a set of 
validated miRNA interactions, probed in the MYCN screen or any of the analogous screens, 
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were used together with the scores for a set of negative control interactions from an empty-
3'UTR vector miRNA library screen to perform ROC-curve analysis and determine the point 
of highest accuracy (interaction score = -1.94, specificity = 99%, sensitivity = 51%). MYCN 
3'UTR-miRNA library screen results were replicated in two independent experiments. For a 
more detailed description of the 3'UTR-miRNA library screen setup and data-analysis we 
refer to Van Peer et al. (in preparation).!
miRNA target analysis 
Potential miRNA target sites in the MYCN 3'UTR were identified as reported previously 40. In 
addition, miRNAs targeting MYCN were predicted using the MirTarget2 algorithm 41. 
miRNA and mRNA expression in patient cohort 
160 MYCN non-amplified primary tumor samples of neuroblastoma patients were collected 
prior to therapy at the Ghent University Hospital (Ghent, Belgium), the University Children’s 
Hospital Essen (Essen, Germany), the Hospital Clínico Universitario (Valencia, Spain), the 
Academic Medical Center (University of Amsterdam, Netherlands) and the National 
Children's Research Centre (Dublin, Ireland). Informed consent was obtained from the 
patients’ relatives. mRNA data from 75 primary neuroblastoma tumors is available at the 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo; Accession Number: 
GSE32664). Correlation of miRNA expression levels and MYCN mRNA levels was 
evaluated with Spearman's rank correlation coefficient. In order to find miRNAs that show 
negative correlation to MYCN activity and hence MYCN protein levels, mRNAs were ranked 
according to decreasing Spearman's rank correlation coefficient for each miRNA. Ranked 
gene lists were used for Gene Set Enrichment Analysis (GSEA) 11 with selected gene sets of 
MYC(N) regulated genes from the chemical and genetic perturbations gene set collections in 
the GSEA Molecular Signatures Database. From all gene sets in this collection that have 
either MYC or MYCN in their name, the six gene sets that contain MYC(N) upregulated 
genes were used for this analysis: COLLER MYC TARGETS UP 12, DANG MYC TARGETS 
UP 13, DANG REGULATED BY MYC UP 13, KIM MYC AMPLIFICATION TARGETS UP 14, 
LEE LIVER CANCER MYC UP 42, SCHUHMACHER MYC TARGETS UP 16 and YU MYC 
TARGETS UP 17. Gene sets with a false discovery rate (FDR) below 25% and a normalized 
enrichment score (NES) below -2 were considered significantly negatively enriched. 
miRNA annotation 
In this study we used data obtained with three different analytical miRNA platforms.  
Platform designs are based on different releases of the miRBase database for miRNA 
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annotation, resulting in non-overlapping annotation of data sets. To allow for correct 
integration of miRNA data, we used miRBase Tracker, an in-house developed web tool for 
miRNA reannotation 43 and applied the most up-to-date annotation at time of publication 
(miRBase release 21). Details of reannotation of the different miRNA platforms, including 
cross-species comparison, can be found in Supplementary Tables S1 - S5.  
SHEP-MYCN-ER model system 
The MYCN-inducible SHEP-MYCN-ER cell model 44 was kindly provided by Johannes H 
Schulte (Department of Pediatric Oncology and Hematology, University Children's Hospital 
Essen, Germany). Cell line authenticity was validated by Short Tandem Repeat (STR) 
genotyping prior to performing the described experiments. In the SHEP-MYCN-ER cell line, 
the cDNA of MYCN is fused to a mutated estrogen responsive domain (ER) which can bind 
4-hydroxy-tamoxifen (4-OHT), but is unable to bind with natural estrogen 44. Addition of 4-
OHT to the culture medium (200 nM final concentration) activates the MYCN-ER expression. 
SHEP-MYCN-ER cells were seeded at 100 000 cells per 6-well and treated with 4-OHT after 
48 h. Subsequently, cells were pelleted for RNA isolation 48 h after treatment. In parallel, 
cells were treated with equal amounts of the 4-OHT solvent (70 % ethanol) as a negative 
control. RNA was isolated using the miRNeasy Mini Kit (Qiagen; 217004) according to 
manufacturer's instructions. Five replicate experiments were performed and analyzed. 
RT-qPCR 
RT-qPCR reactions were performed and reported according to the MIQE guidelines 45. For 
quantification of individual miRNA expressions, cDNA was synthesized from 500 ng total 
RNA with 4 µl of HiSpec Buffer, 2 µl of Nucleics Mix and 2 µl miScript RT Mix (miScript II RT 
Kit, Qiagen; 218161) in a final volume of 20 µl. This reaction mix was incubated for 60' at 
37°C and 5' at 95°C using an iCycer instrument (Bio-Rad). qPCR reactions contained 3 ng 
of cDNA, 2.5 µl QuantiTeckt Mastermix, 0.5 µl miScript Universal Primer and 0.5 µl miRNA-
specific miScript Primer Assay (Qiagen, miScript Primer Assays used are listed in 
Supplementary Table S2) in a total volume of 5 µl. Expression levels were normalized 
against three stably expressed reference miRNAs (hsa-miR-125a, hsa-miR-423 and hsa-
miR-92) validated with GeNorm 46 and analyzed using qbase+ software version 2.6 
(http://www.biogazelle.com/qbaseplus) 47.  
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TH-MYCN neuroblastoma progression model 
TH-MYCN+/+ mice 18 were sacrificed at day seven (n=4) and day fourteen (n=4) of life to 
harvest sympathetic ganglia containing foci of neuroblast hyperplasia, and at week 6 of life 
to harvest advanced neuroblastoma tumors (n=4). Additionally, we have dissected the same 
sympathetic ganglia from TH-MYCN-/- mice at day seven (n=4), day fourteen (n=4) and 
week 6 (n=4) of life to control for miRNA expression changes during normal development. 
Murine total RNA was isolated using the miRNeasy Mini Kit (Qiagen, 217004) according to 
the manufacturer’s instructions. Mature miRNA expression levels were quantified using a 
stem-loop RT-qPCR platform. Briefly, 99 ng of total RNA was reverse transcribed using 
Megaplex™ RT Primers, Rodent Pool Set v3.0 (Life Technologies - Applied Biosystems; 
4444746) followed by a 12-cycle pre-amplification according to the manufacturer’s 
instructions. Pre-amplified cDNA was diluted four times and quantified using the TaqMan 
Array Rodent MicroRNA A+B Cards Set v3.0 (Life Technologies - Applied Biosystems; 
4444909) according to the manufacturer’s instructions on a ViiA 7 Real-Time PCR System 
(Life Technologies - Applied Biosystems). Only Cq values lower than 32 were retained and 
normalized using global mean normalization, as previously described 48. Furthermore, to 
allow for cross-species comparison of miRNA expression data, we only considered those 
murine miRNA assays that target sequences similar to the sequences of the human miRNAs 
included in our 3’UTR-miRNA library screen (see Supplementary Tables S3 - S4). Linear 
regression analysis was performed to evaluate the differential temporal expression pattern in 
ganglia from wild-type mice and ganglia and tumors from transgenic mice. A π-value metric 
was subsequently calculated as the difference in regression slopes between transgenic and 
wild-type samples, multiplied with the statistical significance of this difference: ! − value! =− log!" p!value×Δ!"#$%!!"#!"$$%&'. 
LSL-MYCN;Dbh-iCre tumors 
The LSL-MYCN;Dbh-iCre mouse model is described elsewhere 20 along with details on 
tumor dissection and miRNA expression profiling. In brief, 60 ng of total RNA of normal 
adrenals and LSL-MYCN;Dbh-iCre tumors, isolated with the miRNeasy Mini kit (Qiagen), 
was used to quantify murine mature miRNA expression levels using a stemloop RT-qPCR 
platform (Life Technologies-Applied Biosystems). 
Statistical methods 
All statistical analyses were performed using R Bioconductor software (version 3.0.2). If not 
further specified in the results section, statistical significance was defined as p-value < 0.05 
for all statistical tests.  
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Data accessibility 
mRNA data from 75 primary neuroblastoma tumors are available at the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE32664. miRNA 
expression data from the TH-MYCN neuroblastoma progression model are available in the 
ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-
2618. Furthermore, the processed data can be visualized via the R2 microarray analysis and 
visualization platform (http://r2.amc.nl) under experiment "Exp Nb Hyperplasia TH-MYCN - 
Ghent - 24 - custom - mirbase19mm2". 
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Supplements 
Supplementary Tables 
Supplementary tables from this manuscript are accessible through the following URL: 
https://goo.gl/OfGd8K 
Supplemental Figures 
 
Supplementary Figure 1. Correlation between the interaction scores from two independent MYCN 3' UTR screens. The 
interaction scores resulting from the two screens show high correlation, underlining the reproducibility of the 
generated data. Spearman correlation coefficient = 0.86, p = 2.2 x 10-16.  
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Supplementary Figure 2. Enrichment of miRNAs predicted to target MYCN among the miRNAs with a more 
negative interaction score. Kolmogorov-Smirnov test, p = 5.3 x 10-4.  
 
 
Supplementary Figure 3. Schematic overview of the metrics calculated to study the dynamic miRNA expression 
changes during neuroblastoma development in the TH-MYCN mouse model. Linear regression analysis was used to 
calculate the slope of the regression line of miRNA expression in either transgenic (TG; black) or wild-type (WT; gray) 
samples. The difference between these slopes, ∆ slope, is a measure for the difference in dynamic expression pattern: 
negative ∆ slope values are indicative for decreased miRNA expression in TH- MYCN+/+ versus wild-type samples.  
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Abstract 
LIN28B has been identified as an oncogene in various tumor entities, including 
neuroblastoma, a childhood cancer that originates from neural crest-derived cells, and is 
characterized by amplification of the MYCN oncogene. Recently, elevated LIN28B 
expression levels were shown to contribute to neuroblastoma tumorigenesis via let-7 
dependent de-repression of MYCN. However, additional insight in the regulation of LIN28B 
in neuroblastoma is lacking. Therefore, we have performed a comprehensive analysis of the 
regulation of LIN28B in neuroblastoma, with a specific focus on the contribution of miRNAs. 
We show that MYCN regulates LIN28B expression in neuroblastoma tumors via two distinct 
parallel mechanisms. First, through an unbiased LIN28B-3'UTR reporter screen, we found 
that miR-26a-5p and miR-26b-5p regulate LIN28B expression. Next, we demonstrated that 
MYCN indirectly affects the expression of miR-26a-5p, and hence regulates LIN28B, 
therefor establishing a MYCN-miR-26a-5p-LIN28B regulatory axis. Second, we provide 
evidence that MYCN regulates LIN28B expression via interaction with the LIN28B promotor, 
establishing a direct MYCN-LIN28B regulatory axis. We believe that these findings mark 
LIN28B as an important effector of the MYCN oncogenic phenotype and underlines the 
importance of MYCN-regulated miRNAs in establishing the MYCN-driven oncogenic 
process. 
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Introduction 
The highly conserved RNA-binding proteins LIN28A and LIN28B play important roles in 
glucose metabolism 1 and during development and stem cell reprogramming by regulating 
the self-renewal of stem cells 2. They mediate these pleiotropic functions by modulating the 
translation of target messenger RNAs (mRNAs) and by inhibiting let-7 microRNA (miRNA) 
biogenesis – their main mode of action studied. The let-7 family of miRNAs comprises a 
group of 12 sequence-related miRNAs, encoded by 8 distinct genomic loci. Because these 
miRNAs regulate multiple stemness regulators and bona fide proto-oncogenes, such as 
RAS, HMGA2 and MYC, they play an essential role in stem cell differentiation and tumor-
suppression. As a consequence, deregulated LIN28A or LIN28B expression contributes to 
abnormal development and tumorigenesis. 
Recently, elevated LIN28B expression levels were shown to contribute to neuroblastoma 
tumorigenesis via let-7 dependent de-repression of MYCN 3. Neuroblastoma is a pediatric 
tumor of the sympathetic nervous system and is characterized by high MYCN activity 
through genomic amplification, which occurs in about half of high-stage neuroblastoma 
tumors and marks poor survival. LIN28B is frequently overexpressed in high-risk 
neuroblastoma, and high-level amplifications of the 6q21 region including the LIN28B gene 
occur at a low frequency. In addition, increased expression of LIN28B is associated with 
poor outcome of neuroblastoma patients 3. This prominent LIN28B expression results in a 
strong increase in the amount of MYCN protein via repression of the MYCN-targeting let-7 
miRNAs, as shown by expression analysis of murine Lin28b-driven tumors and a series of in 
vitro LIN28B model systems 3. 
Increased LIN28B expression in neuroblastoma tumors could be attributed to genomic 
amplification in only a few samples. Therefore, additional mechanisms are likely to be 
involved, such as alterations in upstream regulatory pathways as well as transcriptional and 
post-transcriptional control. Indeed, several miRNAs, including the let-7 family miRNAs, 
were reported to target the LIN28B 3' untranslated region (3’UTR) 4-8. Interestingly, also 
MYCN has been proposed to induce LIN28B transcription 9,10 but other studies could not 
confirm these findings 3. Taken together, the present data point at an intimate regulatory 
interconnection between MYCN and LIN28B, let-7 and possibly also other miRNAs. 
In this study, we set about to elucidate the regulation of LIN28B expression in 
neuroblastoma tumors, with particular focus on the contribution of MYCN and miRNAs. To 
this end, we performed a comprehensive, genome-wide exploration of the miRNA-LIN28B 
interactome in neuroblastoma. We combined results from an unbiased and genome-wide 
high-throughput miRNA target reporter screen with miRNA and mRNA expression data from 
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200 neuroblastoma patients and identified twelve LIN28B-targeting miRNAs in 
neuroblastoma. Subsequent integration of the screen results and clinical data from 
neuroblastoma patients prioritized miR-26a-5p and miR-26b-5p for further analysis. Using 
different MYCN-driven in vitro and in vivo model systems, we show that MYCN induces the 
expression of LIN28B via indirect repression of miR-26a-5p and miR-26b-5p. In addition, we 
provide evidence that MYCN further enhances the expression of LIN28B via direct binding to 
the LIN28B promoter region. Hence, our findings clarify the role of MYCN and miRNAs in the 
upstream regulation of LIN28B in neuroblastoma and describe a double feed-forward loop 
between MYCN and LIN28B. 
Results 
An unbiased LIN28B 3’UTR-miRNA library screen identifies 28 miRNAs 
targeting LIN28B  
Potential interactions of 470 miRNAs with the 3'UTR of LIN28B were assayed in a high-
throughput luciferase reporter screen. In brief, human embryonic kidney cells (HEK293T) 
were co-transfected with a reporter construct, containing the LIN28B 3’UTR downstream of a 
luciferase reporter gene, and each of the individual miRNA mimics from a 470 miRNA mimic 
library. Based on the relative luciferase activities in two independent screens 
(Supplementary Figure 5.1), a robust z-score was calculated for each miRNA-LIN28B 
combination (see Material and Methods). Applying this strategy, we identified 28 miRNAs 
with a high probability of targeting LIN28B (average robust z-score score < -3.05; see 
Material and Methods; Figure 5.1a and Supplementary Table 5.1). According to 
miRTarBase 4.0, an experimentally validated microRNA-target interactions database 11, 
scientific literature holds weak (n = 8) 4,5,12 or strong (n = 2) 6,7,13 evidence for 10 miRNAs as 
regulator of LIN28B. Both miRNAs with strong evidence to target LIN28B, let-7b-5p and 
miR-125b-5p, were validated in our screen (Figure 5.1a, red), whereas only 3 out of 8 
miRNAs with weak evidence to target LIN28B, let-7d-5p, miR-125a-5p and miR-484, could 
be confirmed (Figure 5.1a, blue). Additionally, 23 new LIN28B targeting miRNAs were 
identified, of which 14 are predicted to target LIN28B by MirTarget2 14 (Supplementary 
Table 5.1), underscoring the value of our screening method to detect novel, predicted as 
well as non-predicted, miRNA-target gene interactions. Among the strongest hits in the 
screens, a significant enrichment was observed for miRNAs with seed-matched sites 
present in the LIN28B 3'UTR (Figure 5.1b), thus further underscoring the sensitivity and 
robustness of the 3'UTR-miRNA library screen. 
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Figure 5.1: An unbiased MYCN 3’UTR-miRNA library screen identifies 29 miRNAs potentially targeting 
MYCN. (a) Average interaction scores are plotted (Y-axis) for 470 tested miRNAs (X-axis). The 29 miRNAs with 
an interactions core of < -1.94 are listed in Figure 5.2A. The 11 interactions that have been reported in literature, 
are indicated in black. (b) Cumulative distributions (Y-axis) of the interaction scores (X-axis) of miRNAs that 
respectively have 6-, 7- or 8-mer seed-matches in the MYCN 3'UTR.  
miR-26a-5p and miR-26b-5p are top candidate LIN28B-targeting miRNAs in 
neuroblastoma  
miRNAs are known to regulate their target genes in a highly tissue- and cell type specific 
manner 15. As the LIN28B 3'UTR-miRNA library screens were performed in HEK293T cells, 
we next aimed to identify miRNAs specifically targeting LIN28B in neuroblastoma cells by 
integrating the obtained screen results with miRNA expression data from a large cohort 
primary neuroblastoma tumors We reasoned that the expression of a LIN28B-targeting 
miRNA is inversely correlated to LIN28B mRNA expression levels in primary tumor samples. 
Of the 19 LIN28B-targeting miRNAs that were included on the human miRNA expression 
platform, 12 miRNAs showed significant inverse correlation to LIN28B mRNA expression 
(Table 5.1), suggesting that they can indeed downregulate LIN28B expression in primary 
neuroblastoma tumors. In addition, three of the 19 LIN28B-targeting miRNAs that were 
included on the human miRNA expression platform were positively correlated to MYCN 
expression (Table 5.1). Overall, LIN28B targeting miRNAs identified in our screen showed 
stronger inverse correlation to LIN28B mRNA levels compared to non-targeting miRNAs 
(Figure 5.1c), as indicated by a shift of the cumulative distribution of π-values (-log10 p-
value x Pearson correlation coefficient) to more negative values.  
Next, we reasoned that miRNAs with a putative tumor suppressive role in neuroblastoma are 
lower expressed in more aggressive neuroblastoma tumors. Therefore, we assessed the 
relationship between expression of the LIN28B-targeting miRNAs and the outcome of high-
risk neuroblastoma patients (International Neuroblastoma Staging System stage 4, n = 92). 
For three LIN28B-targeting miRNAs, miR-26a-5p, miR-26b-5p and miR-125b-5p, low 
expression is associated with poor outcome (Figure 5.2a-b and Supplementary Fig 5.2).  
0
1
−14.00 6.10
●
●
●
●
●
●●
●●
●●
●●
●●
●●
●●●●●
●●●●●●
●●●●●●●●
●●●●●●●●●●●●
●●●●●●●●●●
●●●●●●●●●
●●●●●●●●
●●●●
●●●
●●●
●●
●
●
●●
●
−14.00
−3.05
6.10
0
1
−11.0 0.0 8.1
Figure 1 
seed match: 
- 8mer * 
- 7mer * 
- 6mer * 
- no 
evidence in  
literature: 
- strong (2) 
- weak (8) 
- no (460) 
a average 
robust z-score 
470 miRNAs 
cumulative 
fraction 
b 
-log10 (FDR) x Spearman rho 
6.1 
-3.1 
-14.0 
6.1 -3.1 -14.0 
1 
0 
cumulative 
fraction 
c 
1 
0 
8.1 0.0 -11.0 
average robust z-score 
LIN28B 
targeting: 
- yes 
- no 
Table 1 
* p < 0.01 
p < 0.01 
102 Chapter 5 
 
 
Table 5.1: Overview of 28 LIN28B-targeting miRNAs, categorized according to LIN28B-targeting potential 
in primary neuroblastoma tumors. LIN28B-targeting miRNAs are filtered for their relevance in neuroblastoma 
according to significant negative correlation to LIN28B expression in a neuroblastoma patient cohort. In total, 12 
out of 28 miRNAs show negative correlation to LIN28B expression and are considered to be relevant for 
neuroblastoma, while 3 out of 28 miRNAs show positive correlation to LIN28B expression. Four miRNAs lack 
correlation to LIN28B expression (n.s.: not significant, Spearman correlation, Benjamini & Hochberg multiple 
testing corrected p-value > 0.05), and for 9 miRNAs no expression data was available (n.d.: no data available). In 
addition, of the 15 miRNAs showing correlation to LIN28B expression, the expression of 3 miRNAs is associated 
to poor outcome of stage 4 neuroblastoma patients (n = 92). n.s.: not significant (log-rank test, p-value > 0.05) 
miRNA mirBase Accession Reference  Spearman rho log-rank OR 
miRNA's with negative correlation to LIN28B expression 
hsa-let-7a-5p MIMAT0000062 
 
-0.35 n.s. 
hsa-let-7b-5p MIMAT0000063 6,8 -0.36 n.s. 
hsa-let-7c-5p MIMAT0000064 
 
-0.23 n.s. 
hsa-let-7d-5p MIMAT0000065 4 -0.59 n.s. 
hsa-let-7f-5p MIMAT0000067 
 
-0.45 n.s. 
hsa-let-7g-5p MIMAT0000414 
 
-0.54 n.s. 
hsa-let-7i-5p MIMAT0000415 
 
-0.60 n.s. 
hsa-miR-125b-5p MIMAT0000423 7 -0.25 14.43 
hsa-miR-26a-5p MIMAT0000082 
 
-0.37 12.48 
hsa-miR-26b-5p MIMAT0000083 
 
-0.31 13.00 
hsa-miR-363-3p MIMAT0000707 
 
-0.23 n.s. 
hsa-miR-98-5p MIMAT0000096 
 
-0.49 n.s. 
     
miRNA's with positive correlation to LIN28B expression 
hsa-miR-516b-3p MIMAT0002860 
 
0.17 n.s. 
hsa-miR-550a-3p MIMAT0003257 
 
0.28 n.s. 
hsa-miR-641 MIMAT0003311 
 
0.29 n.s. 
     
miRNA's without correlation to LIN28B expression 
hsa-let-7e-5p MIMAT0000066 
 
n.s. - 
hsa-miR-125a-5p MIMAT0000443 5 n.s. - 
hsa-miR-367-3p MIMAT0000719 
 
n.s. - 
hsa-miR-383-5p MIMAT0000738 
 
n.s. - 
     
miRNA's with missing data 
hsa-miR-182-3p MIMAT0000260 
 
n.d. - 
hsa-miR-208a-3p MIMAT0000241 
 
n.d. - 
hsa-miR-484 MIMAT0002174 5 n.d. - 
hsa-miR-499a-5p MIMAT0002870 
 
n.d. - 
hsa-miR-552-3p MIMAT0003215 
 
n.d. - 
hsa-miR-561-3p MIMAT0003225 
 
n.d. - 
hsa-miR-569 MIMAT0003234 
 
n.d. - 
hsa-miR-605-5p MIMAT0003273 
 
n.d. - 
hsa-miR-92b-3p MIMAT0003218 
 
n.d. - 
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Figure 5.2: miR-26a-5p and miR-26b-5p are top candidate LIN28B-targeting miRNAs in neuroblastoma. (a) 
Kaplan-Meier curves for miR-26a-5p in a cohort of primary neuroblastoma tumors. Patients are split in two 
groups with either miR-26a-5p expression above (= high) or below (= low) the average miR-26a-5p expression. 
Log-rank test, OR = 12.48, p = 2.4 x 10-3. (b) Kaplan-Meier curves for miR-26b-5p in a cohort of primary 
neuroblastoma tumors. Patients are split in two groups with either miR-26b-5p expression above (= high) or 
below (= low) the average miR-26b-5p expression. Log-rank test, OR = 13.00, p = 1.4 x 10-3. (c) Expression 
(log2) of miR-26a-5p in primary neuroblastoma tumors with MYCN amplification (= 1) versus tumors without 
MYCN amplification (= 0). T-test, p = 4.3 x 10-7. (d) Expression (log2) of miR-26b-5p in primary neuroblastoma 
tumors with MYCN amplification (= 1) versus tumors without MYCN amplification (= 0). T-test, p = 1.9 x 10-6. 
In addition, two miRNAs, miR-26a-5p and miR-26b-5p, were previously reported to be lower 
expressed in neuroblastoma tumors with MYCN amplification, a marker of aggressive 
neuroblastoma (Figure 5.2c-d) 16. These observations highlight miR-26a-5p and miR-26b-
5p as interesting candidate regulators of LIN28B in neuroblastoma. 
Overexpression of miR-26a-5p or miR-26b-5p reduces LIN28B expression 
Following the selection of miR-26a-5p and miR-26b-5p as candidate miRNAs in the context 
of neuroblastoma, we assessed whether these miRNAs regulate LIN28B expression levels 
in the neuroblastoma cell line NGP. As expected from the luciferase reporter screen, 
overexpression of either miR-26a-5p or miR-26b-5p induced downregulation of LIN28B 
expression levels compared with a non-targeting miRNA control (Figure 5.3a).  
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Figure 5.3. Overexpression of miR-26a-5p or miR-26b-5p reduces LIN28B expression. (a) mRNA (upper 
panel) and protein (lower panel) expression of LIN28B upon overexpression of miR-26a-5p or miR-26b-5p in 
NGP cells. T-test, pre-miR-26a: p = 2.7 x 10-2; pre-miR-26b: p = 3.5 x 10-2. (b-c) Result of GSEA. Red-blue color 
bars denote genes ranked based on correlation to miR-26a-5p (b) or miR-26b-5p (c) expression in primary 
neuroblastoma tumors (n = 200). Each vertical bar corresponds to genes upregulated in LSL-LIN28B tumors vs. 
normal adrenal glands. The green line represents the running enrichment score calculated in GSEA. 
Finally, we investigated whether the functions of these miRNAs in neuroblastoma are related 
to the functions of LIN28B using a Gene Set Enrichment Approach (GSEA). To this end, we 
first constructed a gene set of genes upregulated by LIN28B in the LSL-Lin28b mouse 
model 3. This gene set contains 256 genes that are significantly upregulated in LSL-Lin28B 
tumors compared to normal adrenal glands. Next, we calculated the Spearman correlation 
coefficient between the expression of miR-26a-5p or miR-26b-5p and all mRNAs expressed 
in a large cohort of primary neuroblastoma tumors (n = 200). Finally, we performed GSEA on 
these ranked lists to assess the enrichment of LIN28B regulated genes among the genes 
negatively correlated with miR-26a-5p or miR-26b-5p expression in primary neuroblastoma 
tumors. As expected for miRNAs that regulate the expression of LIN28B, the GSEA analysis 
for both miRNAs results in strong negative enrichment for the LSL-Lin28b gene set (Figure 
5.3b-c). This suggests that the functions miR-26a-5p and miR-26b-5p in neuroblastoma are 
strongly related to those of LIN28B. Hence, the putative tumor-suppressors miR-26a-5p and 
miR-26b-5p affect the LIN28B expression levels in neuroblastoma and show inverse 
correlation to LIN28B-induced gene expression patterns. 
miR-26a-5p and miR-26b-5p are downregulated in MYCN-driven neuroblastoma 
Given the decreased expression of miR-26a-5p and miR-26b-5p in neuroblastoma tumors 
with MYCN amplification as compared to neuroblastoma tumors that lack MYCN 
amplification 16, we sought to investigate whether miR-26a-5p and miR-26b-5p were 
regulated by the oncoprotein MYCN. 
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Figure 5.4. miR-26a-5p and miR-26b-5p are downregulated in MYCN-driven neuroblastoma. (a-b) 
Expression (log2) of mmu-miR-26a-5p (a) and mmu-miR-26b-5p (b) in sympathetic ganglia containing 
hyperplastic lesions, and advanced tumors from TH-MYCN+/+ mice at, respectively, 1 and 2 weeks and 6 weeks 
of age (black), and in normal sympathetic ganglia from wild-type mice at 1, 2 and 6 weeks of age (gray). Data are 
presented as mean ± standard deviation of four samples. Two-way ANOVA interaction, mmu-miR-26a-5p: p = 
6.2 x 10-13; mmu-miR-26b-5p: p = 1.1 x 10-5. (c-d) Expression of miR-26a-5p (c) and miR-26b-5p (d) in LSL-
MYCN tumors compared to normal adrenal tissue. T-test, miR-26a-5p: p = 7.6 x 10-10; miR-26b-5p: p = 8.0 x 10-
10. (e) Relative expression of miR-26a-5p and miR-26b-5p in IMR-5/75-shMYCN cells before (gray bars) and after 
(black bars) silencing of MYCN. Data are presented as mean ± standard deviation of three replicate experiments. 
T-test, miR-26a-5p: p = 0.041; miR-26b-5p: p > 0.05. (f) Relative expression of miR-26a-5p and miR-26b-5p in 
SHEP-MYCN-ER cells before (gray bars) and after (black bars) activation of MYCN. Data are presented as mean 
± standard deviation of three replicate experiments. T-test, miR-26a-5p: p = 0.041; miR-26b-5p: p > 0.05. 
To this end, we evaluated the expression of both miRNAs in MYCN-driven neuroblastoma 
models. First, we interrogated a murine neuroblastoma progression model, consisting of pre-
tumorigenic lesions and advanced neuroblastoma tumors from the TH-MYCN+/+ mouse 
model, in combination with matching reference tissue from wild-type mice. Both miR-26a-5p 
and miR-26b-5p expression strongly decreased during TH-MYCN+/+ neuroblastoma 
development as compared to normal development (Figure 5.4a-b). Next, these results were 
confirmed in a second, independent, murine MYCN-driven neuroblastoma model, the LSL-
MYCN;Dbh-iCre model 17 – further referred to as the LSL-MYCN model – as both miRNAs 
were found to be lower expressed in LSL-MYCN tumors compared to normal adrenal tissue 
(Figure 5.4c-d). 
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Figure 5.5. MYCN does not inhibit transcription of pri-mir-26a-1, pri-mir-26a-2 or pri-mir-26b in 
neuroblastoma cells. (a) Relative expression of pri-mir-26a-1, pri-mir-26a-2 and pri-mir-26b in IMR-5/75-
shMYCN cells before (gray bars) and after (black bars) silencing of MYCN. Data are presented as mean ± 
standard deviation of three replicate experiments. T-test, pri-mir-26a-1: p > 0.05; pri-mir-26a-2: p > 0.05; pri-mir-
26b: p > 0.05. (b) Relative expression of CTDSP1, CTDSP2 and CTDSPL in IMR-5/75-shMYCN cells before 
(gray bars) and after (black bars) silencing of MYCN. Data are presented as mean ± standard deviation of three 
replicate experiments. T-test, CTDSP1: p > 0.05; CTDSP2: p = 6.2 x 10-3; CTDSPL: p = 6.2 x 10-5. (c) Relative 
expression of pri-mir-26a-1, pri-mir-26a-2 and pri-mir-26b in SHEP-MYCN-ER cells before (gray bars) and after 
(black bars) induction of MYCN activity. Data are presented as mean ± standard deviation of three replicate 
experiments. T-test, pri-mir-26a-1: p > 0.05; pri-mir-26a-2: p > 0.05; pri-mir-26b: p > 0.05. (d) Relative expression 
of CTDSP1, CTDSP2 and CTDSPL in SHEP-MYCN-ER cells before (gray bars) and after (black bars) induction 
of MYCN activity. Data are presented as mean ± standard deviation of three replicate experiments. T-test, 
CTDSP1: p > 0.05; CTDSP2: p > 0.05; CTDSPL: p > 0.05. 
To verify that the decreased expression of miR-26a-5p and miR-26b-5p in these in vivo 
models is a consequence of increased MYCN activity, we evaluated the expression of both 
miRNAs in multiple in vitro models of MYCN activity in neuroblastoma. First, the effect of 
MYCN knockdown on miRNA expression was evaluated in the IMR5-75-shMYCN model 
system. These cells stably express a tetracycline-inducible MYCN shRNA that, upon 
induction, reduced MYCN protein to 44% (Supplementary Figure 5.3) 18. We observed a 
modest but significant increase in the expression of miR-26a-5p upon silencing of MYCN, 
while the expression of miR-26b-5p did not change (Figure 5.4e). Next, we assessed the 
effect of MYCN activation in the SHEP-MYCN-ER cell line. Here, miR-26a-5p expression 
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level was decreased by 20% (Figure 5.4f) upon 4-hydroxy-tamoxifen-mediated activation of 
the MYCN-ER fusion protein, whereas, again, no significant regulation of miR-26b-5p 
expression levels was observed (Figure 5.4f). Together these in vivo and in vitro data 
support the hypothesis that MYCN could regulate the expression of miR-26a-5p in 
neuroblastoma cells. Furthermore, these data show that miR-26b-5p is downregulated 
during murine MYCN-driven neuroblastoma development; however, they do not provide 
evidence that this is a direct consequence of MYCN activity. 
MYCN does not inhibit transcription of primary mir-26 transcripts in 
neuroblastoma cells 
Both miR-26a-5p and miR-26b-5p are intronic miRNAs that are transcribed from three 
genomic regions, residing within the introns of three coding genes: CTDSP1, CTDSP2 and 
CTDSPL, host genes of mir-26b, mir-26a-2 and mir-26a-1 respectively; both mir-26a-1 and 
mir-26a-2 are processed into the mature miR-26a-5p. In order to evaluate whether 
transcriptional activity of MYCN directly regulates miR-26a-5p and miR-26b-5p, we 
measured the expression of the primary miRNA transcripts and the host genes in the IMR-
5/75-shMYCN and SHEP-MYCN-ER cell lines. Knockdown of MYCN in IMR-5/75-shMYCN 
cells resulted in decreased expression of miR-26a-5p host genes CTDSP2 and CTDSPL, 
but did not affect the expression of pri-mir-26 transcripts (Figure 5.5a-b). Induction of MYCN 
activity in the SHEP-MYCN-ER cells, did not affect miR-26 host gene expression levels, nor 
the expression of the pr-mir-26 transcripts (Figure 5.5c-d). These data suggest that 
downregulation of miR-26a-5p by MYCN in neuroblastoma cells is not the consequence of 
transcriptional silencing of mir-26a-1 or mir-26a-2.  
MYCN induces LIN28B expression in neuroblastoma cells 
Given that MYCN affects the expression levels of miR-26a-5p, and that both miR-26a-5p 
and miR-26b-5p regulate the expression of LIN28B, we postulated that MYCN affects 
LIN28B expression in neuroblastoma cells. To investigate this premise, we measured the 
effect of MYCN activation and silencing on LIN28B mRNA and protein expression in the 
above-mentioned in vitro models. In the SHEP-MYCN-ER cell line, LIN28B expression 
increased by 1.7-fold 48h upon activation of MYCN (Figure 5.6a). Correspondingly, 
knockdown of MYCN resulted in a 2-fold decrease in LIN28B expression levels (Figure 
5.6b). In addition, we evaluated the relationship between MYCN and LIN28B expression 
levels in the murine MYCN-driven model systems.  
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Figure 5.6. MYCN induces LIN28B expression in neuroblastoma cells. (a) Relative expression of LIN28B in 
SHEP-MYCN-ER cells before (gray bars) and after (black bars) induction of MYCN activity. Data represent 
average fold change of three independent biological replicates +/- standard deviation. T-test, p = 4.2 x 10-3. (b) 
Relative expression of LIN28B in IMR-5/75-shMYCN cells before (gray bars) and after (black bars) silencing of 
MYCN. Data are presented as mean ± standard deviation of three replicate experiments T-test, p = 5.7 x 10-3. (c) 
Lin28b expression (log2) in sympathetic ganglia containing hyperplastic lesions, and advanced tumors from TH-
MYCN+/+ mice at, respectively, 1 and 2 weeks and 6 weeks of age (black), and in normal sympathetic ganglia 
from wild-type mice at 1, 2 and 6 weeks of age (gray). Data are presented as mean ± standard deviation of four 
samples. Two-way ANOVA, interaction p = 1.9 x 10-8. (d) Lin28b protein levels in advanced tumors from TH- 
MYCN+/+ mice at 6 weeks of age (indicated as "+/+"), and in normal sympathetic ganglia from wild-type mice at 
6 weeks of age (indicated as "-/-"). (e) MYCN ChIP was performed on MYCN3 cell line either doxycycline treated 
(MYCN high) or untreated (MYCN low). Two assays (Supplementary Table 5) for MYCN binding site at LIN28B 
promoter was designed by analyzing MYCN ChIP-Sequencing database. Negative control IgG ChIP and Input 
material was also analyzed and used for normalizing the MYCN ChIP data. Two sets of control primers were 
used to confirm the specificity of immunoprecipitated genomic DNA. Fold enrichment in site occupancy was 
calculated by comparing normalized MYCN ChIP Cq values between treatments. ChIP-qPCR reactions were 
performed in triplicates and represented here as mean ± SEM. T-test, p < 0.001. 
As expected from the in vitro data, LIN28B mRNA expression levels strongly increased 
during MYCN-driven murine neuroblastoma development in the TH-MYCN+/+ model 
compared to normal development (Figure 5.6c). Accordingly, we detected LIN28B protein in 
murine neuroblastoma tumors, whereas expression was absent in wild-type sympathetic 
ganglia (Figure 5.6d). In addition, LSL-MYCN tumors were characterized by 1.8-fold higher 
LIN28B mRNA levels as compared to normal adrenal tissue (Figure 5.6e). Finally, LIN28B 
expression showed significant correlation to MYCN expression in a large cohort of primary 
neuroblastoma tumors (n = 200) from different clinical stages (Supplementary Figure 5.4a) 
and was higher expressed in MYCN amplified neuroblastoma tumors (n = 40) versus MYCN 
non-amplified tumors (n = 160) (Supplementary Figure 5.4b). 
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Thus far, our study supports a mechanistic model in which MYCN can enhance LIN28B 
expression in neuroblastoma via indirect repression of miR-26a-5p, which regulates LIN28B 
expression levels. Several studies, however, have reported that MYC, a family member of 
MYCN, can directly induce LIN28B expression via binding to an E-box sequence in its 
promoter region 19,20, and a similar mode of action for MYCN has been proposed 9,21. To 
verify whether MYCN indeed binds the LIN28B promoter region and activates its 
transcription, we have evaluated direct interaction in the MYCN3 cell line, a neuroblastoma 
model of doxycycline-inducible MYCN overexpression. Here, overexpression of MYCN 
resulted in a 1.7-fold increase in LIN28B expression levels (Supplementary Figure 5.5) and 
a > 5-fold increase in LIN28B promoter occupancy by MYCN as demonstrated by ChIP-
qPCR with two independent assays (Figure 5.6f). Together these data support an additional 
mechanistic model in which MYCN enhances LIN28B expression via induction of LIN28B 
transcription through direct promoter interaction. 
 
Discussion 
The elucidation of the LIN28B–let-7–MYCN axis in neuroblastoma and its role in sustaining 
proliferation and cell viability and suppression of differentiation of neuroblasts, offered 
exciting insights in MYCN-regulating pathways in neuroblastoma 3. However, little is known 
about the regulation of LIN28B expression in neuroblastoma. Given the importance of 
miRNAs in regulating key oncogenes 22,23, we believe that the contribution of miRNAs to the 
regulation of LIN28B in neuroblastoma is underexplored. Here, we report on the first 
unbiased and genome-wide high-throughput miRNA target reporter screen to identify 
miRNAs targeting LIN28B. From the total of 28 LIN28B-targeting miRNAs identified in this 
study, 23 interactions were novel, whereas 5 out of 8 previously established LIN28B-
targeting miRNAs were confirmed (Table 5.1). Subsequent filtering of the screen results 
through clinical data of neuroblastoma patients highlighted two miRNAs, miR-26a-5p and 
miR-26b-5p, for their potential tumor suppressive activity in neuroblastoma. To our 
knowledge, these miRNAs have not been associated to neuroblastoma tumor biology 
before. 
The most studied LIN28B-targeting miRNAs are the let-7 family members [32]. In our 3'UTR 
library screen, we identified all let-7 family members as LIN28B-targeting miRNAs. 
Moreover, these miRNAs displayed negative correlation to LIN28B expression levels in 
primary neuroblastoma tumors (Table 5.1), thus confirming previous data and validating our 
3'UTR library screen. However, in contrast to both miR-26a-5p and miR-26b-5p, the let-7 
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family members did not show association to patient outcome in a cohort of aggressive 
neuroblastoma tumors. 
We revealed that induction or knockdown of MYCN activity in vitro respectively represses or 
induces the expression of miR-26a-5p, and that both miR-26a-5p and miR-26b-5p show 
decreased expression levels in murine MYCN-driven mouse tumors. The observed effects of 
MYCN perturbation on miR-26a-5p expression levels are modest (~ 20%); this could raise 
questions regarding the relevance of such regulation. However, it has been suggested that 
the capability of miRNAs to regulate multiple targets within the same pathway can amplify 
their biological effects 24. As a result, even relatively small changes in miRNA expression 
may be biologically significant 25,26. Therefore, it is our opinion that MYCN does affect the 
expression levels of miR-26a-5p and that this regulation could have significant biological 
consequences. However our observations do not fully support the regulation of miR-26b-5p 
expression levels: we observed no significant changes in miR-26b-5p expression levels 
upon perturbation of MYCN expression in in vitro models. Additional experimentation in cell 
culture systems may be useful to identify the exact role of miR-26b-5p in the proposed 
regulatory network. 
Several reports have demonstrated that MYC, a MYCN family member, is capable of down-
regulating expression of miR-26a-5p and miR-26b-5p in breast cancer 27 and hepatocellular 
carcinoma 28. For miR-26a-5p, it has been demonstrated that this down-regulation occurs 
through a cooperative effect of MYC and EZH2 and the promoter region of its host genes 
CTDSPL (mir-26a-1 host gene) and CTDSP2 (mir-26a-2 host gene) in aggressive 
lymphomas 29. However, our data do not support a similar mode of action in neuroblastoma 
as we did not observe direct regulation of the primary mir-26a-1, mir-26a-2 nor the mir-26b 
transcript by MYCN. This observation indicates that regulation of miR-26a-5p by MYCN is 
rather in keeping with an indirect mechanism, possibly via regulation of genes that contribute 
to or inhibit the stability of miR-26a-5p. For instance, nuclear modifiers that recognize unique 
motifs on pre-miR-26a can regulate the export of pre-miR-26a. If pre-miR-26a cannot be 
exported into cytoplasm and is retained in the nucleus, mature miR-26a-5p cannot be 
produced. Alternatively, Dicer processing can be blocked by cytoplasmic modifiers that bind 
to pre-miR-26a, or, as in the case of pre-let-7 regulation, Dicer processing efficiency can be 
decreased by TUT-mediated uridylation 30. The discrepancy between pri-mir-26 and mature 
miR-26 levels may also result from the turnover rate of mature miR-26a-5p. Mature miRNAs 
have been thought to be very stable. However, studies have shown that extracellular signals 
can induce the rapid degradation of specific miRNAs 31,32. Unknown modifiers may work on 
mature miR-26a-5p to affect its stability.  
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Figure 5.7. Proposed working hypothesis for the regulation of LIN28B in neuroblastoma. (a) MYCN 
enhances the expression of LIN28B via direct binding at the LIN28B promoter region. In turn, LIN28B inhibits the 
processing of the let-7 miRNAs, which results in loss of MYCN repression 3. (b) MYCN indirectly represses the 
expression of miR-26a-5p via an unknown factor, indicated as "?". Reduced miR-26a-5p expression levels 
results in increased LIN28B expression, which again, in turn, inhibits the processing of the let-7 miRNAs, 
resulting in loss of MYCN repression 3. 
Finding such modifiers of miR-26a-5p will be instrumental in understanding the nature of 
miR-26a-5p regulation. Further experimentation in cell culture systems may be useful to 
identify miR-26a-5p post-transcriptional regulators.  
Our LIN28B-3’UTR library screen and subsequent validation experiments showed that miR-
26a-5p regulate LIN28B expression levels in neuroblastoma. In addition, we showed that 
MYCN activation, both in vitro and in vivo, leads to decreased miR-26a-5p and increased 
LIN28B expression levels. From these observations, we concluded that MYCN can regulate 
LIN28B expression levels via indirect repression of miR-26a-5p. However, we further 
showed that MYCN regulates LIN28B mRNA levels via a second mechanism: MYCN can 
directly control LIN28B expression thorough binding of its promoter as shown by ChIP-
analysis. This result is not unexpected as it had been reported that MYC induces LIN28B 
expression levels in B-cell lymphoma 19, while induction of LIN28B expression by MYCN in 
neuroblastoma had been suggested by several additional reports 9,21. 
In conclusion, our integrated analyses uncovered a double regulatory feed-forward loop, 
enhancing the expression of both LIN28B and MYCN in neuroblastoma. The proposed 
molecular model consists of two alternative paths that are probably not mutually exclusive, 
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but appear to differ between different cellular contexts, such as the different model systems 
analyzed here. The shortest path involves direct regulation of LIN28B by MYCN through 
binding at its promoter region (Figure 5.7a). Subsequent induction of LIN28B expression 
results in reduced levels of mature let-7 miRNAs due to inhibition of miRNA processing by 
LIN28B. Finally, reduced let-7 levels results in loss of MYCN repression, which closes the 
proposed loop. The second path involves an intermediate step where MYCN indirectly 
represses the expression of the LIN28B-targeting miRNA miR-26a-5p (Figure 5.7b). Again, 
subsequent induction of LIN28B expression results in reduced levels of mature let-7 miRNAs 
due to inhibition of miRNA processing by LIN28B. 
Understanding this regulatory mechanism upstream of LIN28B in neuroblastoma can open 
new perspectives for targeting the MYCN-LIN28B pathway in neuroblastoma tumors, a 
strategy that holds great promise. Moreover, the identification of additional target genes of 
the miRNAs in the described LIN28B-miRNA interactome might prove useful in the search 
for novel therapeutic targets. 
Methods 
LIN28B 3’UTR-miRNA library screen 
Since the wild-type LIN28B (ENST00000345080, Ensemble release 78) 3' UTR is longer 
than 3.5kb, GeneCopoeia (Rockville, MD, U.S.A) provided the UTR into two constructs with 
overlapping sequence; further referred to as construct A (1 - 3084bp, catalog number: 
HmiT010363a-MT01) and construct B (2905 - 4548bp, catalog number: HmiT010363b-
MT01). HEK293T cells were seeded at a density of 1x104 cells/well in 96-well plates. 
Twenty-four hours after seeding, cells were co-transfected with 100 ng of one of the two 
LIN28B reporter vectors and 20 ng of pRL-TK control vector containing the Renilla luciferase 
gene (Promega, Madison, WI, USA) together with a library of 470 miRNA mimics (2.5 pmol) 
(Ambion's Pre-miR miRNA Precursor Library - Human V3, design based on miRBase v9.2 
with exclusion of hsa-miR-122a; Life Technologies, Carlsbad, CA, USA). Lipid based 
transfections were performed using 0.4 µl Dharmafect Duo reagent (GE Dharmacon, 
Lafayette, CO, USA). Forty-eight hours post-transfection, luciferase reporter gene activities 
were assayed using the Dual-Luciferase Reporter assay system (Promega) according to the 
manufacturer’s protocol with minor changes (LARII and Stop & Glo buffer volumes were 
reduced to 50 µl). Firefly reporter gene activities were normalized to Renilla values and then 
log-transformed. Subsequently, robust z-scores were calculated; the robust z-score is a 
variation of the outlier-sensitive z-score that substitutes the outlier-insensitive median and 
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median absolute deviation (MAD) for mean and standard deviation in the z-score calculation. 
In order to determine the robust z-score cutoff that separates interactions from non-
interactions, the scores for a set of validated miRNA interactions, probed in the LIN28B 
screen and in 36 analogous screens (of 17 cancer and disease associated genes), were 
used together with the scores for a set of negative control interactions from an empty-3'UTR 
vector miRNA library screen to perform ROC-curve analysis and determine the point of 
highest accuracy (z-score = -3.05, specificity = 97%, sensitivity = 31%, accuracy = 86%). 
LIN28B 3'UTR-miRNA library screen results were replicated in two independent experiments 
for both reporter constructs. To allow for correct integration of miRNA data, we used 
miRBase Tracker, an in-house developed web tool for miRNA reannotation 33, to re-annotate 
the miRNAs in the miRNA mimic library to the most up-to-date annotation at time of 
publication (miRBase release 21) (Supplementary Table 2). 
miRNA target analysis 
Potential miRNA target sites in the LIN28B 3'UTR were identified as reported previously 34. 
In addition, miRNAs targeting LIN28B were predicted using the MirTarget2 algorithm 35. 
miRNA and mRNA expression in patient cohort 
200 primary tumor samples of neuroblastoma patients were collected prior to therapy at the 
Ghent University Hospital (Ghent, Belgium), the University Children’s Hospital Essen 
(Essen, Germany), the Hospital Clínico Universitario (Valencia, Spain), the Academic 
Medical Center (University of Amsterdam, Netherlands) and the National Children's 
Research Centre (Dublin, Ireland). Informed consent was obtained from the patients’ 
relatives. mRNA data from 75 primary neuroblastoma tumors is available at the Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo; Accession Number: GSE32664). 
Correlation of miRNA expression levels and LIN28B mRNA levels was evaluated with 
Spearman's rank correlation coefficient. 
Tissue culture 
Human neuroblastoma cell lines were cultured in RPMI 1640 medium (Invitrogen, Waltham, 
MA, USA) supplemented with fetal bovine serum (10%), kanamycin (1%), 
penicillin/streptomycin (1%), L-glutamine (1%) and HEPES (25mM) (Life Technologies). 
Cells were kept at 37°C in a 5% C02 / 95 %02 humidified environment. Cell line authenticity 
was validated by Short Tandem Repeat (STR) genotyping prior to performing the described 
experiments. Experiments with the IMR5-75-shMYCN, SHEP-MYCN-ER and MYCN3 cell 
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lines were performed as previously published 18,36,37. In all cases, three replicate experiments 
were performed and analyzed.  
RT-qPCR 
Total RNA was isolated using the miRNeasy Mini Kit (Qiagen, Venlo, Netherlands) 
according to manufacturer's instructions, including on-column DNase treatment. RT-qPCR 
reactions were performed and reported according to the MIQE guidelines 38. For 
quantification of gene expression, cDNA was synthetized from 500 ng total RNA with the 
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer's 
instructions. qPCR reactions were performed with Sybr green detection chemistry, using the 
LC480 real-time PCR detection system (Bio-Rad). qPCR reactions were performed in a total 
volume of 5 µl consisting of 2.5 µl of SsoAdvance Universal SYB Green Supermix (Bio-Rad), 
0.5 µl forward and reverse primer (5 µM; primer sequences are listed in Supplementary 
Table 3) and 2 µl of 2.5 ng/µl cDNA (total RNA equivalents). Cycling conditions were as 
follows: 2 minutes at 95 °C followed by 44 cycles of 5 seconds at 95 °C, 30 seconds at 60 
°C and 1 second at 72 °C. Expression levels of LIN28B were normalized to reference genes. 
Expression analysis as well as error propagation was done using qbase+ software version 
3.0 (http://www.biogazelle.com/qbaseplus) (Biogazelle, Zwijnaarde, Belgium) 39. Measuring 
the primary miRNAs transcripts was done using stem-loop TaqMan assays. qPCR was 
performed according to the manufacturer's protocol using 10 ng of the RT product, TaqMan 
universal master mix (2x) and TaqMan Pri-miRNA assays (20x) (Applied Biosystems) in 8 µl 
reaction volume. The following cycling conditions were applied: 95°C for 10 min followed by 
40 cycles of 95°C for 15 s and 60°C for 1 min. Expression levels were normalized to 
reference genes. Expression analysis as well as error propagation was done using qbase+ 
software version 3.0. For quantification of individual miRNA expressions, cDNA was 
synthesized from 500 ng total RNA with 4 µl of HiSpec Buffer, 2 µl of Nucleics Mix and 2 µl 
miScript RT Mix (miScript II RT Kit, Qiagen) in a final volume of 20 µl. This reaction mix was 
incubated for 60' at 37°C and 5' at 95°C using an iCycer instrument (Bio-Rad). qPCR 
reactions contained 3 ng of cDNA, 2.5 µl QuantiTeckt Mastermix, 0.5 µl miScript Universal 
Primer and 0.5 µl miRNA-specific miScript Primer Assay (Qiagen, miScript Primer Assays 
used are listed in Supplementary Table 4) in a total volume of 5 µl. Expression levels were 
normalized against two stably expressed reference miRNAs (hsa-miR-423-5p and hsa-miR-
92) validated with GeNorm 40 and analyzed using qbase+ software version 3.0.  
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Protein isolation, antibodies and Western blotting 
Total protein lysates were harvested after washing with ice-cold PBS and total protein 
isolation was carried out using RIPA lysis buffer, containing cOmplete Protease Inhibitor 
Cocktail Tablet (Roche Diagnostics, Basel, Switzerland) and PhosSTOP Phosphatase 
Inhibitor Cocktail Tablets (Roche Diagnostics). 30 µg of protein lysate was loaded. The 
antibody directed against LIN28B (4196), secondary anti-rabbit and anti-mouse antibodies 
were obtained from Cell Signaling Technologies (Danvers, MA, USA). The antibody directed 
against VCL (V9131) was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
anti-MYCN ChIP-qPCR in MYCN3 cells 
MYCN ChIP was performed on 1x107 MYCN3 cells either treated or untreated with 
doxycycline for 24 h using ChIP-IT Express Chromatin Immunoprecipitation Kit (53008; 
Active Motif, Carlsbad, CA, USA) according to manufacturer’s instructions. Samples were 
sonicated for 20 cycles of 30 sec intervals in a Bioruptor UCD-200 sonicator (Diagenode). 
ChIP-grade Anti-MYCN anti-body (ab16898, abcam), IgG control anti-body (12-370; EMD-
Millipore, Billerica, MA, USA) antibodies were used for ChIP and input was generated by 
purifying DNA from the sonicated lysates of each sample. ChIP-qPCR primers were 
designed by analyzing putative MYCN binding sites on LIN28B promoter from previous 
MYCN ChIP-seq data 37 and are listed in Supplementary Table 5. Control primers for a non-
specific genomic region and a distal site on LIN28B promoter was also designed and used to 
validate the specificity of ChIP DNA. Real-time qPCR reactions were performed in triplicates. 
The amount of genomic DNA co-precipitated with specific antibody was calculated by 
normalizing and comparing Cq values of MYCN CHIP with input and control IgG. 
Statistical methods 
All statistical analyses were performed using R Bioconductor software (version 3.0.2). If not 
further specified in the results section, statistical significance was defined as p-value < 0.05 
for all statistical tests. 
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Supplements 
Supplementary figures 
 
 
Supplementary Figure 1: Correlation between the robust z-scores from two independent replicate LIN28B 
3' UTR screens for two constructs (A and B). Since the wild-type LIN28B (ENST00000345080, Ensemble 
release 78) 3' UTR is longer than 3.5kb, GeneCopoeia provided the 3'UTR into two constructs with overlapping 
sequence (referred to as construct A and construct B). The robust z-scores resulting from two independent 
replicate screens of construct A (a) and construct B (b) show high correlation, highlighting the reproducibility of 
the generated data. Spearman correlation; construct A: r = 0.84, p < 2.2 x 10-16; construct B: r = 0.86, p < 2.2 x 
10-16. (c-d) Schematic overview of the two LIN28B 3'UTR luciferase reporter constructs. 
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Supplementary Figure 2: Kaplan-Meier curve for the expression of miR-125a-5p in high-risk (INSS stage 
4, n = 92) primary neuroblastoma tumors. high (gray lines): expression higher than mean expression; low 
(black lines): expression lower than mean expression. Log-rank test; p = 1.6 x 10-5 
 
 
Supplementary Figure 3: Knockdown of MYCN in the IMR-5/75-shMYCN cell line. mRNA (a) and protein (b) 
levels of MYCN before (gray bar) and after (black bar) knockdown of MYCN. T-test; p = 1.2 x 10-3. 
 
 
Supplementary Figure 4: Expression of LIN28B in primary neuroblastoma tumors. (a) Correlation between 
MYCN and LIN28B expression in primary neuroblastoma tumors. Spearman correlation coefficient = 0.31, p = 
8.6 x 10-6. (b) Expression of LIN28B in primary neuroblastoma tumors with and without MYCN amplification. T-
test, p = 2.6 x 10-3. 
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Supplementary Figure 5: Relative expression of LIN28B in MYCN3 cells before (gray bars) and after (black 
bars) induction of MYCN. Data represent average fold change of three independent biological replicates +/- 
standard deviation. T-test, p = 5.0 x 10-3. 
 
Supplementary Tables 
 
Supplementary Table 5.1: Results from two independent LIN28B-3'UTR library screens. For each assayed 
miRNA, the average z-score (av. rob. z score) and the standard deviation (st. dev. int. score) are disclosed. 
Furthermore, it is indicated (x) whether the miRNA is predicted to target MYCN according to MirTarget V3, used 
in the web tool miRDB version 5.0 
see https://goo.gl/OfGd8K 
 
Supplementary Table 5.2: Annotation update of miRNAs from Ambion's Pre-miR miRNA Precursor 
Library - Human V3. The most up-to-date annotation at the time of publication (miRBase release 21) of 
Ambion's Pre-miR miRNA Precursor Library - Human V3 (design based on miRBase release 9.2) was retrieved 
using the miRBase release comparison query option of the miRBase Tracker.  
see https://goo.gl/OfGd8K 
 
Supplementary Table 5.3: RT-qPCR primers. Target type: TOI = target of interest, REF = reference target. 
Fwd = forward, Rev = reverse. 
Primer 
Name 
Target 
Type Sequence Fwd Primer Sequence Rev Primer 
LIN28B TOI ATATCGGTGTGCTGTGATGC TGAGCAACGCTTATCATGTTTT 
CTDSP1 TOI GTGTGCTGTTCACTGCTA TCACTCATGTTGTCAAACCA 
CTDSP2 TOI AAGGCCTCTTGAGCACATA CAACAATGCTGACTTCATAGTG 
CTDSPL TOI GGAGCTGAGCAAAGTGAT CACAGGCACTGCATTCTC 
SDHA REF TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 
TBP REF CACGAACCACGGCACTGATT TTTTCTTGCTGCCAGTCTGGAC 
UBC REF ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 
YWHAZ REF ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 
B2M REF TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCTAAGT 
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Supplementary Table 5.4: Qiagen miScript primers. Target type: TOI = target of interest, REF = reference 
target. Fwd = forward, Rev = reverse. 
Primer Name Target Type Qiagen Catalog Number 
hsa-miR-26a-5p TOI MS00029239 (Hs_miR-26a_2) 
hsa-miR-26b-5p TOI MS00003234 (Hs_miR-26b_1) 
hsa-miR-423-5p REF MS00009681 (Hs_miR-423-5p_1) 
hsa-miR-99b-3p REF MS00032165 (Hs_miR-99b_2) 
 
Supplementary Table 5.5: ChIP-qPCR primers. Target type: TOI = target of interest, REF = reference target. 
Fwd = forward, Rev = reverse. 
Primer Name Target Type Sequence Fwd Primer Sequence Rev Primer 
LIN28B assay 1 TOI CGCAGTTTCAGTTAGTGATTCC  TTTCAGCGAAACTATTCTCTCC 
LIN28B assay 2 TOI TTGTGTGAGTGTGATTAAGCG GGAGGAAAGAGAAATCGTGAAG 
Control1 REF CCTGGAGGGCTTGGAGATG GATCCTACGGCTGGCTGTGA 
Control2 REF TTCTGTGAAAGAAGCACTCTAGG GGAAGTTGGAAAGGGAGAGAAG 
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Abstract 
Neuroblastoma, a childhood cancer that originates from neural crest-derived cells, is the 
most common deadly solid tumor of infancy. Amplification of the MYCN oncogene, which 
occurs in approximately 20–25% of human neuroblastomas, is the most prominent genetic 
marker of high-stage disease. The availability of valid preclinical in vivo models is a 
prerequisite to develop novel targeted therapies. We here report on the generation of 
transgenic mice with Cre-conditional induction of MYCN in dopamine β-hydroxylase-
expressing cells, termed LSL-MYCN;Dbh-iCre. These mice develop neuroblastic tumors with 
an incidence of 475%, regardless of strain background. Molecular profiling of tumors 
revealed upregulation of the MYCN-dependent miR-17–92 cluster as well as expression of 
neuroblastoma marker genes, including tyrosine hydroxylase and the neural cell adhesion 
molecule 1. Gene set enrichment analyses demonstrated significant correlation with MYC-
associated expression patterns. Array comparative genome hybridization showed that 
chromosomal aberrations in LSL-MYCN;Dbh-iCre tumors were syntenic to those observed in 
human neuroblastomas. Treatment of a cell line established from a tumor derived from a 
LSL-MYCN;Dbh-iCre mouse with JQ1 or MLN8237 reduced cell viability and demonstrated 
oncogene addiction to MYCN. Here we report establishment of the first Cre-conditional 
human MYCN-driven mouse model for neuroblastoma that closely recapitulates the human 
disease with respect to tumor localization, histology, marker expression and genomic make 
up. This mouse model is a valuable tool for further functional studies and to assess the 
effect of targeted therapies.  
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Introduction 
Neuroblastoma is the most common deadly solid tumor of infancy, and accounts for 15% of 
pediatric cancer deaths.1,2 Primary tumors derive from precursor cells of the sympathetic 
nervous system along the sympathetic chain.3 Neuroblastoma most frequently arises in the 
adrenal, but also develops from the superior cervical or celiac ganglia.4 The most prominent 
genetic marker of high-stage disease is amplification of the MYCN oncogene, which occurs 
in 20–25% of all neuroblastomas.5 Mouse models for human neuroblastoma can be helpful 
to understand the molecular mechanisms underlying pathogenesis and serve as important 
tools for preclinical studies. Weiss et al. has previously demonstrated that MYCN has the 
potential to drive murine neuroblastoma in a transgenic model, in which MYCN expression is 
driven by a rat tyrosine hydroxylase (TH) promoter.6 Transgenic mice expressing MYCN in 
the abdominal ganglia developed neuroblastoma. Although representing an excellent and 
broadly used tool, some limitations exist: (i) the transgene integration site and its genomic 
context is ill-defined, potentially resulting in less robust MYCN expression, (ii) tumors 
predominantly originate from abdominal ganglion structures, thus resembling only a subset 
of human neuroblastoma, (iii) no intrinsic option for in vivo tumor imaging is included and (iv) 
tumor incidence of heterozygous TH-MYCN mice is 70% in the 129 × 1/SvJ strain 
background, but only 5% in C57Bl6/N background, reducing the potential for combination 
with other cancer-relevant alleles. We aimed to overcome these limitations by developing a 
novel mouse model with targeted Cre-conditional MYCN expression in the neural crest.  
Results 
Characterization of LSL-MYCN mice  
LSL-MYCN transgenic mice were viable and fertile without obvious physiological or 
morphological phenotypes. Offspring resulting from breeding LSL-MYCN mice with wild-type 
mice were born according to the expected Mendelian ratio (data not shown). We next 
confirmed the molecular integration site and localization of the transgene. Representative 
examples of PCR analyses validating transgene integration in heterozygous and 
homozygous LSL-MYCN mice are shown in Figure 6.1b. PCR analyses validating the 
presence of a wild-type allele at the ROSA26 locus in wild-type and heterozygous LSL-
MYCN mice are shown in Figure 6.1c. 
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Figure 6.1. Generation of transgenic LSL-MYCN mice. (a) Graphical representation of the ROSA26 locus with 
recombinase-mediated cassette exchange (RMCE) sites used to introduce the RMCE exchange vector 
containing the MYCN transgene. The Rosa26 locus is displayed before (top) and after (center) insertion of MYCN 
by RMCE, and after cre-recombinase-mediated removal of the transcription termination site 5′ to the MYCN allele 
(bottom). Localizations of primers used for genotyping (A1 and A2) and the PCR-based validation of floxing out 
the transcriptional site 5′ of the MYCN allele (B1 and B2) are displayed. Splice acceptor site (SA), 
polyadenylation signal (pA), internal ribosome entry site (IRES), chicken actin gene promotor (CAG), 
transcriptional STOP cassette made of the human Growth Hormone polyadenylation signal (hGHpA), human 
MYCN open reading frame (MYCN). (b) Representative genotyping PCR validating the MYCN knock-in allele in 
heterozygous and homozygous LSL-MYCN mice (primers used: A1 and A2); wild type (wt), heterozygous LSL-
MYCN (+/−), homozygous LSL-MYCN (+/+). (c) Representative PCR validating absence or presence of the 
transgene inserted into the ROSA26 locus in wt, heterozygous (+/−) and homozygous (+/+) LSL-MYCN mice.  
Targeted expression of MYCN in the neural crest causes abdominal tumor 
formation in double-transgenic LSL-MYCN;Dbh-iCre mice  
Double-transgenic LSL-MYCN;Dbh-iCre mice developed palpable abdominal tumors with an 
incidence of 76% in a mixed C57/Bl6/129 × 1/SvJ strain background (n = 38). Tumor onset 
was detectable between 26–337 days of age, and the mean age at tumor onset was 79.6 
days (Figure 6.2a). Interestingly, Kaplan–Meier analysis revealed a significantly prolonged 
tumor-free survival of mice heterozygous for TH-MYCN compared with LSL-MYCN;Dbh-iCre 
mice (P = 0.001; Supplementary Figure 6.1). Of note, none of the single transgenic LSL-
MYCN or Dbh-iCre mice developed a tumor (Figure 6.2a); P<0.0001. Cre-mediated 
recombination in tumors, but not in control tissue from LSL-MYCN;Dbh-iCre mice was 
validated using B1 and B2 primers (Figure 6.1a). In the presence of the transcriptional 
termination site, a 2241-bp band was present in control tissue, whereas Cre-mediated 
excision of the transcriptional termination site upstream of the MYCN allele was indicated by 
the presence of a 703-bp band (Figure 6.2b and Supplementary Figure 6.2). 
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Figure 6.2. Double-transgenic LSL-MYCN;Dbh-iCre mice develop tumors derived from the neural crest. 
(a) Kaplan–Meier analysis indicating the presence and the time to detection of palpable tumors in mice (that is, 
tumor-free survival) heterozygous for LSL-MYCN and mice double transgenic for LSL-MYCN and Dbh-iCre (Log-
rank test). (b) Representative result of PCR validating the removal or presence of the transcriptional termination 
site 5′ to the MYCN transgene in tumor and control tissues, respectively. Wild type (wt), double-transgenic LSL-
MYCN;Dbh-iCre (+/−). (c) Bioluminescence imaging of three representative LSL-MYCN;Dbh-iCre mice carrying 
palpable tumors at the superior cervical ganglion (I), adrenals (I, II, III) or celiac ganglion (III). Color code 
indicates luciferase activity (low = blue; high = red). (d) High frequency ultrasound images of palpable tumors 
arising from superior cervical ganglion (left) and adrenal (middle), and three-dimensional reconstruction of 
adrenal tumor (right). (e) Growth curves of tumors, as detected by high-frequency ultrasound. (f) Macroscopic 
images during autopsy of mice carrying palpable tumors arising from both adrenals and the celiac ganglion (left) 
and from the superior cervical ganglion (right).  
Tumor localization, histology and expression of marker genes in LSL-
MYCN;Dbh-iCre mice recapitulate the patterns of human neuroblastoma  
In vivo bioluminescence imaging (Figure 6.2c) revealed that tumors in LSL-MYCN;Dbh-iCre 
mice arose from the superior cervical ganglion (I), the adrenals (I, II, III) or the celiac 
ganglion (III). Several tumors were shown to originate from adrenal structures using high-
frequency ultrasound imaging (Figure 6.2d-e). Macroscopic images acquired during 
dissection of mice carrying palpable tumors (Figure 6.2f) also confirmed that tumors arose 
from both adrenals and the celiac ganglion (left) and from the superior cervical ganglion 
(right). 
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Figure 6.3. Tumors of LSL-MYCN;Dbh-iCre mice resemble human neuroblastoma in terms of histology 
and molecular expression patterns. (a) MYCN expression (qPCR) in four representative tumors from LSL-
MYCN;Dbh-iCre mice compared with control tissues. Expression was normalized to normal adrenal glands. 
Student’s t-test: ***P<0.001. (b) Western blot analysis confirms MYCN expression in tumors (tu) compared with 
heart (he) tissue collected from four representative double-transgenic mice. (c) Hematoxylin and eosin (H&E) 
staining shows small, round blue cells typical for neuroectodermal tumors. Scale bars=100µm (left) and 50µm 
(right). (d) Electron micrographs show neuronal structures, including neurosecretory vesicles (red arrows). Scale 
bar = 500 nm. (e) RT-qPCR confirms significantly increased expression of the murine orthologs of the human 
neuroblastoma marker genes dopamine β-hydroxylase (Dbh), tyrosine hydroxylase (Th) and paired-like 
homeobox 2b (Phox2b) in tumors compared with normal control tissues (Student’s t-test; Dbh: P = 0.005, Th: P = 
0.02, Phox2b: P = 0.0006). (f, g) Immunohistochemistry confirms expression of neuroblastoma markers, Ncam1 
and Th. Scale bars = 200 µm.  
Table 6.1. Genomic aberrations in tumors from LSL-MYCN;Dbh-iCre mice compared with tail 
LSL-MYCN; Dbh-iCre tumors  Human neuroblastoma 
Chromosomal 
region 
Genomic 
aberration 
Frequency (%)  Syntenic 
region 
Genomic 
aberration 
Frequency 
(%) 
Reference 
1 Partial 
gain 
8  2q Gain 12 (43) 
1 Focal loss 8  1q41, 1q32.2, 
1q32.3 
   
3 Gain 69  1q Gain Often (10) 
6 Gain 38  7 Gain 40 (9) 
6 Focal gain 15  3p25.3    
8 Fical loss 15  -    
11 Partial 
gain 
31  17q Gain 50 (8) 
12 Gain 23  7q Gain 12 (9) 
16 Focal 
loss/gain 
8  16q13.3    
16 Focal Gain 8  21q22.13, 
21q22.2, 
21q22.3  
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Tumors had elevated expression of both MYCN mRNA and protein compared with normal 
tissues (Figure 6.3a-b). Hematoxylin and eosin staining of histological tumor sections and 
electron microscopy showed a small round blue cell tumor with cells harboring 
neurosecretory vesicles (Figure 6.3c-d), indicative of neuroblastoma. Furthermore, tumors 
strongly expressed the neuroblastoma-specific marker genes, dopamine β-hydroxylase 
(Dbh), tyrosine hydroxylase (Th) and paired-like homeobox 2b (Phox2b), as observed by 
quantitative PCR (RT-qPCR; Figure 6.3e). The neural cell adhesion molecule, Ncam1, a 
marker for neuroendocrine tissues, was strongly expressed in tumors from LSL-MYCN;Dbh-
iCre mice (Figure 6.3f). Expression of tyrosine hydroxylase was also confirmed on the 
protein level (Figure 6.3g). To analyze early or even premalignant stages of neuroblastoma 
development in our mouse model, we collected adrenals for histological examinations at day 
of birth, at days 14 and 28 of life. Hyperplastic cells were present in the adrenal medulla of 
some, but not all, of adrenal glands from 0-day-old transgenic mice and most 14- and 28-
day-old transgenic mice.  
Especially at day 28, the adrenal medulla of LSL-MYCN;Dbh-iCre mice had an atypical, 
nodal tissue architecture. In contrast, no hyperplasia was observed in adrenal glands from 
control mice of any age. The observed hyperplasia is in line with the hyperplastic lesions (in 
superior cervical ganglia) previously described in TH-MYCN mice by Hansford et al.7 Taken 
together, we demonstrate that LSL-MYCN;Dbh-iCre mice develop neuroblastomas that arise 
from the adrenal medulla and other neural crest derivatives. 
Murine MYCN-driven neuroblastomas are characterized by genomic 
aberrations syntenic to human neuroblastomas  
An overview of all genomic aberrations detected in tumors from heterozygous LSL-
MYCN;Dbh-iCre mice compared with tail DNA is depicted in Table 6.1 and Figure 6.4a. A 
partial gain of murine chromosome 11q was detected in the tumors of four mice (Figure 
6.4a-c). This region is syntenic to human chromosome 17 (Figure 6.4c), for which gain or 
partial gain (17q) occurs in the majority of human neuroblastomas.8 Five tumors exhibited 
gain of the entire murine chromosome 6 (Figure 6.4a and Supplementary Figure 6.3c), 
which is partially syntenic to human chromosomes 7p, 7q and 12p. In human 
neuroblastomas, gain of an entire chromosome 7 occurs in 40% of tumors and appears to 
be prevalent in all tumor stages, whereas gain of 7q, observed in 12% of human tumors, is 
more common in higher stage tumors.9 Three tumors harbored a gain of the entire mouse 
chromosome 12, which is syntenic to human chromosome 2p and includes the MYCN locus, 
as well as human chromosome 14q and parts of human chromosome 7p and 7q (Figure 
6.4a and Supplementary Figure 6.3d). 
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Figure 6.4. Murine neuroblastomas recapitulate genomic aberrations of human neuroblastomas. (a) 
Mouse karyotype overview of all genomic imbalances detected in 13 murine neuroblastomas (green bars: gained 
regions, red bars: lost regions). (b) Partial ratio plot for the mouse chromosome 6 region encompassing the 
ROSA26 amplicon in tumor 9 (right) and copy number of the MYCN transgene in 13 tumors from heterozygous 
LSL-MYCN;Dbh-iCre mice (+/ − ), as assessed by qPCR (insert left). Bars represent mice with normal 
chromosome 6 copy number (white), with whole chromosome 6 gain (black) and with focal chromosome 6 
amplification (striped). (c) Tumor/control ratio plot for mouse chromosome 11 in tumor 9 showing partial 
chromosome 11q gain, corresponding to gain of almost the entire human chromosome 17.  
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Eight tumors displayed gain of the entire chromosome 3 (Figure 6.4a and Supplementary 
Figure 6.3b), which is partially syntenic to human chromosome 1q, a region often gained in 
human neuroblastomas.10 Interestingly, two tumors showed a focal gain on chromosome 6 
that encompassed the ROSA26 locus, in which the human MYCN transgene was integrated 
(Figure 6.4a-b). This focal gain resulted in a 20- to 25-fold increase in MYCN transgene 
copy number in these two tumors, as measured by qPCR (inset Figure 6.4b). Consequently, 
the two tumors containing this aberration had elevated expression of the human MYCN 
mRNA (Supplementary Figure 6.3e), as assessed by RT-qPCR.  
No chromosomal deletions and only few focal deletions were observed in the tumors from 
heterozygous LSL-MYCN;Dbh-iCre  mice. The region on murine chromosome 8 that was 
lost in two murine tumors, which is syntenic to human chromosome 4, does not harbor any 
annotated genes (data not shown). Each of the remaining focal losses were only observed in 
one tumor, and are not syntenic to regions often lost in human neuroblastomas. From these 
data, it appears that chromosomal and focal losses observed in human neuroblastomas are 
less well represented in the LSL-MYCN;Dbh-iCre mouse model. Nevertheless, the spectrum 
of chromosomal aberrations in these MYCN-driven murine tumors recapitulates many of the 
observed chromosomal imbalances observed in human neuroblastomas.  
Murine MYCN-driven neuroblastoma transcriptomes show patterns of 
canonical MYC-related mRNA and microRNA (miRNA) signatures  
The consequences of MYCN overexpression on downstream gene expression were 
analyzed using transcriptional profiles obtained from normal murine adrenal gland and 
tumors from LSL-MYCN;Dbh-iCre mice. Unsupervised hierarchical clustering using the 1% 
of genes with the highest standard deviation in expression across all samples revealed 
distinct clustering of normal adrenal medulla and MYCN-driven tumors (Supplementary 
Figure 6.4). Interestingly, a similar hierarchical clustering approach revealed that tumors 
from LSL-MYCN;Dbh-iCre mice are very similar to tumors from the well-established TH-
MYCN mouse model,6 both at the level of mRNA and miRNA expression (Supplementary 
Figure 6.5). Consistent with the role of MYCN as a transcriptional activator, there was a 
predominance of upregulated over downregulated genes: 2315 genes, represented by 3680 
probe sets, were significantly upregulated, whereas 1190 genes, represented by 1726 probe 
sets, were significantly downregulated (false discovery rate < 0.05; Supplementary Table 
6.2). 
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Figure 6.5. Tumors from heterozygous LSL-MYCN;Dbh-iCre mice recapitulate human neuroblastoma at 
transcriptional level. (a) Table of selected gene sets from the MSigDB C2 collection, enriched among genes 
upregulated in the tumors from heterozygous LSL-MYCN;Dbh-iCre mice based on GSEA. (Rank of gene set in 
overall list of gene sets, ranked according to decreasing normalized enrichment score (NES; rank), number of 
genes in each set (size), NES). (b) GSEA enrichment plots showing upregulation of a gene set representing cell 
cycle (I) and markers downregulated during neuronal differentiation (II) in the transcriptional profiles of 
neuroblastoma tumors from heterozygous LSL-MYCN;Dbh-iCre mice. Depicted is the plot of the running sum for 
the MSigDB gene set within the LSL-MYCN;Dbh-iCre neuroblastoma data set, including the maximum 
enrichment score and the leading edge subset of enriched genes. FDR = false discovery rate. (c) The LSL-
MYCN;Dbh-iCre signature score in the 967 cell lines in the Cancer Cell Line Encyclopedia13 showing the highest 
signature score in neuroblastoma cell lines, followed by medulloblastoma cell lines. (d) The MYCN mRNA (I) and 
miRNA (II) gene signature in normal adrenal medulla and MYCN- and ALKF1174L-driven tumors. P < 0.05 (*) was 
considered significant. (e) The cumulative distribution of the significance score [-10log(pfp)] associated with 
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differential expression in tumors from heterozygous LSL-MYCN;Dbh-iCre mice (+/ − ) versus normal adrenals, for 
genes in the human non- MYCN-amplified neuroblastoma signature (black) and all other genes (gray). Genes in 
the human non-MYCN-amplified neuroblastoma signature show more significant differential expression 
compared with all remaining genes (Kolmogorov–Shmirnov test, P < 0.001).  
The differential expression profiles of regulated transcripts were functionally annotated using 
Gene Set Enrichment Analysis (GSEA),11 which seeks to estimate the significance of 
overrepresentation of an independently defined set of genes in gene expression data sets. 
LSL-MYCN;Dbh-iCre tumors were characterized by a strong association with MYC-
upregulated target genes, whereas MYC-downregulated target genes were enriched in the 
normal adrenal glands (Figure 6.5a). In addition, a large number of DNA replication-related 
gene sets were statistically enriched among genes upregulated in LSL-MYCN;Dbh-iCre 
tumors (Figure 6.5a-b(I)). Furthermore, upregulation of a gene set representing genes 
repressed during neuronal differentiation is in line with the undifferentiated phenotype of 
LSL-MYCN;Dbh-iCre tumors (Figure 6.5a-b(II)). Finally, one of the most strongly enriched 
gene sets among genes upregulated in the MYCN-driven tumors is the 
WHITEFORD_PEDIATRIC_ CANCER_MARKERS gene set, consisting of differentially 
expressed genes in a panel of xenografts representing eight common pediatric tumors 
(neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, acute lymphoblastic leukemia, Wilms’ 
tumor, osteosarcoma, medulloblastoma and ependymona), compared with normal tissues12 
(Figure 6.5a). This pediatric cancer phenotype is also apparent when comparing a LSL-
MYCN;Dbh-iCre signature in 967 cancer cell lines from Cancer Cell Line Encyclopedia,13 
representing more than 20 tumor entities. The LSL-MYCN;Dbh-iCre signature, composed of 
the top 100 most differentially up- and downregulated genes in LSL-MYCN;Dbh-iCre tumors 
compared with normal adrenal gland, is significantly higher in neuroblastoma cell lines than 
in any other cancer cell line (Kruskal–Wallis rank sum test, P < 0.001; Figure 6.5c). To 
specifically evaluate the magnitude of MYCN activity on transcriptional profiles both at 
mRNA and miRNA level, a MYCN signature score14 was calculated for all samples. As an 
additional reference, profiles from neuroblastoma tumors arising from targeted 
overexpression of mutated ALK15 were included. The MYCN signature score was 
significantly higher in MYCN-driven tumors than in the ALKF1174L-driven tumors and normal 
murine adrenals, demonstrating that MYCN is strongly activated in the tumors arising in 
transgenic mice with targeted MYCN expression (Figure 6.5d(I), Supplementary Figure 
6.6a and Supplementary Table 6.3). Known human MYCN-upregulated (Cad, Cdk4, Odc1) 
and MYCN-downregulated (Dkk3, Rgs5) target genes were also significantly regulated in 
LSL-MYCN;Dbh-iCre tumors compared with normal adrenals from wild-type mice 
(Supplementary Figure 6.6b). The miRNA expression profiles obtained from normal murine 
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adrenal gland and both MYCN- and ALKF1174L-driven neuroblastomas showed similar 
MYCN-driven patterns (Figure 6.5d (II), Supplementary Figure 6.7 and Supplementary 
Table 6.4). Of the 380 expressed miRNAs that were measured on the platform, 26 miRNAs 
were upregulated and 38 miRNAs were downregulated in LSL-MYCN;Dbh-iCre tumors 
compared with normal murine adrenal gland (Supplementary Table 6.5). Several miRNAs 
from the MYCN-induced miR-17–92 cluster (miR-17-5p, miR-18-5p, miR-20a-5p and miR-
92a-3p) were significantly upregulated in LSL-MYCN;Dbh-iCre tumors compared with 
normal adrenals from wild-type mice (Supplementary Figure 6.7b). The conformity with 
human neuroblastoma is further supported by the observation that genes, differentially 
expressed between high- and low-risk human neuroblastomas, either without or with 
inclusion of MYCN-amplified tumors, are more significantly altered in LSL-MYCN;Dbh-iCre 
tumors compared with normal adrenals from wild-type mice (Kolmogorov–Shmirnov test, P < 
0.001; Figure 6.5e). In summary, these observations support the relevance of our new 
MYCN-driven mouse model for the study of human neuroblastoma.  
The mNB-A1 cell line, explanted from LSL-MYCN;Dbh-iCre tumors, reflects 
characteristics of its origin  
In vitro cultured cells derived from a tumor of a LSL-MYCN;Dbh-iCre mouse presented 
neuronal structures resembling human neuroblastoma cells (Figure 6.6a). The presence of 
both MYCN and the Dbh-iCre transgene as well as Cre-mediated recombination in tumor-
derived mNB-A1 cells was validated (Figure 6.6b-c). Furthermore, mNB-A1 cells were 
positive for luciferase expression as revealed by bioluminescence imaging (Figure 6.6d) 
and expressed MYCN mRNA and protein levels similar to LSL-MYCN;Dbh-iCre tumors 
(Figure 6.6e-f). To monitor their tumorigenic potential in vivo, mNB-A1 cells were inoculated 
into nude mice (Figure 6.6g). Bioluminescence imaging revealed that tumors from mNB-A1 
cells maintained their luciferase activity (Figure 6.6h), and that luciferase imaging could be 
used to follow these tumors in vivo. Analysis of re-grafted tumors in nude mice revealed a 
strong correlation of tumor size with activity detected by luciferase imaging (Supplementary 
Figure 6.8).  
Treatment of cultured mNB-A1 cells with JQ1, a pharmacological inhibitor with a high target 
potency against BET bromodomain proteins,16 significantly reduced cell viability (Figure 
6.7a).  
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Figure 6.6. (a) Macroscopic images of cells cultivated after explantation of LSL-MYCN;Dbh-iCre tumors. Scale 
bars = 100 µm. (b) Representative genotyping PCR validating the MYCN knock-in allele (left) and the Dbh-iCre 
transgene (right) in cells cultured from murine neuroblastoma. Heart (he) from wild-type (wt) and heart (he) and 
tumor (tu) from heterozygous LSL-MYCN;Dbh-iCre mice (+/-) as controls. (c) PCR validating the removal of the 
transcriptional termination site 5′ of the MYCN allele in cells cultivated after explantation of LSL-MYCN;Dbh-iCre 
tumors. Wild-type (wt), heterozygous LSL-MYCN;Dbh-iCre (+/−), heart (he), tumor (tu). (d) Bioluminescence 
imaging of mNB-A1 cells. Luciferase activity: low = blue; high = red. luciferin (luc). (e) MYCN expression (qPCR) 
in mNB-A1 cells compared with various control tissues and to a representative LSL-MYCN;Dbh-iCre tumor. 
Expression was normalized to that in normal adrenal glands. Student’s t-test: ***=P<0.001; NS = not significant. 
(f) Western blot analysis confirms MYCN expression in mNB-A1 cells compared with heart and LSL-MYCN;Dbh-
iCre tumor. (g) Tumor growth after engraftment of 107 mNB-A1 cells into three nude mice at day 0. (h) 
Bioluminescence imaging of mNB-A1 cells growing in nude mice. Luciferase activity: low = blue, high = red.  
Although MYCN expression in mNB-A1 cells remained unaltered by treatment with either 
JQ1 or the dimethyl sulfoxide (DMSO) control (Figure 6.7b), transcriptomic data closely 
mimic the observed transcriptional changes after JQ1 treatment of neuroblastoma cell 
lines16 (Figure 6.7e). Furthermore, a strong reduction in MYCN signatures was observed, 
confirming the effect of JQ1 treatment on MYCN transcriptional programs (Figure 6.7f and 
Supplementary Figure 6.9). Treatment with MLN8237, a pharmacological inhibitor that 
decreases MYCN protein levels by abolishing autophosphorylation of Aurora A,17 also 
significantly reduced cell viability (Figure 6.7c) and MYCN expression (Figure 6.7d). 
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Figure 6.7. Treatment of mNB-A1 and re-grafted tumors. (a) JQ1 treatment of mNB-A1 cells significantly 
reduced cell viability in MTT assays compared with untreated or DMSO-treated cells. (b) Western blot analysis 
confirmed no MYCN protein regulation in mNB-A1 cells treated with JQ1 compared with DMSO-treated cells. (c) 
MLN8237 treatment of mNB-A1 cells significantly reduced cell viability in MTT assays compared with untreated 
or DMSO-treated cells. (d) Western blot analysis confirmed MYCN downregulation in mNB-A1 cells treated with 
MLN8237 compared with DMSO-treated cells. (e, f) A mRNA signature score established from genes 
differentially expressed after JQ1 treatment of neuroblastoma cell lines16 (e), and a MYCN mRNA signature 
score14 (f) for mNB-A1 cells treated with either DMSO, JQ1 or MLN8237. (g) Western blot analyses of Brd4, 
MYCN, Myc, E2f1 and Cyclin D1 expression in re-grafted tumors from LSL-MYCN;Dbh-iCre mice treated with 
JQ1 or DMSO. Actin and Gapdh were used as loading controls. (h) Re-grafted tumors from JQ1- or DMSO-
treated mice were examined histologically after hematoxylin/eosin (H&E) staining or immunostaining for cleaved 
caspase 3 (apoptotic cells) or Ki-67 (actively proliferating cells). Representative images are shown. (i) Bar graphs 
show the mean relative apoptosis (left) and proliferation (right) calculated from three representative images from 
each re-grafted tumor from groups of mice treated with either JQ1 or DMSO. Significance was calculated by 
Student’s t-test: *P<0.05, **P<0.01, ***P<0.001.  
Gene expression profiles of mNB-A1 cells after MLN8237 treatment show similarities with 
the transcriptional changes observed after JQ1 treatment of human neuroblastoma cell 
lines16 (Figure 6.7e), and closer similarities to mNB-A1 cells treated with JQ1 (Figure 6.7f 
and Supplementary Figure 6.9). These data support a MYCN transcriptional program 
repression resulting from both MLN8237 or JQ1 treatment, although slight differences are 
observed, which is to be expected for treatment with compounds having a different mode of 
action. We conclude that cells derived from tumors of LSL-MYCN;Dbh-iCre mice retained 
their malignant capacity upon transplantation, and that growth remains depended on MYCN 
function, indicating oncogene addiction.  
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JQ1 treatment induces apoptosis and decreases proliferation of re-grafted 
tumors from LSL-MYCN;Dbh-iCre tumors  
We next aimed to analyze whether JQ1 treatment also affects tumors from LSL-MYCN;Dbh-
iCre mice in vivo. For that purpose, nude mice harboring re-grafted tumors from LSL-
MYCN;Dbh-iCre mice were treated with JQ1. Western blotting of fresh-frozen re-grafted 
tumor lysates showed that JQ1 treatment did not suppress MYCN or Brd4 protein 
expression in the tumors (Figure 6.7g), but clearly downregulated E2f1 protein expression. 
Immunhistochemical analysis of the tumors revealed that JQ1 treatment also significantly 
decreased Mki67 (Ki-67) expression, an indicator of cell proliferation, and increased the level 
of cleaved caspase 3, indicating the induction of apoptosis (Figure 6.7h-i). Taken together, 
the effects of JQ1 treatment in vitro were recapitulated in vivo.  
Discussion 
Although treatment advances in many pediatric cancer types have resulted in increased 
survival of affected patients, the prognosis for advanced stage neuroblastoma remains poor, 
especially after tumor relapse.18 Preclinical models to better understand the molecular 
features of aggressive neuroblastoma and that can be used to evaluate novel therapies are 
urgently needed. Here, we present a novel conditional MYCN-driven mouse model that 
resembles human neuroblastoma. Using Cre expression driven by the Dbh promotor, which 
is active specifically in noradrenergic neurons of the peripheral and central nervous 
system,19 we restricted transgenic MYCN expression to the presumed tissue of 
neuroblastoma origin. Double-transgenic LSL-MYCN;Dbh-iCre mice developed tumors with 
a high incidence and regardless of strain background, thus overcoming one of the major 
limitations of existing models. Bioluminescence imaging identified tumors recapitulating 
human neuroblastoma localization and histology. LSL-MYCN;Dbh-iCre tumors also 
mimicked molecular marker expression and reflected chromosomal aberrations of human 
neuroblastomas. Interestingly, the most common genomic aberrations in human 
neuroblastomas, including gain of chromosome 17q, were also observed in tumors from 
LSL-MYCN;Dbh-iCre transgenic mice. Therefore, this mouse model offers the possibility for 
cross-species genomic analyses toward identifying the presumed oncogenic drivers on 
human chromosome 17q. In addition to a gain of the region of mouse chromosome 11, 
which is syntenic to human chromosome 17q, several other recurrent aberrations were 
observed that resemble aberrations observed in human neuroblastomas. Interestingly, 
chromosomal gains of human neuroblastomas are better recapitulated in our model than 
respective deletions. Specifically, loss of 1p36, a region frequently deleted in human MYCN-
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amplified neuroblastomas, was not recapitulated in our model. Our findings are in line with 
previous findings in the TH-MYCN neuroblastoma mouse model.20,21 Of note, numerical or 
partial gain of mouse chromo- some 11 resembling human chromosome 17q gain and 
amplification of the MYCN transgene was observed in both MYCN-driven mouse 
neuroblastoma models. In addition, gain of mouse chromosome 3 has been observed in all 
analyzed neuroblastoma mouse models to date.15,20–22 Taken together, LSL-MYCN;Dbh-
iCre mice develop neuroblastic tumors that share histological features and genomic 
alterations of human neuroblastomas.  
Compared with the existing MYCN-driven mouse model of neuroblastoma, which expresses 
a human MYCN cDNA under the control of a rat tyrosine hydroxylase promoter,6 the novel 
LSL-MYCN;Dbh-iCre bears several advantages. First, transgene integration is better defined 
in LSL-MYCN;Dbh-iCre mice. The ROSA26 locus is commonly used for the generation of 
genetically engineered knock-in mice, because it is ubiquitously expressed and a 
discontinuation of that locus causes no known phenotypic effect in mice.23,24 In contrast, it is 
not known whether transgene integration into the distal region of chromosome 18, reported 
for the TH-MYCN mice, also causes positional effects that could possibly have an impact on 
tumorigenesis.21 Second, tumors developing in TH-MYCN mice are limited to abdominal 
ganglion structures,6 whereas LSL-MYCN;Dbh-iCre tumors develop predominantly from both 
adrenals, but also develop from the celiac and superior cervical ganglia, thus covering all 
locations in which human neuroblastomas arise. Third, TH-MYCN tumor penetrance is only 
high in a genetically near pure 129 × 1/SvJ strain background, probably due to differential 
expression of specific modifiers.25 This hampers the combination with other transgenic 
mouse strains modifying neuroblastomagenesis, as they need to be backcrossed genetically 
to achieve the same tumor incidence. By contrast, the LSL-MYCN;Dbh-iCre model also 
develops tumors in other mouse strain backgrounds, such as C57Bl/6N, at a high frequency. 
Taken together, the novel LSL-MYCN;Dbh-iCre neuroblastoma mouse model overcomes the 
limitations of the only existing MYCN-driven neuroblastoma model, TH-MYCN.  
Beyond the advantages discussed above, the new LSL-MYCN;Dbh-iCre is strikingly similar 
to the widely used TH-MYCN mouse model in regard to the occurrence of chromosomal 
alterations, mRNA and miRNA expression profiles. Therefore, subsequent experiments with 
the LSL-MYCN;Dbh-iCre mouse model can easily build on the many excellent results 
obtained with the TH-MYCN mouse model in the previous years. The LSL-MYCN;Dbh-iCre 
model also represents an excellent tool to evaluate new targeted therapies in vivo. However, 
the LSL-MYCN;Dbh-iCre mouse model can only be used to analyze those factors or 
compounds that regulate or interfere with the MYCN protein itself or MYCN downstream 
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signaling. Regulators of MYCN transcription or interactors with the MYCN mRNA, such as 
miRNAs targeting the MYCN 3′-untranslated region, cannot be analyzed in this model, as 
the MYCN cDNA that is ectopically expressed lacks any regulatory untranslated regions. A 
mouse model in which neuroblastomas are driven by over-expressed endogenous Mycn, 
such as the LSL-Lin28b;Dbh-iCre mouse model,22 is more appropriate for the latter 
analyses.  
We have used the LSL-MYCN;Dbh-iCre mouse cell line to evaluate two drugs, MLN8327 
and JQ1, which are known to target MYCN. MLN8327 destabilizes the MYCN oncoprotein 
by inhibiting the interaction between MYCN and AURKA. We confirmed that MLN8327 
treatment downregulates MYCN protein in our model cell line, leading to a strong reduction 
in cell viability and a decrease in the MYCN activity score. First, this confirms that cells 
derived from tumors arising in the LSL-MYCN;Dbh-iCre mice exhibit oncogene addiction to 
MYCN. Second, our results support and extend the preclinical evidence indicating MLN8327 
as a promising targeted therapeutic agent to treat MYCN-amplified neuroblastoma. The 
mode of JQ1 action includes the down- regulation of MYC(N) mRNA transcription and, 
thereby, MYCN protein expression. As MYCN is ectopically expressed in our model system, 
a downregulation of MYCN expression after BRD4 inhibition is not necessarily expected. In 
line with this, we observed no change in MYCN expression after JQ1 treatment. Alternative 
mechanisms that could explain why JQ1 treatment still reduces cell viability in our model 
system include either MYCN-independent effects of JQ1 or the interference of JQ1 with 
MYCN-driven transcription rather than with transcription of the MYCN gene itself. The 
significant decrease of the MYCN activity score, which we observed following JQ1 
treatment, implicates the latter effect, at least in combination with MYCN-independent effects 
of JQ1. P-TEFb has been previously demonstrated to be a factor required for MYC-driven 
transcription.26,27 Therefore, P-TEFb is most likely also required for MYCN-driven 
transcription as well. As BRD4 is an important factor for P-TEFb recruitment,28 we 
hypothesize that inhibiting Brd4 by JQ1 impairs recruitment of P-TEFb, and thereby 
attenuates MYC(N)-driven transcription. Although not in the focus and beyond the scope of 
this manuscript, this hypothesis should be taken into account and explored where it has 
weight for explaining JQ1 treatment results in future experiments attempting to finely assess 
the mode of action and side effects of JQ1. These should also help delineate the mechanism 
by which JQ1 decreases the MYCN signature score without downregulating MYCN protein 
levels.  
A prerequisite for using LSL-MYCN;Dbh-iCre mice in preclinical research is assessing the 
dynamics of tumor development and a sufficient treatment window. With the dynamics of 
tumor development that we observed in LSL-MYCN;Dbh-iCre mice, the acceleration or delay 
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of tumor development as well as an increase or decrease in tumor incidence could be used 
as measurable end points of experimental manipulation, including the introduction of further 
genetic alterations. A treatment window must be defined to use the LSL-MYCN;Dbh-iCre 
mice for preclinical analysis of potential therapeutic compounds or therapeutic strategies. 
The treatment window is the time from tumor detection to the time the mouse succumbs to 
disease or must be killed due to tumor burden. Our ultrasonography experiments clearly 
indicate the presence of a sufficient treatment window in the LSL-MYCN;Dbh-iCre mouse 
model (Figure 6.2e), although the number of mice analyzed was too low to exactly define the 
boundaries of the treatment window. Exact delineation of the treatment window for the same 
animal model will also vary between studies, as it depends on the techniques used to detect 
and follow the tumor (palpation, luciferase, ultrasonography or nuclear resonance imaging), 
the end points used in the study (hyperplasia versus an established tumor) and the time at 
which a mouse must be killed due to tumor burden (ethical considerations and varying 
national animal protection regulations).  
As genetic features of human neuroblastomas are preserved in LSL-MYCN;Dbh-iCre-
induced tumors, positional approaches might help to identify other crucial driver genes in 
neuroblastoma development. Thus, a plethora of options is already available to uncover the 
full potential of LSL-MYCN;Dbh-iCre transgenic mice in terms of neuroblastoma genetics 
and future therapeutics, and we expect the LSL-MYCN;Dbh-iCre mouse model to be a 
valuable tool for the neuroblastoma research community. In fact, the LSL-MYCN mouse line 
has already been transferred to several laboratories, and is available on request to the 
research community. To prepare for a future expansion of requests, sperm and frozen 
embryos are being conserved to allow easier transfer, and the mouse line will be submitted 
to one of the available public repositories, such as the European Mouse Mutant Archive. As 
MYC(N) is a key driver of tumorigenesis not only in neuroblastoma, combination the 
conditional LSL-MYCN mouse with other cre-transgenic models bear the potential to also 
model tumorigenesis of other human malignancies.  
Methods 
Generation of LSL-MYCN mice and tumor detection  
Human MYCN (Ensembl gene ID: ENSG00000134323) was cloned downstream of a 
chicken actin gene (CAG) promoter followed by loxP-flanked strong transcriptional 
termination site (LSL). The transgene was placed upstream of an internal ribosome entry 
site (IRES) and a second open reading frame coding for the luciferase gene (Fluc) in a 
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proprietary plasmid (Taconic-Artemis, Cologne, Germany). The CAG-LSL-MYCN-IRES-Fluc 
vector (LSL-MYCN) was introduced into the ROSA26 locus of B6S6F1 embryonic stem cells 
by recombinase-mediated cassette exchange (Figure 6.1a). Recombinant clones were 
isolated, validated by Southern blotting and mice were generated by injection into tetraploid 
blastocysts. LSL-MYCN mice were crossbred with Dbh-iCre mice.19 Genotyping and 
confirmation of Cre-mediated recombination were performed as previously described.15 
Primer sequences are provided in Supplementary Table 1. Abdominal tumors were detected 
by weekly palpation, and confirmed by high- frequency ultrasonography using a Vevo2010 
device (Visualsonics, Toronto, ON, Canada) and/or by in vivo luciferase imaging.15 Time to 
tumor detection was displayed as tumor-free survival in Kaplan–Meier analysis. Growth 
curves for tumors were obtained by volume measurement using high-frequency 
ultrasonography.  
Gene expression analysis  
The RNeasy Micro Kit (Qiagen, Hilden, Germany) was used to isolate total mRNA from cells 
or tissue, and cDNA was generated by SuperScript II Reverse Transcriptase (Invitrogen, 
Darmstadt, Germany). qPCR was performed using the TaqMan Fast Advanced Master Mix 
(Applied Biosystems, Darmstadt, Germany) and the StepOnePlus Real-Time PCR System 
(Applied Biosystems) according to the manufacturer’s instructions. Cad1, MYCN, Dbh, Th 
and Phox2b mRNA expression levels were normalized to endogenous Gapdh and 
calculated using the dd-Ct method using Biogazelle software (Biogazelle, Ghent, Belgium) 
as previously described.29  
Western blot analysis 
 Cells or small tissue slices were lysed on ice in RIPA buffer (50 mM HEPES, 10 mM NaCl2, 
1% NP-40, 0.1% SDS and 1% Triton X-100) supplemented with cOmplete Protease Inhibitor 
Cocktail Tablets and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche, Mannheim, 
Germany) and 30 µg of the resulting proteins were separated on 10% SDS-PAGE then 
transferred to Amersham Hybond-C Extra (GE Healthcare, Solingen, Germany) membranes. 
Membranes were blocked in 5% milk powder in TBS-T0.1 then incubated with primary 
antibodies against Brd4 (1:200; #sc48772; Santa Cruz, Heidelberg, Germany), E2f1 (1:1000; 
#AF4825; R&D Systems, Minneapolis, MN, USA) or MYCN (1:1000; #9405; Cell Signaling, 
Frankfurt am Main, Germany) and Actin (1:2,000; #A3853; Sigma-Aldrich, Taufkirchen, 
Germany) or Gapdh (1:2000; #MAB374; Millipore, Darmstadt, Germany) as a loading 
control. After washing twice with TBS-T0.1, membranes were incubated 1h at room 
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temperature with horseradish peroxidase-conjugated secondary antibodies against mouse 
IgG (1:2000; #NA9310V; GE Healthcare), rabbit-IgG (1:2000; #NA9340V; GE Healthcare) or 
sheep IgG (1:2000; #HAF016; R&D Systems). Protein detection and visualization were 
performed as described previously.30  
Immunhistochemistry and electron microscopy 
Briefly, 3-µm-thick sections of formalin-fixed paraffin-embedded tumors and adrenals were 
deparaffinized, and antigen retrieval was performed by boiling the section in citrate buffer at 
pH 6 or EDTA at pH 9 for 20 min. Staining was performed as previously described31 using 
anti-cleaved caspase 3 (#9661, Cell Signaling, 1:200), anti-tyrosine hydroxylase (ab76442; 
Abcam; 1:200), anti-Ki-67/Mib-1 (RM-9106, Dako Deutschland GmbH, Hamburg, Germany, 
1:25) and anti-Ncam1 (ab6123; Abcam, Cambridge, UK; 1:500) as primary antibodies. 
Corresponding secondary antibody detection kits for reduced background in murine tissues 
were used (Histofine Simple Stain Mouse MAX PO, Medac, Hamburg, Germany), and 
antibody complexes were visualized using an automated stainer (LabVision Autostainer 
480S, Thermo Scientific, Langenselbold, Germany). All slides were scanned with a 
Pannoramic 250 slide scanner (3D Histech.com Budapest, Hungary, Electron microscopy 
was performed as previously described.32  
Array comparative genome hybridization (arrayCGH)  
DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen) according to the 
manufacturer’s instructions. ArrayCGH was performed using a 180K (AMADID 027411) 
mouse whole-genome arrays (n = 13; Agilent Technologies Santa Clara, CA, USA. Random 
primed labeling (BioPrime ArrayCGH Genomic Labeling System, Invitrogen) was used to 
label 400 ng of tumor DNA and matched control DNA with Cy3 and Cy5 dyes (Perkin Elmer, 
Waltham, MA, USA, respectively. Hybridization and washing were performed according to 
the manufacturer's instructions (Agilent Technologies). Fluorescence intensities were 
measured on an Agilent scanner (G2505C, Agilent Technologies). Data were extracted 
using the Feature Extraction v10.1.1.1 software program (Agilent Technologies), and further 
processed with arrayCGHbase (http://medgen.ugent.be/arraycghbase). Gains and losses 
were determined using the circular binary segmentation algorithm.33,34  
mRNA expression profiling  
Primary murine tumors, normal murine adrenals and treated mNB-A1 cells were profiled on 
Affymetrix Murine 430 version 2 oligonucleotide microarrays according to the manufacturer’s 
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protocol. Microarray profiling results for eight LSL-MYCN;Dbh-iCre tumors have been 
deposited at the Gene Expression Omnibus under accession number GSE51297. 
Microarray profiling results for mNB-A1 cells have been deposited at Gene Expression 
Omnibus under accession number GSE57810. Profiles for three non- malignant adrenals 
from wild-type mice were used as controls. These profiles have been previously described 
by Molenaar et al.22 Profiles were compared with mRNA profiles of tumors from ALK-
transgenic and TH-MYCN mice that have been published previously.15 Microarray.CEL files 
were normalized and summarized to gene levels using the Bioconductor repository of the R 
statistical language to do gcRMA normalization.35 Probes with a log2 expression of o5 in o11 
of the 14 samples were considered not expressed and filtered out. Only the probe with the 
highest average expression over all samples was retained for each gene.  
miRNA expression profiling  
Murine mature miRNA expression levels were quantified using the stem- loop reverse 
transcription-qPCR platform (Life Technology, Darmstadt, Germany). Briefly, 60 ng of total 
RNA was reverse transcribed using the rodent stem-loop RT Megaplex primer pools A and B 
(v2.0) followed by a 12-cycle pre-amplification according to the manufacturer’s instructions. 
Pre-amplified cDNA was diluted and quantified using miRNA-specific Taqman assays (Life 
Technology) in a 3.5-µl qPCR reaction containing 1.5 µl of Taqman assay (1/17 dilution of 
20X solution), 1.75µl Taqman gene expression master mix, 0.02 µl of cDNA and 0.23 µl of 
water on a 7900 HT qPCR system (Life Technology). Raw miRNA expression values were 
filtered using a Cq-cutoff of 32, and normalized using the global mean, as previously 
described.36,37  
GSEA  
The GSEA software was used to identify pathways or groups of functionally related genes 
deregulated in tumors from LSL-MYCN;Dbh-iCre mice compared with normal adrenal 
gland.11,38 GSEA was run on the collections of 3272 curated gene sets (c2) from version 3.1 
of the MSigDB.39 Gene sets with less than 15 genes or more than 500 genes were excluded 
from the analysis. Gene sets with a false discovery rate ⩽0.25 and a nominal PP⩽0.05 were 
considered significant. The gene ranking metric in the weighted enrichment score was the 
two-sided signal-to-noise ratio, and P-values were calculated using 1000 permutations of the 
phenotype.  
144 Chapter 6 
 
 
Gene signature scores  
Gene signature scores were calculated with adaptation of a previously reported algorithm.40 
The LSL-MYCN;Dbh-iCre signature was composed of the top 100 most differentially up- and 
downregulated genes in LSL-MYCN;Dbh-iCre tumors compared with normal adrenal gland. 
The signature score was calculated for a panel of 967 cancer cell lines in the Cancer Cell 
Line Encyclopaedia,13 for which normalized gene expression data were downloaded from 
http://www.broadinstitute.org/ccle/home. Signature scores based on the expression values 
of MYC-regulated mRNAs or miRNAs, as previously defined by Westermann et al. and 
Mestdagh et al., respectively,14,41 were calculated for a series of tumors from ALKF1174L,15 
LSL-MYCN;Dbh-iCre mice and normal adrenal gland tissue. Additional MYC (N) signatures, 
retrieved from curated gene sets (c2) from version 3.1 of the MSigDB,39 were calculated for 
mNB-A1 cells treated with either JQ1, MLN8237 or DMSO. The published 
PUISSANT_NB_JQ1 signature22, composed of the 316 genes differentially expressed in 
neuroblastoma cell lines upon JQ1 treatment, was calculated for mNB-A1 cells treated with 
JQ1, MLN8237 or DMSO.  
Human neuroblastoma signature  
A human neuroblastoma signature was generated using a published data set of 69 human 
primary neuroblastomas.41 The signature was composed of the most differentially expressed 
genes (Rank Product analysis, P < 0.001) in high-risk compared with low-risk patients, either 
with or without inclusion of MYCN-amplified neuroblastomas, resulting in the human 
neuroblastoma signature and human non-MYCN-amplified neuroblastoma signature, 
respectively. To compare these gene signatures with expression data from LSL-MYCN;Dbh-
iCre tumors, only genes with a known human and murine homolog were retained, yielding a 
list of 10 433 genes for further analysis.  
Establishing of a cell line from a LSL-MYCN;Dbh-iCre tumor  
Murine tumor was minced manually with scissors and the pieces digested with 2 mg/ml 
collagenase in PBS for 30 min at 37 °C. Tumor pieces were passed through sieves with 
different pore sizes (400, 100, 70 µm) to obtain a cell suspension. Cells were maintained in 
RPMI medium supplemented with 10% fetal calf serum, penicillin (100 U/ml), streptomycin 
(100 µg/ml), 1% N2 and 2% B27. The mNB-A1 cell line was in continuous culture for more 
than 4 months, and all experiments performed here have been obtained after 3–4 months in 
culture. Cells were seeded onto 96-well plates and treated with 250 nM JQ1 (BPS 
Bioscience, San Diego, CA, USA) or MLN8237 (Axon Medchem, Groningen, The 
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Netherlands). Metabolic activity was analyzed by 3-[4,5-dimethylthiazol-3-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay (Roche). We used this metabolic activity as a 
surrogate for the number of living cells, thus, cell viability.42  
Engraftment of mNB-A1 cells into nude mice  
Six-week-old female athymic NCR (nu/nu) mice were subcutaneously inoculated in the left 
flank with 107 cells derived from the LSL-MYCN;Dbh-iCre tumor suspended in 200µl BD 
Matrigel (BectonDickinson, Heidelberg, Germany). Mice were measured for tumor growth 
three times per week using the formula (breadth x length x height)/2.  
JQ1 treatment of transplanted tumors from LSL-MYCN;Dbh-iCre mice  
A Murine tumor was minced manually with scissors and the pieces were digested with 
2mg/ml collagenase in PBS for 30min at 37°C. Tumor pieces were passed through a sieve 
with 400 µm pore size to obtain a cell suspension. Cells were washed with PBS and 
suspended in 1.5 ml Matrigel (BD Bioscience, Heidelberg, Germany) for subcutaneous 
inoculation (200 µl per mouse) into the left flank of 6-week-old female athymic (nu/nu) mice. 
Mice were treated with JQ1 (50 mg per kg body weight) or vehicle control (12.5% DMSO in 
PBS) twice daily by intraperitoneal injection for 3 consecutive days when the volume of the 
subcutaneous tumor reached 500–1000 mm3, and animals were killed 4 h after the last 
injection. Half the tissue was snap-frozen in liquid nitrogen then stored at − 80 °C and the 
other half was formalin fixed and paraffin embedded for immunohistochemical analyses.  
Statistical analysis  
Statistical analyses were conducted using Graph Pad Prism 5.0 (GraphPad Software Inc, 
San Diego, CA, USA). Kaplan–Meier analyses were used to analyze overall survival. Mean 
relative apoptosis (calculated by positive staining for cleaved caspase 3) and proliferation 
(calculated by Ki-67 expression) in the transplanted LSL-MYCN;Dbh-iCre tumors from the 
control and JQ1-treated groups of mice was calculated from three representative images of 
each tumor using ImageJ 1.47 (National Institutes of Health, Bethesda, MD, USA). 
Significance was calculated by Student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001). 
Differential gene expression analyses were performed using the RankProd package in the R 
statistical language.  
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Supplementary Figure 6.1. Tumor incidence is higher in LSL-MYCN;Dbh-iCre mice than in TH-MYCN 
mice. Kaplan-Meier curves indicating time to detection of palpable tumors in mice heterozygous for TH-MYCN 
(strain background: 129x1/SvJ) and mice double-transgenic for LSL-MYCN;Dbh-iCre (mixed strain background: 
C57Bl6 predominant). Wilcoxon rank-sum test.  
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Supplementary Figure 6.2. Flox-out PCR. PCR validating the removal of the transcriptional termination site 5’ 
of the MYCN allele in eight representative LSL-MYCN;Dbh-iCre tumors (Primers used: B1 and B2 – see Figure 
6.1a).  
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Supplementary Figure 6.3. Murine neuroblastoma tumors recapitulate genomic aberrations of human 
neuroblastoma tumors. (a) Tumor/control ratio plot for mouse chromosome 1 in tumor 10 shows partial 
chromosome 1 gain corresponding to partial gain of human chromosome 1p, 2q, 5q, 6p, 8q and 18q. (b) 
Tumor/control ratio plot for mouse chromosome 3 in tumor 6 shows gain of entire chromosome 3 corresponding 
to partial gain of human chromosome 1p and q, 3q, 4p and q, 8q and 13q. (c) Tumor/control ratio plot for mouse 
chromosome 6 in tumor 7 shows gain of entire chromosome 6 corresponding to partial gain of human 
chromosome 2p, 3p and q, 4q, 7p and q, 10q and 12p. (d) Tumor/control ratio plot for mouse chromosome 12 in 
tumor 9 shows gain of entire chromosome 12 corresponding to partial gain of human chromosome 2p, containing 
the endogenous Mycn locus, 7p and q, and 14q. (e) Relative MYCN expression levels in 13 murine 
neuroblastoma tumors. Tumors 1 and 9 (gray bars) harbor gain of chromosome 12, containing the murine Mycn 
locus. 
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Supplementary Figure 6.4. Analysis of gene expression patterns from three normal adrenal glands and eight 
tumors from LSL-MYCN;Dbh-iCre mice using Affymetrix murine 430 Version2 oligonucleotide microarrays. 
Unsupervised hierarchical clustering using the 1% of genes with the highest standard deviations in expression 
across all samples revealed distinct clustering of adrenals and MYCN-driven tumors. Data are presented as row 
normalized.  
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Supplementary Figure 6.5. Comparative analysis of the transcriptome of murine LSL-MYCN tumors and murine 
TH-MYCN tumors at (a) mRNA and (b) miRNA level. 
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Supplementary Figure 6.6. (a) Analysis of gene expression patterns from three normal adrenal glands and eight 
tumors from LSL-MYCN;Dbh-iCre mice using Affymetrix murine 430 Version2 oligonucleotide microarrays. 
Hierachical clustering using MYCN mRNA signature published by Westermann et al.32. (b) Expression (log2) of 
MYCN upregulated (Cad, Cdk4, Odc1) and MYCN downregulated (Dkk3, Rgs5) target genes in MYCN-driven 
tumors compared to normal adrenals from wild type mice. Student’s t-test.  
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Supplementary Figure 6.7. (a) Analysis of miRNA expression patterns from five normal adrenal glands and 
eleven tumors from LSL-MYCN;Dbh-iCre mice using Affymetrix murine 430 Version2 oligonucleotide 
microarrays. Hierachical clustering was performed according to a published MYCN miRNA signature15. (b) 
Expression (log2) of miRNAs from the MYCN upregulated miR-17-92 cluster in tumors from LSL-MYCN;Dbh-iCre 
mice compared to normal adrenals from wild-type mice. Student’s t-test.  
 
 
Supplementary Figure 6.8. Analysis of re-grafted tumors in nude mice revealed a strong correlation of tumor 
size with activity detected by luciferase imaging 
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Supplementary Figure 6.9. Activity scores of three distinct MYC signatures in mNB-A1 cells treated with JQ1, 
MLN8237 or DMSO. Significant differences in activity scores are marked with (*); T-test, P < 0.05 
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Discussion 
MYCN has been at the center of neuroblastoma research ever since the first discovery of its 
genomic amplification in high-risk neuroblastoma tumors. Amplification of MYCN is observed 
in 25% of cases and has served as the most well-known prognostic marker of 
neuroblastoma risk classification. Recent discoveries have further strengthened the central 
position of MYCN in neuroblastoma tumor biology. MYCN can be activated by a number of 
re-occurring events other than genomic amplification. Indeed, two neuroblastoma 
oncogenes that were identified more recently – ALK 1-4 and LIN28B 5 – enhance the MYCN 
pathway upon activation. LIN28B boosts MYCN levels via let-7 suppression 5 while ALK 
activates MYCN activity through several mechanisms, i.e. transcriptional activation 6, protein 
stability through GSK3ß and PP2A 7 and suppression of HBP1, a negative regulator of 
MYCN (Claeys et al., submitted). Taken together, current data place MYCN in the center of 
neuroblastoma oncogenesis, yet the oncogenic regulatory network driven by MYCN is still 
incompletely defined thus preventing to unlock the full therapeutic potential of the MYCN 
signaling pathway.  
In the context of this thesis, we aimed to study and functionally characterize the regulatory 
network downstream of MYCN in neuroblastoma development. In the previous chapters, we 
reported our findings and proposed mechanistic models to integrate the data generated. 
This last chapter provides an overview of the conclusions, discusses open questions and 
offers perspectives for further research.  
PLAG2 is a novel candidate oncogenic master regulator in MYCN-driven 
neuroblastoma tumorigenesis 
One of the primary aims of my PhD was to gain novel insights into the regulatory networks 
that are driving early neuroblastoma oncogenesis and progression. To this end I 
successfully generated an in vivo MYCN time series mRNA and miRNA expression dataset 
through profiling of different stages of tumor development in the TH-MYCN mouse model. 8 
This dataset – referred to as the "hyperplasia dataset" – played key roles in three papers 
that aimed to improve our understanding of the impact of MYCN on gene expression 
network in neuroblastoma. 
My initial goal when engaging on this research project, was to shed light on miRNA-mRNA 
regulatory networks in neuroblastoma tumor development. At that point, our research group 
had contributed significantly to the understanding of miRNAs in neuroblastoma through 
mapping MYC/MYCN-regulated miRNAs 9 and elucidating the roles of the MYCN-activated 
oncogenic miR-17-92 cluster in neuroblastoma 10. Through comparative cross-species 
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analysis of dynamic miRNA and mRNA expression data, the aim was to further build upon 
this expertise and to expand the knowledge on miRNA-mRNA networks in neuroblastoma 
development. The advantage of time-resolved or dynamic datasets over static datasets is 
the superior ability to understand and model biological processes, which are dynamic in 
nature. Owing to this advantage, a number of time series experiments have been performed 
in neuroblastoma cell lines, i.e. assessing the effects of perturbations on gene expression 
profiles. 11,12 However, in vitro studies may lead to results that do not necessarily recapitulate 
the conditions occurring in a living organism, thus warranting the study of biological 
processes in a more complex context. Despite the many benefits, time-series data also raise 
several experimental and computational challenges (reviewed in ref 13). Moreover, the 
traditional gene expression data-analysis strategies yield long lists of differentially expressed 
genes – cancer signatures – that display a certain gene expression profile indicative for 
oncogenic or tumor-suppressive functions during carcinogenesis.  
After assessing a number of advanced computational methods for integrating our time-series 
mRNA and miRNA expression, we decided to apply the MARINa algorithm to search for 
master regulators that drive gene networks during neuroblastoma development (see Chapter 
3). In this approach, generating cancer signatures becomes only a starting point for a gene 
network analysis, where a causal regulatory model identifies the driver genes controlling the 
signatures and related phenotypes. In this thesis, the hyperplasia dataset was applied to 
generate gene signatures for neuroblastoma development, and gene expression data from a 
large set of primary neuroblastoma tumors was used to construct a causal neuroblastoma-
specific regulatory model, using a bioinformatics approach that has not been previously 
applied in neuroblastoma. The MARINa algorithm relies strongly on the neuroblastoma-
specific interactome that was reverse-engineered from gene expression data from primary 
neuroblastoma tumors using ARACNe. ARACNe is an information-theoretic method for 
identifying transcriptional interactions between gene products using gene expression profile 
data. Similar to other algorithms, ARACNe predicts potential functional associations among 
genes by identifying statistical dependencies between gene products. In this context, 
ARACNe has proven effective in identifying bona fide transcriptional targets, even in 
complex mammalian networks. 14 Given that the MARINa algorithm strongly relies on the 
outcome of the ARACNe algorithm, the limitations of ARACNe should be taken into account 
when interpreting the MARINa-inferred master regulators. More specifically, ARACNe can 
introduce false negatives for triplets of interacting genes as the algorithm will open all three-
gene loops along the weakest interaction. Moreover, because mRNA abundance 
measurements only serve as a proxy for the interacting molecular species, the type of 
physical interactions corresponding to the irreducible statistical dependencies identified by 
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ARACNe are not always clear. Consequently, predictions made by ARACNe should be 
directly experimentally verified. 15 
Using the unique hyperplasia dataset in concert with this robust and innovative data-mining 
strategy (Figure 3.2), 22 master regulators of MYCN-driven neuroblastoma development 
were identified. Further characterization of these master regulators and their regulated 
neuroblastoma signatures highlighted MYB, E2F2, EZH2, PLAGL2 and MXD3 as master 
regulators of both MYCN-driven and MYCN-independent neuroblastoma development. 
Additionally, two synergistic master regulator pairs were identified. The data obtained in this 
study are highly exciting for several reasons. A number of inferred master regulators were 
previously described in relation to MYCN: for example MXD3 and E2F proteins can regulate 
MYCN expression 16,17; MYCN amplified tumors are addicted to MYBL2, a family member of 
MYB displaying functional redundancy with MYB 18; and EZH2 was shown to physically 
interact with MYCN at promoters of repressed target genes 19. The identification of known 
MYCN interactors/regulators serves as a firm proof-of-principle for the value of the 
performed dynamic regulation analysis on data from developing MYCN driven tumors. One 
particularly interesting candidate master regulator identified is the C2H2-type zinc finger 
transcription factor PLAGL2 (Pleiomorphic Adenoma-Like Protein 2) that is involved in 
cellular transformation and apoptosis. Of the inferred master regulators, PLAGL2 caught our 
attention for a number of reasons. First, while PLAGL2 is one of the top candidate master 
regulators in our study, only one published study has reported on the relationship between 
PLAGL2 and neuroblastoma. 20 Intriguingly, in their study, the authors found that 
overexpression of PLAGL2 cDNA – exogenously 20 or in response to iron depletion or 
hypoxia 21 – in a murine neuroblastoma cell line, Neuro2a, induces apoptosis through the 
induction of a pro-apoptotic factor, Nip3. This observation is in line with another report that 
investigated the effects of PLAGL2 overexpression in human promonocytic cells. 22 Here, 
PLAGL2 expression inhibited cell proliferation which correlated with an accumulation of cells 
in G1, apoptotic DNA-laddering, an increase in caspase 3, 8, and 9 activity, and a loss of 
mitochondrial transmembrane potential. Simultaneously, the authors observed a significant 
increase in the TP53 homologue, TP73, with PLAGL2 expression, possibly via direct 
activation of TP73 transcription. Both reports are inconsistent with the strong oncogenic role 
of PLAGL2 in a number of tumor entities 23-27, and with our data showing that high PLAGL2 
expression strongly corresponds to poor survival of neuroblastoma patients (see Chapter 3, 
Figure 3.3c). However, such conflicting functionalities have been attributed to a number of 
oncogenes, including MYCN: conditional expression of MYCN in some MYCN non-amplified 
neuroblastoma cell lines has been shown to significantly inhibit cell growth and to induce 
apoptosis. 28 Supporting a putative oncogenic role for PLAGL2 in neuroblastoma is the 
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observation that enhanced PLAGL2 expression strongly suppresses neural stem cell 
differentiation while promoting their self-renewal capacity upon differentiation induction. 24 In 
their study, Zheng and colleagues found that PLAGL2 functions to activate WNT/β-catenin 
pathway while repression of WNT activation in PLAGL2-expressing NSCs sensitize them to 
differentiation. 24 
As indicated in Chapter 3, although we speculate that therapeutic targeting of the identified 
master regulators – and synergistic master regulator pairs – will contribute to the regression 
of both MYCN-driven and MYCN-independent neuroblastoma tumors, further mechanistic in 
vitro and in vivo experiments are needed to support the presumed oncogenic role of 
PLAGL2 in neuroblastoma. One possible approach is to screen for compounds that target 
the identified master regulators and test their efficacy and putative synergistic effects on 
neuroblastoma cell lines and the LSL-MYCN mouse model. Efforts such as lincscloud † that 
aims to develop comprehensive signatures of cellular states and tools to analyze them, can 
aid in the selection of candidate compounds to include in such screens. In addition, targeted 
knockdown or overexpression of the identified master regulators in neuroblastoma cell lines, 
followed by functional screens and gene expression analysis, will contribute to our 
understanding how deregulated master regulator expression can contribute to 
neuroblastoma development. To support the in silico findings, these experiments are 
currently ongoing at the CMGG. 
While interesting candidate mRNA master regulators were identified, no miRNA master 
regulators could be inferred. Indeed, in literature, far less miRNAs than mRNAs, are 
considered as master regulators of a given phenotype. Several possible explanations can be 
proposed to explain our observation. First, multiple miRNAs can be involved in the regulation 
of one particular gene which may blur the effects when investigating the regulatory effects of 
one single miRNA. Secondly, it is well known that miRNAs act, not only by degrading their 
target mRNA but also by repressing translation (see also Chapter 1). The latter effect cannot 
be inferred from the datasets used in this study. While we failed to identify miRNA master 
regulators, the generation of the novel miRNA hyperplasia data set has proven to be an 
important resource for further studies addressing the role of miRNAs and their regulators in 
neuroblastoma development. More specifically, the miRNA hyperplasia data set proved to 
be an essential data mining resource as part of my endeavor to explore the regulatory 
miRNAome targeting two major neuroblastoma oncogenes, MYCN and LIN28B. In addition, 
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I could make use of a powerful novel unbiased screening assay in order to identify miRNAs 
regulating target genes of choice (Van Peer et. al., submitted).  
Deciphering the MYCN and LIN28 targeting miRNome 
In previous studies, individual miRNAs targeting MYCN have been identified. 29,30 Although 
the applied approach was valuable, it was biased towards canonical miRNA-mRNA 
interactions, identified by available prediction algorithms. In contrast, our approach was fully 
unbiased as it included the majority of miRNAs present in the miRBase repository (version 
9.2, released in May 2007). Furthermore, the integration of the results from this unbiased 
screen with patient expression data allowed us to identify MYCN-targeting miRNAs in 
neuroblastoma context. This additional step is important as miRNAs are known to regulate 
their target genes in a highly tissue- and cell- type specific manner. Finally, we showed for 
the first time that MYCN specifically downregulates the miRNAs by which it is targeted, 
providing a mechanism to sustain its upregulated expression levels. Although our approach 
is unbiased, it still holds a number of limitations. First, as our 3'UTR library screen included 
the majority of miRNAs present in the miRBase version 9.2 (released in May 2007), it was 
limited to those miRNAs known at that time. Between May 2007 and June 2014, when the 
latest miRBase version (v21) was released, 2124 new human miRNAs were included in the 
repository, while 343 entries have been changed and 7 were deleted. 31 In addition, as we 
integrated the results from the 3'UTR library screen with human and murine miRNA 
expression data, our approach was further restricted to the miRNAs detected by the 
respective miRNA profiling platforms. Therefore, of the 2588 human miRNAs known to date 
(miRBase v21), only a small fraction of 187 miRNAs could be assessed. It should be noted 
however, that the vast majority of the newly detected miRNAs are often highly tissue 
specific. 
Of the 12 MYCN-targeting miRNAs in neuroblastoma context, the majority were shown to be 
downregulated during MYCN-driven neuroblastoma development. Using the SHEP-MYCN-
ER cell line with inducible MYCN activity, I could show that only two of these miRNAs (miR-
29a-3p and miR-29c-3p) are directly downregulated upon induction of MYCN (Figure 4.5), 
suggesting that downregulation of MYCN-targeting miRNAs during tumor formation is likely 
to result from secondary (epi-)genetic events downstream of increased MYCN activity. 
Notably, for the let-7 family of miRNAs, it has been unclear whether these miRNAs could be 
considered as direct targets of MYCN. Some papers have suggested regulation of let-7 
miRNAs by MYC 32,33, while others have argued against the direct regulation of let-7 by 
MYC 34. Our findings described in Chapter 4 therefore greatly contribute to resolve this 
ongoing debate concerning miRNA-MYCN interregulatory control in neuroblastoma. 
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In Chapter 5, I further extend this understanding by demonstrating that the indirect regulation 
of the let-7 family of miRNAs occurs via induction of LIN28B. More precisely, I sought to 
identify whether LIN28B is regulated by MYCN in neuroblastoma via suppression of LIN28B-
targeting miRNAs. Regulation of LIN28B by MYCN (or MYC) could offer an explanation for 
the observed regulation of let-7 miRNAs in MYC(N) driven systems. To this end, we 
performed a LIN28B 3'UTR-miRNA library screen and translated the results from this screen 
to the neuroblastoma context. Using a number of in vitro neuroblastoma models with 
controllable MYCN expression constructs, I showed that MYCN regulates the expression 
levels of the LIN28B-targeting miRNA miR-26a-5p (Figure 7.1). Notably, alterations of 
MYCN expression or activity did not affect the expression levels of the  primary mir-26a 
transcripts. This indicates that altered miR-26a-5p levels are not the direct consequence of 
transcriptional activity of MYCN at the mir-26a promotor regions. Also here, downregulation 
of these LIN28B-targeting miRNAs during tumor formation is likely to result from secondary 
(epi-)genetic events downstream of increased MYCN activity (Figure 7.1). To our 
knowledge, these events are not yet identified, but elucidating them will increase our 
possibilities for developing new strategies for targeting MYCN in neuroblastoma. We believe 
that the discovery of the MYCN–miR-26–LIN28B regulatory axis in neuroblastoma marks 
LIN28B as an important effector of the MYCN oncogenic phenotype and underlines once 
more the importance of MYCN-regulated miRNAs in establishing the MYCN-driven 
oncogenic process. Consequently, LIN28B can be regarded as a prominent therapeutic 
target for MYCN-driven neuroblastoma tumors. Finally, given the role of both MYCN and 
LIN28B as bona fide stem cell markers, these novel findings are of broader significance for 
beyond cancer, notably in normal development and stem cell biology. 
 
 
Figure 7.1: Schematic overview of 
the MYCN–LIN28B axis in 
neuroblastoma. The expression 
levels of MYCN and LIN28B are 
strongly interconnected via a 
network of miRNAs. A considerate 
number of these interactions have 
been established or confirmed in this 
thesis. The question mark represents 
a yet unknown factor in the proposed 
network. 
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Indeed, given the unbiased study design of both the MYCN 3'UTR-miRNA library screen and 
the LIN28B 3'UTR-miRNA library screen, the results generated in chapter 4 and 5 apply to 
regulation of MYCN and LIN28B in any cellular context; especially now that a myriad of high-
throughput miRNA and gene expression data are publically available to translate this 
prioritization catalogue to any cellular context of interest. 
Expanding cross species genomics through novel neuroblastoma transgenic 
animal models  
Throughout this thesis, studying the genetic landscape of the well-established TH-MYCN 
mouse model has provided exciting new insights in the perturbed miRNA-mRNA networks in 
neuroblastoma. Although representing an excellent and broadly used tool, this mouse model 
holds some limitations related to the transgene integration site, the anatomical location of 
the observed tumors, implementation of in vivo imaging and tumor incidence in different 
genetic backgrounds. In Chapter 6, I therefore presented a novel mouse model – generated 
by our collaborators (Schulte lab, Essen, Germany) – with targeted Cre-
conditional MYCN expression in the neural crest. 
The Schulte lab developed a transgenic mouse strain harboring a floxed transcriptional 
termination cassette upstream of a MYCN allele integrated into the well-characterized 
ROSA26 locus, and observed no phenotype in the single transgenic mice. These mice were 
crossed with transgenic Dbh-iCre mice specifically expressing Cre recombinase in cells of 
the developing neural crest. Double-transgenic mice, termed LSL-MYCN;Dbh-iCre, 
developed tumors in all locations in which human neuroblastoma tumors arise. Tumor 
formation, enabled by transgenic luciferase expression, was monitored by ultrasound and 
bioluminescence imaging. Importantly, tumor incidence in LSL-MYCN;Dbh-iCre mice was 
independent of the strain background. Using different molecular analyses, I showed that this 
novel neuroblastoma mouse model closely resembles the genomic aberrations and MYC-
related mRNA and miRNA signatures occurring in human neuroblastoma tumors. Thus, 
potential neuroblastoma-relevant genes and miRNAs as well as novel treatment options can 
be investigated in a setting genetically mimicking human neuroblastoma. Combining this 
conditional LSL-MYCN mouse model with other transgenic mice carrying cancer-related or 
cancer-modifying alleles bear the potential to also give insights into other human MYCN-
driven malignancies. I therefore anticipate that the LSL-MYCN;Dbh-iCre neuroblastoma 
mouse will have a similar impact as the TH-MYCN mouse has had on the scientific 
community, and could functionally replace it as a model system. In addition, the Speleman 
lab in Ghent has also introduced the MYCN and mutant ALK zebrafish neuroblastoma model 
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which will allow further in depth cross species analyses in order to decipher perturbed 
regulatory networks in further depth as a prelude towards identification of novel therapeutic 
targets. 
Future perspectives 
I envision that the resources established in the frame of this thesis can be further exploited 
in a number of follow-up studies. First, the hyperplasia dataset can be further applied to 
prioritize candidate neuroblastoma oncogenes or tumor suppressor genes in a cross-
species approach. One such example is to prioritize candidate genes located on aberrant 
genomic regions in neuroblastoma tumors. Indeed, neuroblastoma is to a large extent a 
DNA copy number cancer type, and pinpointing the causal genes in these genomic 
aberrations has been hindered by the large size of these chromosomal gains and losses. In 
particular gain of chromosome 17 in the majority of aggressive neuroblastoma tumors 10,11 is 
an interesting chromosomal region for which the causal cooperative genes have not been 
unequivocally identified 12,13. The commonly gained segment on chromosome 17 is 
completely synthetic to the distal part of mouse chromosome 11 that is gained in roughly 
one third of all LSL-MYCN;Dbh-iCre tumors (Chapter 6), strongly supporting a highly 
selective advantage of this cooperative event during tumor formation in this mouse model. 
As such, my PhD work has paved the way for the currently ongoing intensive research 
efforts in relation to several top ranked 17q candidate driver genes. For one of these genes, 
BRIP1 {Fieuw:2014tv}, convincing in vitro data have been obtained and further in vivo 
studies in mice and zebrafish are ongoing (Van Hauwaert et al., unpublished).  
Second, the hyperplasia dataset allowed to study the dynamic transcriptional landscape of 
TH-MYCN driven neuroblastoma and to identify a set of strong candidate master regulators 
synergistically implicated in MYCN-driven neuroblastoma development. Currently, the 
enhancer landscape linked to these master regulators is largely unknown. Enhancers are 
cis-regulatory elements that function to activate or repress target genes and prime genes for 
rapid induction for change of cellular state and have recently come prominently to the 
forefront of cancer research. Further, a central role for long noncoding RNAs in relation to 
enhancer activity and epigenetic control of active transcription is emerging. This additional 
level of epigenetic regulation has thus far not been extensively explored in the TH-MYCN 
transcriptional landscape study. Therefore, a full delineation of the enhancer landscape of 
MYCN-associated master regulators will unlock novel therapeutic potential for targeting 
MYCN overexpressing neuroblastoma tumors. Thus, the current study could be extended 
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with an in-depth analysis of the underlying (epi)genetic landscape during neuroblastoma 
development. 
Finally, comparing the implications of perturbed MYCN activity in the LSL-MYCN;Dbh-iCre 
mouse model with similar insights obtained from ALK- or LIN28B- driven mouse and 
zebrafish tumors or the insights obtained in Chapter 3, could contribute to a more thorough 
understanding of both common and different effects of these important neuroblastoma 
oncogenes in the biology of this embryonic tumor. 
Conclusion 
The work in this thesis has significantly contributed to our understanding of the impact of 
MYCN activation in neuroblastoma tumor biology. As MYCN is the most important driver 
gene in neuroblastoma known to date, this will facilitate to the development of drugs 
suppressing neuroblastoma progression. While considered undrugable, at present multiple 
angles are being actively explored to target MYCN (see Chapter 1) and therefore the new 
insights of the present work can be directly applied to support such efforts. In addition, in this 
thesis I present the genomic characterization of a new MYCN-driven neuroblastoma mouse 
model, which overcomes a number of issues related to the previously only murine MYCN-
driven neuroblastoma model and faithfully recapitulates the genetics of MYCN driven human 
neuroblastoma formation. 
Therefore, the combination of the accomplishments in this thesis contributes to a more clear 
understanding of the genetic landscape of neuroblastoma and the molecular implications, 
generating opportunities for the development of targeted therapies. Indeed, through these 
and other efforts in the field, the understanding of the genetic basis of neuroblastoma is 
starting to keep up with advances in other cancer entities. Ultimately, this increased 
knowledge of normal and perturbed cell biology will lead to the development of more 
focused neuroblastoma therapies, characterized by an increased efficiency and decreased 
toxicity.  
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